var title_f14_21_14672="Nonoccupation HIV PEP algorithm";
var content_f14_21_14672=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 479px\">",
"   <div class=\"ttl\">",
"    Algorithm for evaluation and treatment of possible nonoccupational HIV exposures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 459px; height: 489px; background-image: url(data:image/gif;base64,R0lGODlhywHpAdUAAP///4CAgH9/f0BAQMDAwAAAAD8/P7+/v/Dw8NDQ0DAwMODg4FBQUKCgoP8AAGBgYCAgILCwsJCQkHBwcO/v7y8vL9/f38/Pz/+AgBAQEE9PT//AwF9fX5+fn/9AQK+vrx8fH4+Pj29vbw8PD/9QUP8QEP/Q0P9wcP8wMP/w8P8gIP+wsP/g4P+goP9gYP+QkAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADLAekBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw8TFxsfISQQBzM3Oz9DR0tPU1dbXAQSUy9jd3t/g1drJcQEGAujp6uvs7e7v8PHy8gYBlObz+fr7/Pr15OUEaBJgb1IAgZkIAoRzcGBBSQ0TPlzIJiImhQYRXpxIUY3FSxghagTJsSOaj5ZCRkJZSaXJkyNTlnTEkpLLl2ZqTrpJM2bL/5k4x+hEQqGDgBAWkBjwQuHCkQ4dpvBsNHTJgaQALGBdckFE1q1EtAIQ4XQIWS5Tg4apaqSCgAMhQCApoASdkwNLAXQ9YldK2kVskxSoIKSv1aVQn0Y1cIAIY7RA1YIJPATvEAoADjQGgLBABwNeAXwwYOADANICLBzQYIAD5gMfODwWAOKthairW2M2DOWvIspHCgiI2leAbgAUjIvAvVRzVtlvMzc+p0ED5scXWJu24lsyF+DIR4g4gJlzZyEFGmsIcQEEhdsAOHAgfyFpCA6cDVhoD6BDhauW1QfAfeZJFRlgPjlRAAWE2SWCQKONJdBnmS1l13/xCWTXOQNqcP/aVRVYQMFjVXTnnRbgZWXcCPj1RRcAL+JlwQghbNYXBSFoUIGF51lWIXI57ligXwf+lmATdA1n1wjp0DXCa83xeAFhBW64GV2MhXCOcUc6YeKJWKRIBAgHuIieEJZZIICQfVUQAgWWmemjZW7CyaOB93S5BF0M2pWeZo3FGKV5Ptpl5ZmMCTCfZmARCSYZ4F2wGQUgWBCCVxa8+KIISCVFQZKhLdjfnTBmRqVlolLI2xNfGiLmEC/SJpABIQjhFIYRxikABU9KWOBjH3jI2AHu2cpdkY+GqWcRFmgAggEVmEYpaJpC65oFO1YQFbYGXNDBs7IN+SJpHVj2bWukRtH/aiGvnhmeQBToWIGHU1Y3qF3+sabhrDt2+2F/2W5HxbrJStHuIQQPcnAT5XWAnxHlcRDVGQkX/MTChVQcCMZLnGtAeUVwUEEFoVGMrMVUcDyIxoCoLAjLKCvhciAw+zEzIDXHfMTNZWxWRF6snnwIz2I0ZcRe6gqt88XL1gE0ES8GnacfSBPhY29KL91EVRRAp1etX/cXrHXIcYlZdhw6x1lhaorodVjlaoicbK6VOqDAdWVNyFBom/bBdn9zNlpoq2mw2Wil9ZcUfLeVqZd2RWgGFXxoC2RZcmUxkbPWQ1SF4YMAaLDrCE6B1mGGnOFHOo7ioncOto2BXtkIope6/55oTtElQgUg5z31EdiKyBilmhVbgGnrWVCp8vu5B99jlh1Ae2ohjugzZ+KVu9TqtdL5cBObcw4A37UpuhSD2gpBopNDjAAACOPtdp7d7aETbmVA08WBBh9g5RnvXtKbwo6kJXRwqD0VKIugQoCQo8yoRuprTPTyUkAuEaEvloEfeSokH6yJLwtDOcB/NFMWEfTqX6WKGp9y9CQz2U2EgMrcj9zlsBEECgTf05wABaETRQEKK0JyF16KIxA1CQl6g0rdDy+IkMuxEE4FAMHEAvhBZSWBV2VxygeiRSVgeYh/mfHQZv5zqaxoSghYNBb+YJUZIYCOLhrIoe8yggRilf/HKSLIY6jcyJ4u1sdTcDQNheZULL0wEU3NEcIIPyZFqVXRClWZErQE0J6kdBBapHHKBUjjL3l5ZVoiOKOtsjWSqyWpX5jhUwXkiITw6WEo/oHWB/yDnPQVwFq7GVkRs4UbcCURYLI85I88+aMLjGCKS3Cl1jBGIpztcGNNEwwhlLk0Zl7PD9S8w8KiRrNnPlIIROtDNu0QTj6ME2Xl3MM56ZBOPayzYO3MwzvlEE88zPNR9bzDPRkSzUbs80T5tMM/3RDQOgxUMvjoh0IXytB4/MMgW2qoRCeq0Id+cwrcCIdGmzGAAWz0o80YhyQyCtJwdLSkGxXpRW3mTXS2dKX/mGAGTJEg05muoqY2JQJOc3qKnfLUpzwlBVBtOtSghqKoMEWqUT2h1Is2dambeOojpQrVJpAUpVg1qUezytVwqPSoL60qOLfa1bKa9awo9WgpqCpWmYW1F2y1RFzburO38mKu97ArVPE6DL5CRK9L9WswBAsJwtLVsL5ALFUAy1MIFOCxBcgAThwLWcmKQrFLfQBkC8AAnGgWsp29LGNz2oDNSgAnpYXsaUVLVyosYLMJwMlrIRtb1rZ2Cgp4LATUktsC7HYUmF3qBB77ALUMtwDFBe5ocxqBxzZALc0twHOVe1sqPHYBkrmuUJeb0wEowDveXSt3iToB7wSgvNut/+4UEhAB77BXvOqNr1zHK9/6loO+9s1vRfD7i6ui9b/X+Ood/AvgAndDwAzhb2IjStEGO9iACr5CQh9M4QobJ8JQCO4xCtqGg6asn4zw8NYwvAsOs0HEBgPxIlC8BA0bw8RrYHGGVawIGSfBxcWAsRps7AQdw4HHdRWfj9EAZCYM2Q1FLgKOiXFkMyRZZjROxJM7R2JdNLkMU6ZplBGR5fFVORcqA5RziiIAvAlBLGjC8pdTvAUxN4bMZv5KZdLQ5SX3dctZCY066BKCGnFImHYbQ5eNcLM9D8jPMTEMN9VMzjXf4lWfmU8RHGa1pw3phdVpDHwUJx2odO044HP0jP+n8KDeEYHSawR0jDKdlYl1ICmS68Cn65a0RgtZxSGoE8RGABZFFYFL6KAL85jno9lk73YfkOEcX4nnSCubV72WI7AFIOzlVarYjRHAsWuVbEfVwc7CSFHh4uzrIbTH1D7UDJ8b6OcIDml//XMks62wyaeV21aFHEK6D7DuwrT7X32Bd6Oo+G1R1+JVavpzeLbSHmVfOkkNfEteZqORGl4zCYNWMp7DaLjL8NrcIHC4ooeEDmxf2uLeZqfBabEwgd274XzRCF2mpL4L0JxB2W6iG/uZcZ1ueYsiaNTLQx5zNtL8NDYnDM6HtBnZebDgt4aCCDhJGjR+XH3PqrqqC6P/SyHoSEc55zppTI3xlW9tyxssArSHYICsW3rknOl66OaFoeKgMuVzAPdgN45NsxuZ79P0u5IFD4srk6HnnQP8yghP5ahLAvHgVPzLGA9OyrfC8IK2PKEl301bc45rDu/8HihjtBpbXu/AiGTJAs8HylSNy6fX/E1jUrlWZyY2JBoNGPtmBOO4JjmYAX4HxhZ8s81NN5t+dX8uAEHf9w7y4ztS7eEDG9kczgC7h9yvdQP8shWF+GU7R/Dp9h5XJ6UDzM82qHsfe8e37wKsi5N++LPF8gfPekQAXYS0dJpamS5HqONryCYpEzcdtXEA+mdvsudzSMA9P2IczSMavHMb//fXTL6yf0tBK6fhFQDIARqCHwNocm33FgnYSu33eTGhQVDSOmAkBBWkcADAJMEmBCLzMOsTg+0TH/wDawWIQjJIbRe0gImHBCr4gOfRggOyJTD4gy9Sg+5WKu4jBO4jcDP0GCTChCboecsUEziiAU+iK4jiM/sGFn+iNh+QHk9IFyokBBYnglciZkHYekfShV9IKlgihotyFVADh6KBhiikhmzUHxxgQ26IHnzIflpYTTExRpphh6ljK3akRuoDNk6hPMSSFF4UOqaxGm0kITeHISSigYakb0IYeXWkSI3YOuUmKYUkQ6JYiWRSKf8SLJoYRp34IJ84HZvxilkIdf8oWATEBIal0jU7MiEBQwTxMjLWES0AMyL9okmc5BRrMnZzB3YolIzzEoejdyTB6IjEyCGxxIyXIS/LKEi8g0n+Um/+Mo0fU42gOCnk2Isq535rYIFfAH2YZ49iUGel2FOcRwX62AX4+I9WEJBgwI/0+AgD6RCJqDOYt4/9+JBEdoJbuBMRSZB915AxI5EHeZEM6YsV+XgeKREaiU4MZmEouQ8WlQcTlpIuuVArSU/9aAoE9l8nZWDOgGB1UJMFdpM4CQ06SVAzaRKoFwtFuTFD2RFH+QpL+QdNOVVJWQlP2QdT+UFVqQpX+UpRuRBZiQpdiQdf6ZBbaRBjKRRlmQz/YQlf6aVfRnaWheWWkwGXi8CTP0kNPlmXB5YJAUBWeNmXQTl4OLGXfTmYZqVWmECXhHlWhtmWgSmXbZCWqSc0kAkKk8lDjumVknmZiFCZSBlYmdmYLKeZpkBVnNkJpemUoqmWjNkRlPVYluUKrRlZQUWaqTkIn/VYoeUKt8lZs/mZHZFaj7VargCcBSCcROWbFDFbj1VbrqCcBcCcx9ljtTkIvfVbsFCdRkWbL3FcyQUL3JmdyEkR0TVdsDCe4CmdOKFdsqCePxWeFBFeswCfvYmeL3FeLIde8zliOPFes8Cf+bmabBmgJRlkAlqgeeeeBpqga6CdpYCYiWlWf4lR/w+KlxEKZghKmSf5khr6DjEZJhm6oSCqDh2aWBf6CRwZBtR0oh3JZCXKVBhpT4ylovc4nQNKaDQqYS+qTzGaowJ1o/Oon2vFowa1oz/BovQpVEJKBymapHMAfZvZoqbJpHKwpEXaV1DKCTLqBVRqEz56oEcKXFIaB1tqkUYKpEhapVuQpQLZpTL5pZd1JB+ADqGnBmg2MER6BHFKSXFQp3hipW56VAkiAobzGRfnZAiRGJqTIGOaf4NqkId3qMiEcYrKpvf1p5SZINz0GqyWfLB2AImhe36Dfco2fNWhqceBGqrxZm9DqhqAia/za3daBJnKcZpmfp0WFaAqGqI6af/glxt1g6pjtqpj46qpAatlCqBgegTYF29ZYW2q0YPathz1dxvB8h75toGnIyAEIh/kcSGxMysigCP4wa3oFquOsYNn5qwmF63DN4Gkaq2983/0Yh/jOh/JIRCfA67iGh/2aqx+aqbJCjE5AgK8w0D+tq4IgYRxhA5k4hhXAiQ6QipyWj7hgkSXpo1pmiBdSLA4wm4I63UCs7C0cT032IVsEnH1Yz7/Ioz+Gm5XGlXL4oFE9LEo1H+AEq8PWyfCWHIjdAClI0HpgrEoErPpUBgS52590Uy0crMOeyY6K7Fv0bM/a4R8QakJZqkmmiBgEzro50e5SHIPcwEC4CHIARb/mZgqFqJno5NFK5u2VdsFNbG1GtC1Nfe1xRG2Y4tGZtsYtIi2nKG2aWRIFisAq0eKx9piVhsFNcEBz+IWXOe47hh2c1OMY5EtZvuM/eFLWbEjYisQkuS4FsstyraoQ8C4k/S4CUt3kvuNArE70HK5mZS56LK53WIXnzsrQEu7o5u4Qom1LtoGjrqmcBumSlGoM3q4bjWaxKusxqul5poGwQsZyHtjvMs0aDq01xuZvhul2WtFXDq9NFW9PdY0r8cG5ft0GVsiBhCpS3AWOya+C/qymhAYVwMG0Vu/tfYdzeYhZKcE0bui/4qsb8oEl0NJt2EcYFM4EqRppgEfrAoW/8rjgbQaOW6xvraifcuGvQxjfKhaGTZSGKNhg3xbKw8cfruyNv2BGa92wKKoQ+BLoGd6GACwSplBJpSiFeq6FLvzK+FKIJfhJlfhrFZTKZRSH9UTvaSbBBLsa+Sqb/PjGVz7IR9AOhu4r0uMH8NzTKVCLOQhiy4cwIirvATcGg+DbQbLGbWCJRyQHbo4Q2zXGGd8FJVmtC+4LEncgDm4Ki4UK7MSF2VhsVGIg+hgFBqwSVXYvEKrvQA7wFYRRRODbUR0Gh0gAh8QF+6GvxRntHNsHmOYTM8rTWeix0+syW0HQG0baHRROCNiFIccai9so2J8GJTCHBF0dP6Sa6XTg/+YbBq2LEM+kkCROIplN7xOAEacuCpllCnuYiW5dh25a8xkS8O5lrs1m8GKLMCAOsZ6cUzrKnf8gTqnTARbZCFyNzunC0ziOMz66wTqKI1c+CyhtMy4Gx/nmLvt7HXbIihP6MmvDJhB2r04CtBwJb96ubxI9skKCb8eQdAxZdAdhtCO4KRDw9CXoKbSu87fC8bJ+89MUKeaxih1WnpUcE0iXSIQnQQenRUgvRUlfdD9rFMK3WLRNHJ4wRhHNxZbOwVJdL54B0I0RtOk4bNUgtNJgL+ptgUS7SoULVczLXOa/D5Y4cVogntlEWmeQn5rIytXIWsasSufNtMn3UpOPST/XizVj8MhWm0BslHInHGAatNAuypvg7XUUjnTEcXHfKQXQ10YH2NM/WEdxBI63JY7AAMgS0F0/JGvX5y+vXHXT80pel0EDugfV7EfeiEXlK0m5wGAFxBn1vwLDBrDyZSHeB3ZkC1MjNFxSEeFW5wXlrGt6Eexlva2GM0qpP3UNHfaQ1CEV+MwBpDKeWEm/oF++euy24ulTR2IhlEpZj0kjBGKjYFywI1IyOEe7gFDJLTYGswqY73czKN2T+QjIsABSTHdrZMZIlAb6DvXxw2z4NPdGuG6vQcv7lNGlHKLApHKp5IXdBMebMvPte0l8G0WQWQ1qChC6tPA+u2CmDJz/5gRIXJ9zWHM0cnk1N/SSGbEvrQRTMTIjOyYSuqzvj5yAQWAFber3T6tLhYOAhieKexLTKexvu1BLSEua/BMF+OcQOst4Rst2gfp0LTN2GSq0dQbyygK5IgY4JGQ1OxC178z5EIuki/deBQu5UoOCUy+N05ORxkd5Use0yex5SIh0FVg0UgN5mcQ2gEL5dtt5ca9yNnc5W3+5VNeeUbu5nOO5WieE2K+Eh8aoiE6opD054C+oYJ+V30OCQ5aVnf5kxUaBYveVY2Ok4/+aIluZXte5pn+lu2dY5s+BaeJ6Z1e5z316TRx6RYamp456sEQm6/ZCq7+nxNOEbuZm61Q6/+y3uMLQZzGyQq8nutF3hHOCZ2sMOzAHr4vgZ2xoOztyerB8J2xAO3NDufkYJ6xYO3Tjs0AwZ6wwO3RSe3kIJ+xIO45peYUYZ+zgO45Feuz3hH+GQvvPlO4ngTsrqD2bga/ngTzfu/8LgbGngT53u8C/wXMjgT/PvAIvwXSngQFTwqRPqEaVelP8PAQ31USLwvYngQLL1SEXugUdugp0/EeD6IgjwvefgQZ7+MrFtZ6LgzkLhgFgF3+mNDETJKDhZ9L8PJrHmIsT/PBEO83hvNVvvI1vxFBAfQ7T/RXLucJv6BIfng9H9GbTvEVDw4Xr01Pn3lFTxJHJfIj72AlL4f/YpCqZZGqmkEBcKI2Z771SNC5ng0FPP2+ce7z7JKkXBJH+ZEOqlEbu9O/dsr2vVcaByDBVWDUMbbpZn4sQ0OQZdYaT/0fvCHe/3jHIIeMY0Ea22EcbP3VRiBCxoGrmwEbaicb4eqrZ6MvQqB7c9qyv9vyrkKQUDy3ZC22EfWsNJjTV0D5hVG4olHdlkIvpqHYQywiIQfhiUME6ZNs2qo68Mdt1qE8fp/IyE3nr88FeM0ljr9vcFIbIhP9Pe29Yt35U2dDw61Jsh3jSWQX1jYqMr7XJnvY8RM6MtuwAJ611F/31q/JPoQVkQ8ElcMFUDQekUklQBBYPqHFgADa0SA//xWi4QA4iECCg/AwRB4MRQE1xBGFzmljJURBAyghzYhiCJUPKKKYnAYNDxETFZ+mFh0fIY2aIikrpagsiwrUqNaOPI3uMj8LRxufKEa6ACw+BETwhC4EPwxSiQBwQ+W08EBABI9SLfAsCgQ70laFBK6KBydHpacHT6mvF6Oxt4+sLTeZOjHVQAzML0SntTO9lS40KswD4+EPsgx6L+IrxosORvCNc6PkngELHcpxSAOvAiwAIvYRi7KOW8VK7SChOyDRAqBAdspYlFRK5DWMJStSvNgP5REQElGqbDkTyklHBjgIqNCBiYE1AjqGgRjsULpEMmlGsplUGlJIS0V24P9A0ylTplChCKg1FQAXPJtA+ZMjol+HDxo0EKMgwKcgAWFWIapqNRFWupHmLrJ791peviL3KinAUwNPrxZG9PzZUQ4HOEYMiMgzNSeTqR2EwDzk9y8jlp0rcUYUGLQl0aWpkUYCzhPOtzwFcABkJwyHCkS7drmTuEhio3JJoj6k2qoIXUqMk5q2V840CscNPQ8dXHhJ4kZYU/ETiNORMWaQeL0DDsCm35upV6/5ubrXJ+7VpFfKPgn51ZEuOBwELv909TOv06Q7+MLxrrnwdFvoAy+uGMOR06rz5qADqHjHgAUBqEWDBQ9AaxWz0FrLD1Y6YKuDd9JSAydB7FFolQ7/NQChCwsxhFFG5aSBKhkO+NPgQi8KEIAnDYmYsJNaJHORRC8+UPIhczgMsoOD8GBLAEEOYuuxrOT7D5sAyxswLibKOee8IsRL4wJzDMDFHJ6O6tLLbvr5RwOgKrCgD3tuO8iCl/4kJrI8hKDgpQNkNPTKNh6iopaeLLgABFbypCCzSrmwoFIhcDSFvgw1oMAYSvXMtIAhzhIVGDupGAwAtCKd9A62Yi1iQUMtMGaIOyqLzYtEX5pIzjlz/JRYaIYl1htRQvDJyg2NCAETAeBIE80y5LB2hJ/AwmSTEBziotk1fAL32k7Z+RTaMMe1MsxXc3oLW+y6C3NWb/0RwQBV/97dzQjfsh1TCQiPdQTMYwlGbVk5YgPEAvhAaS3Ba0Wx9lRACgwTFC4aLsOCjcdMeL33VgFLNo/f3a4MO5rLTsB7Bcxiiy7AGY/eigVOQuSCRzOW5yV27mxhf4Ap4gJfc9EHzZm9CBjnprt6jAhQNnkUADKKzsVqTkda7lOyvvo1GCKOYcIZUdNx2d40qGYCFktpZlFBBqHOTdiftzmY2KD/GroIzPD5gALbfGKiAn7OxfnpOyhg6Iq2H6rAti4Ar2BBiCZH15Kl+vAJnMoX1AkWiPBhjN6MzWMbX0sNqMdwEe5Y85y6CRw4Wbwf0XumA5E7jm++dFfvdySCx3143P+TKL4k+5Qg8HirlEft+UuQp2T66gHAqIwOhmwdFw059FANJAc/rEQDToRVRQ5YbNK9HXv8kcEYQ77dy+hLux7/gq+vHiMBRiACEKmKAlkQ1ZQAFSxXwUpSvwpEGCbTqAyxzSANTNWoNFWqjWyqftijngeBZr+egfBBIiThyJAACg3ES0brAoC01AAHtaUucWnY1hq6JaB1fctZ5QpXBz24v87oz2cn1JkJjaiE/2FCZYGA2LRaVS8a2m08HkGd3TR2so2ATHO4E+JfiJhE4IjxKZ+J2Nk+xpULKK0rZJMi7SY2olxcEWwUME/WLrA1IGLvi3wJIxmRBUiDmXEcpKv/FOE6cTh8XXFxaWjc4R63OnMI4HP7uJzkuBYfEAbAWT/x5CdBGUpRjpKUpTQluZBYjU6ekpWtdOUrTWmAVAqyj2CcZWkIEABd7pKXvfTlL4EZTGEOk5i7JMA0cllMZS6Tmc1k5jEFqYha+vGW0bTmNbFZLGv2L5vd9OY3PyhIboKTnOUU4zTvMk5zrpOdXiwi9tTZTnnOUz3opEs86ZlPfdKFk7D05z8B+hNZ7pOgBQVhMp2ZUIUu1JgGdehDIRpRiU6UohW16EUxmlGNbpSjHfXoR0EaUpGOlKQlNelJUZpSla6UpS116UthGlOZzpSmNbXpTXGaU53ulKc99elP/4EaVKEOlahFNepRkZpUpS6VqU116lOhGlWpTpWqVbXqVbGaVa1ulas9XQEGMLCCJ3jgBNswgQdasASyPuGsaU3CWpeAAQ94IBEb2EARWLABFqTArnbN613xqtdy2jUFAOArCw7RVgCcgK5KUCxcjQBZQ7TAAyZQgmSPkAIXYBYKfLUsAEywgRT81a8b+CxoRVvRFKDAAR5gLQaW0NooeMABicCAA+7KAgwANgmyXYJueXsE3yahBQ4gAWwR4YDaAuC2u1WucjdQAgcgFgAucMBpv6lcEgBgAw5A7iC6C9sWfBcJwAXAcIuAXvBigLpIUK8RrHsCtxqiu42l7QZu+/9cEzhABUZQQQksetuygnYF5jVva+WKXBNslgQt2IAKvKvXzZK1sONdAQlIYAIW0NYFLTDvBkgw1xekt7F43e0KPLxbwzLWA7CVrQnCaoQNO8AFd72wB0YMgPGy4AXtPe9ym5ve5cbXsCXo7xFATOEUYGDESx4xBlrwghYXIQWMdcFnb1xjA+8WuCgGAAs2e2WLPNeu3i0CZXFcBBNgGKx5NfN41cxm9h64xVM+b2OTfILCGgG/JnAwfhG7YA80+M6gjXERHuxdxEqZBGJlbgtgjGTf3pe7voWwWLvrAiTkOQUwFqundbsCxjpa0HougpTJmlf2cpe9fXYwd0NsavX/FBfBlg1vpV1cghOQwAE9dgAKMOCCBksXrRtosXU1TVsVsFYFJoAwCk5w62DL1QFpRW93iX3r/2LgBP1tbQpKgII9g/bZLViBcU/ggLLSVrrBVS5YaYtc5aqZvzru9RHOTYJ0b/e2LbCuZR2ga16PGAUlwEDBWVDc4x731uHFdmtZEG4MlADAFfm1kc8N23TvutcRN/h9b03bL1Oc2mXONcdHLNt87/sIt5UuWHHLgl8He7vfDve4W0BsE2yc12IN+Lz5zF+wQviu9T01jat7XXyj27gA8EAJNoACFfBV6KzVsMTDnfQTHBy/uGUubl3u3ZU3/T8Tf66DzXxr2aag/7X7VcEJXlBYkZ95s7KdO2u/XnQzp+AFJHhtoYM+4FtT3AWrbu3TsZt3APC6sAV3ugPGbYTnPlfeywUAa0EM+SPweujLJYF0c7z2tqsbAOd+wQtmntaGR5j0AEB94SnNjdYWN94AMDLMW1ztvIe8tv3evZlFT1fZch4DEG65Axx9W9PyF+6FPXwJEj/3rLO95ihIQncn73WjGzbg4Lb+5r1b/Nqm4L9Kv3XGUS/WdK/ZuCpWft5v62jiG189e955a1fv4saq/Om/fnwRNs7o5k7k3u/WCu70gK/EcA3RzGzNIKwEZI6/vO747moAa2vu3AvIzOzHjAD1aGu7jiDewP8KuWiNunwL/9LOzKhN3fLv1r6u8NrM4uiKtoBPBUZwvLxO+XhP8XQwAUms0EQQrCiwCN5vBfrP+pSL6JBg7k5Q+BSQAe1L+4aL12grxyIr/IQw6Y4s/95P+TSLtZCvC8FuAoOQvFBDrhzMujBgvz4O+FBgA6zrBeBwBaILwGhrBc4K+Wjv//6vuUzuvFRgA9JN/yQNuULOwWhrv1DA7SLv/VAvrJoOA4VLAzGA6nCrsNhOuRytA41rA1ZA00ygBJ5O3M7rDePQ9gKR10zgBaJN4diQ2pxLwX6NDk8g8ahBtrAPtjhvAyysE0HOzEQu34wNt9TOFO9NtlCPBDxR04z/4P12zwXokOJKkRFD0PPC8BifsNKiUK9Q7w2L4NyUK/JcrxM/0d54TdMyLequa7+U8b+qSw7TDQGBjeicMRmX8T+GUegAkL/U8Lyki/RYAAwXsfRALxRby+6WS+RYAMKU8c2Uq/aubQNvjdf4y9ro6rZAkAgn8ASkiwTkzvImUSOdi8yKwLqODAnEz7hWqwSoTtMCTroGzASYLa1WAMJUcrH4kfW+awUE0seuwbf6UbOky+BwMtyIERiXK92M8g9/rvV8KyUzUvHyLiCVayBlCyOrkcp4Tdd+cNMmbQyfy7+QLgmgMhQvstq66wHdqgWezbLMjitTgLZQgNe6jreg/7KrKuG9okkOeVLzlIAvWUscCcoF8VI99FKQbBIFNjEJEnMxDYowCzMyJXMyKbMyLfMyMTMzNXMzObMzPfMzQTM0RXM0SbM0TfM0UTM1VXM1WbM1XfM194kAZFM2/wMBHmAAJkCoZpM21cM2cTOqCiA4g/M/HqAAJqABhEo4h1M9ivM4gbMAZhMAJCAAEEA6qbMBAoAABuABqlM6B4ABIqAIEGACBmAAnCAAkDN7kBM7F0ACFgAAGqA8JSAJJOA7w5MAIKAAAuA9gyo4o3M6qxNAsVM7ubMI6hM8xZM8zVM9pWA999M94VM+6dM+AQA/9ZM/nyo4dQk5CaAAHqABCv9gPgfAQyegABgAAEp0AhigAMITAjIgACYAAspjADSBRkc0A6AzRVd0Po1AR1m0AXB0ABIgOfUTPSvUQ0FUREnURFHUOFe0RV80Rme0RgHgRnPUSUP0CHw0AoC0AIT0OYOTRqWzADLgRKsUHBRgEzJAAQAAAZg0AzLgAfZzSqd0RLszAyBAl7z0CNa0TZl0RIlKOcVUAsjUTAEVANIUAPrUTU8UTuX0Pfe0TgvgTvM0ACK1CBb1T5nHqZbTCBYgONPzUAE1Uvc0ARggPzPgU8V0Tw+1PCrVSLFjVW10U32qU4vgUwsgVMFhVGUVAEwVVVWVSlu1AF41PalUUqdKQ3X/qU0VIAMGIAOGdEQJgFBP9EktVUQbQDsLIAFwdAKKc1aNYEWzEzuPwFqztFX7s0idAAGa9VmjFTqpFQDMFVu1lVuN81vPNFz1kwDIVV8j4FrzVaqUcxOKkwAQYE0RYETzcwCqEwFWNANyU16DEwLWE05LFFzF8wFw9EWPwGHJNGLRFagGFgAK9mAVIGGJ1Usb9mEjdkWJtWIhllXJwzY3liQ8FmKLIGS3Smdbk2dhMwp8djWD9meJtmiN9mj/AposKgEilhvEFHeUtqKY1iKeNpqqFhu0k4SytkKvdhQGAJpo9Vi6lhq21oO2tmyn4WsFhGciAJoIIAIW4DYZYEgj/1ROpQAAFgA7B4BHFTQ8l6ABEkACjikAtrM7CfcBEiAA8pRf3zNvpSACcNM3oxYJIHdupZM/ATd7CncJ8pZwAZcBGOA9EYBwqRM+Gxc5FTc7tZNweVQJ4nYA0hNwBfcICAB0j2kBIMBuWXQ7jeBwq1N2J3ca2rYI3vZ1LbduC8EJOndvi6BvnwB4NbdAozdxF7cBTvdxI/c2g9cIKndIIRQ+h9R3OVdvPzd025R0f/d6U1c2zZN5Ofc2Yzdwo7Z2GeB2c9cJdvcBendzoZcvGsBMGcB6hzQBZDQCGAABPlVA8NNgIeA9wxMBGngJBmBxJ8AJIBdF9TcBuFQBCGAB1P92a3NVXkOXgJfAgBEYAsZzXTMghQHggpVggSGYOiVAf+02APT3g2m0ATh4AWA4gpUAAgw2gKt0cT21gXF3Adh1dkNYiCu4hW2UiLfhf4sggBdggAv4gBM4THrYgdvUh5NggrOziS/YW311gzsYhzUBOUG3imVUCUwYd1n4YFnYhZOgh2WYhs/zho8pa3W4g7d4CYDYYZETjJX2iI84iY9piZFTjJ84OzsjVXG3CBrgNjcBQd9lE7b2g8kzA7a3SqHpRfVUUbuTa3N2j1dVCgohbBlAThW3g2V0khV1l8I2k01ZUY0gAzyZlM9WTNU2CRJATGs3l49gOqVARMEWlWP/OZR7uSIguY0nGVAtGRwwmZf3eJM7uZdB2VJF2QhomZTfZVnfJQlWWZeAOJJhOZtnmZpJGZcxNZezdpdLWQl+mXhPdJkNNHmNeW2XFZ2FWWgCgJi9FVKFWZq9+WsjQAGi9ZrBdjfDuaBr+ZtTWYIFVzarM4ARujwY+oXVOWvJYxPQGJ77mXaB2UYnF5yXtZfBYVmhMzrtOW/+2QkCOkxQWoGp+aATWoIXOjrto5tBGJkb+gj2djYrWoeHdKV5s443mkY72p1pFKRbmnhHOqSzJ3mdYKanGqNZupOZAncjeADCM4Gb2E1pupRhlFn32G+NoJfdN1rTMwEIgE3lNTzj/1OfIzp7Rjl7zBSBKxQCeJlH6bZ0uTmp47pCq1WumxqueRqtMbU6/1mqEwCuv9Sr6bpK/VqqsYGr31OywXpdCZqWy5pdzxoJ1LqyYbcI3BquEXSuIVqf7zoA8vo98bOvTVsK7pqnaRRBgzm1Dxuq4/ltkWCFsyefj+CxczZa/Talq5q0tZopVtm0+bpE27Q8oVuLqZldv5OD5dVY47lNGUABFOBEf7k8w7M8s5Wvb3Oyw4SEkWACFGAAFIA/IcBvHda7wbuNA7u3aTS8vzS2z7tKYbebhfgIDloBCvSpA8C7C+GglRqZ5/u7LRsbmttXn3sTEhY3O7u627u7jynA0/8amhocvMtTssmbv0/5qtPbvnu0vd+7COJbPLvbwdX7vpnaV0N8SEk8Z/9bnTm8CAa8wIP3wBUgwdt7tT/8wXvzVlHcEJLcIiSgdZ8gkpegyUtiyb2pO6EcEaicG6Q8Cq6cPp2cG7JcnwjYven2ENoTQO56CT6UEdL8sr/8m8b8ohHhzFsCsKFgzZfAzrmBzpG2z/38z7dqaksjAdp8GiagzCs0pAT9sjF0ThAA0VMKbf/i0JXgqZVoWOx5bDVK0qehAbRbxqOA07Fh0e/DEMLWIgIAcidAcisUmgrBVJn3ddOzEGjTN6WXeCPgNjWYd32VASQ7e1Sd1d/ac6VgAfb/03nh04DNN3oLvUJzvZfp19UhV39NF9h5F3ftNj4XtE1vc9XLc07313LVNgLmU3n19s09FX6Jl18/nR2CXXtb/W57PdbVPXvWnds3l5uffdepHdb9NtWz94ODvLSzx9gXANkbQNn5U3xf+JgSfo2zZ3FrN98Pl3odOd0Jvn+xl9pH1zyr823h3XFB/oP103rllm4rt21LniaWeIRlFJw3AXcJfT4DWYiRW17nMwIQnXCrOAPU2HrfO2ETWY1dfq+RGAKK2jwX4IG7etVnGEUtWNN5noQNOYIVOZcVGZErdKgRFTl1/gEewGCNQALAe7zfFlq1OJC9GAlqHnUhtt2//4Ho2djEYx7pEYDmgxg5b54Bcn7nB6Dnf34Bgl5tW37u8fPok34/mT6znV5/GTnPq7rx4XOHE+A9n56MNbiPG73th/ji0zi7STaPNdfwaXTqZfRTCaDyrbiFTzZvUR/SReLmwwTmpbNp55mwV/sBwLPR6R6V61OXFlT2pxmZyYMArHnG+fnSBYSYg3u1CR+Ze9nYwZi4ezc4dDhzKRvpx/rBbz+YwfkahL/3JcD2gflEb1734ZZ46lqXfp90V5u6iZ+bjx+Nkz95qrqWt/buu5tGgRsIAADCQGhMFIcMwIBgNBaEgQAgY7ROhVEiIAuIfo2NxyDKiDzBzzW77X5Dpf/UsDfqHSa5YO844zTWyQU8EBQuhHXNbSVlgUUoJDA5NeF9FRa6BXo1ykkiZlEuQKBNcQHOPRFMQFANQCggaFV6sply3cHlvu0pJsre2RbxCvX9dX5OERoiy5pyAjxGUlLqXRqvgTpxmSpIIOilJhkF06Z1qtn13vYiTjwcRlHG6dLXm/uGSUwALGxBCEXKECuAhCqxHlD5MwEVPl4EIMQCEGlYGG4TpexDoGCStiIDCkqUEvFYlAQKhAy46IvSsAFoCJwEgBBBhkMIFgTY9yRBrAgeCUiAVTFJKJBXBhbEZa8exSj6+PkDaLBLQYEyEwpZ+CRQoocRVQay+CnjRk//XD5K7TJyZcchMQvEauCxAUCYbKwSLDcvyxklDStxhcsETb8uD6QKXqp4F0kACCAMmLBHwYAljxQ8iCUBMgMqASgPWMs1SwPKCtA0HZJhgAJ2GiuXpVYEAQMFCpYk+LeV3efWstgye1TkAeXO0EAvWEA5khDhkDwRR7AIpRMJh59czoxvMb3UjyNPrnwcs2bOnkGL5k2lNGvUjQms9o3odW2OlWjbxq37lFmiAxo0ABkZEg1QIBoF0mVEdrHIc08WSBQYSVhFjKbABLmB5xhxA5ynE3cfghiiiCO2IYFRJKIYIgPMpdiiiy+iaCKMM9JYo4031hjAWjja6CGPPwIp/6KOQRJZpJFHIpmkkksy2aSTT0IZpZRTUlmllVdimaWWI164045bghnmkmpMSSYcZoq5ZIMAdBnlmm5e88abaS4VgE86IUDGHA0kIIETAQzwQAKYdDFEAQHQNYGBUvh0XZ4cCrEAGQnOgUkCDED6xKMTIIAAoEMu0ACgBRFwaKKLSoSpn6bSeSSgK3oSQUENJCcqWm5I+p8QhQD4RAMRMMBARIBqxytdPp1BKBWiIASAXJn+GuwhXQQai6ccxnVIqBpWi02gkcj1Dj+2FsQsFYq6BJCq5ra6WAFoMFBQWVq5EoAqhyUQQSD9EBAJGo/BQxcDdM1LBQQE0EbXMBnwdP8iAAocm0CzgwxxMMD8+usYBMlB0DDG7RIpAW4HEhABw5I8hPDGblg8cBcZTJAgSvuIzCYVPr0c8yM3idqLRn4OEYvLkSFgnc3QDOfZYbIBEC80LLKJbwQNCPtQxSov8LMT/24sSsNag7wUGETklsxPQljVGCJDKOoHMmUPklIeSwwDwQQI7xQT2lfMwtI4bQPlI5ph31ganyhtxlwTpsxJ4K5LKEVLFBlMEUA6QvSltjw41dtfFZVPzjfTD5wx7VFGMPBHSozbx/YAfjxlROOEuzF2ExsVIs0fZAbW3HN+d4V7v+QMUzQDac/y21DUIRKNJLgMTnuNqrDCxCsRLU7/VJy75kEhQ8yHUYA1+DTIVSijAFfNJWvH05azD7g9D/jZM0+J803gMrv0a4AxgTcnh0QeupLIUwrzhYGQxQm8oAlzAoKUqTTrD2URAk1ssoC+EGAJrDtgFxJotZAkZn824gnSJBEUBhVCe/xwGF6S8r1YLeFWEpoDxQi4DwOmyy5X8ZwMm/aSJfRFLkPICkMG2KeM/GOD6cqJY3CnG2mgQYRnYo12TMKaVvwBQi75jmSkYCH6lGUYVvTNggCwmcpQoTYWWoNwBrAALUZig5/hVHHK8hnxzFGKNXKO7mQCC/p5wmjYsY12IseaCDlGjZCbQ54ooyPIdPE4wykOFu+j/0gCIfIhgaIQenZSoC0S5zR92xplwPin4khSj7VTJStpB6vF6K+VshTbLGspJh8tJZa23CUve+nLXwIzmMIcJjGLacxjIjOZylwmM5vpzGdCM5rSnCY1q2nNa2Izm9rcJje76c1vgjOc4hwnOctpznOiM53qXCc72+nOd8Iznu8clLUIMC1MRIYN+ZRnlOjpGHvuahK4ZMJA+aklyaynABoswEkQZShFiMOgTUKosxRqqIbSpVQQlaiYIlCA4RQACwXYh0Mf8FEqfFQC3eJokjwKUpGSlC4mhVRKV8rSK4W0CgooABLE94Ui7BQyX2AoBApwnZseKacZ2GlPFQjUAv8ItQBENSpSr1SGBryrABLIABg++lAtzMarVTXSVbO61a4WQaNgdYxYxzolCUA1Cgoo6hJ++lW74tWtQYJrUR9G17WqFa9t1SuUEiBVyEkVJF4tVV/EOljC4siwFrWcVgGrUNQk4bGQbRJXCyJZ5oi1DFZwbEQ3e6POSkSqoCVKTklr2tfCNraynS1ta2vb2+I2t2ErbZvq0dssIQBqb0hAQVsU3Cb1akbJMdJvYUTCEd7QdMQ0ky7XUN3CFncNpnCRKYgbpMgdA0bJJdJ1YakQ4cKIC+MlEniTVAC56IQawfpDBlP3OAYczA2XyhSyIhEqQPFJWlLoVrQYIN0nSGD/WnzKYLeuFbNxDSECZHBCrmC13eYs6lGMJAOnjIU0WAWAFfaky7WGVLIJc0s7beAT0Ig1rG8VKAALYHAhX7iUbTnrECxeX4Gn1V9ckSsrqHoVuGIMPnXxtzLMQRYpcJI1PfEDAs2ilbMCNS07BQrD6WrDozJT4TimtV8JWkBB0BXFNvhkicTIFrWKhSntxPjA7nWC05ogCo7h+c7KydoE79IwaAhLFN+wGCuKdhit4IxogmTDA0BSkwQcwmhaEeIt3JgbfkTi0hfODc8e5gStQOxpAYBZtG4CkdLYkwsTOwyg3vgPp0UAvSgRMaKL4A6JSJgQwY00q21sDyWKGBSc/zIasEz9pasBDBoaI/PIgtY0uqyJYUUDtLF3tq2TKufTOuoGR6g2aC0IjE8QwTEbYA3pTCfRewuwghkPwzU5S2Tc0EZYBhR2NJxBut0y0bWTbGdCGpoI4LGbnd3wxgCEhDiFzOMC5abQvuSt4dJjcIzIKDOVbXjvN2MoA8TXDTS4kcEku8Ecwg9GDnZX4S+kiwC8wddwy03lGMazeHvrocQ/ZKMSB59CfmuhQlW8jgCGYw7nqremggut5Bk8MyJAfjZJ2JcJYJFxBoDmhpUrmAzT4QtdVgb0+K3B4zhHVABWVISXR2HmGX+Sv/FHw8oJYg6zM55APnKJb/xcGONjmv8bmmDfbuAdERj/izvgAXF+3BEmlxhURL1g90IEvhLo+Mv7wG7d3Y2Pd3MA/DpCdPNOMO3xePM5de6njVXIGH05NwLdESB6119jbMLroyQEqMBO4MTibihG4ZeXBbIVwfS4uqMShPUflI6P82vvd1YK0gSRSx36KcGZp1eoXSFspOwUnHHemQCSPpricL5yhRbiAtStpXXt8SDMdIywXOkwECAVdAxOaFjXm+iQCxhcZDOIGOHLI45UGBETcZAQ1Rw9iJxGtE7O3cL96RjUsA4TKSAJ+YQONcuaSBABaB/91ZBKxF8ARVETPMVj/MYUvN8erIVCAAr7AcYcQAZdSGD/WZTME5wg9h1GUEzC9xUghXjIkCjJR5GHJ/QGDdnGHEwAZpTFomGObejEEbIG9y3cbFwS39XEXSRIgGySRNwGprSgLGBIF12YcrAGXYzRzSDHHTihAhwCgnABHP3FHYXGswFgIuUHJrmEGCYAFg7IAdJDbdQHLTBgEqThIVThOGiPKfGRH6GRXqhRE5rGkznS2pRhKjVBI4kSMohhqF3aVqDHF27dHGwGBdURnckMP5hGgriMAeHHbTiLgBQBHm4i4bzSjVyKYkTExIHMfuxPLcqSjNCILsKILxJOdr1IBGxPLmBhHLYLmemRMc6SD8IIM+bIselWNVrjNWIjOC0X/4mU1o84gXetV5F04+6VYhvsVzhGinSh45McF7WU44g8l5cwwRo0F5G0IzfuEh+844dEz2JcmC6k33YYST9ig68ZQcd4io2tFx9yxz+GCDguATWuUi7UY5dQ1zGCCEHqFzEaoi5opJMQGbdsGNF42I/FGSbkyhUCi4GlGDW+1z7tWJvFAo3Fwn55hoj5ykpeC0gkRMYlADRqyqfMpNCV4rPsyUpmDSoA5UvqREpGChlgi1KOhEb1TKEMgTZQGFQapBvUF845GSDg5I992bhoILXMIoTF2ThImDyEyyFQJetJJZWFJJUxZenRF9O1GU8I5biMykOdypZhGaeg2LacWP8okAGIhaWSEUOgfCST1Ey+VB+oRcyo6UygQcQD6FoWtAy0DdthmFvt0Jnz0drNFEG+GY20zcpGSJeibUSyfeK67eMOUQxllqLBcaahVZ8OQUFoAsBmVl+zyKDeQEW/PEMWZEFZNIs96NnKYJsYqGaxCdobxZtqdMZjMp2q8duAuZqzVM0/fMxBopsJNRtL8GYTUN+WZYXUrBqydY34ZIxrCoyBaRqFWJp3hieqLQB0QgR0NuaSDF28mQ30HcPOJdwmBAASPI7nYB1jVII8oB3F1UYRIN3heY4nbN0RxmbK7U3kFF0lqddhPEA52g6CKgH0kQaIiug5dMIUmOhWsoH/BADc2nRk0yjd+3Bc+EGMcHXeyIVB1KWEjAqB0YSoJPynhXKPJ3QNMCIPylnBBqnB193eX+woGGxc+xHowWROfy4J9djL7F2Y4/kJ5BkoOfBdMUzkWWDe+igfhAqEQ/Kd39xCBnQMg9LB94gCKXhoEjAMys0DEQSDM8zBnrLBMAxDKTCCixakimoXUYQpwvRe+7FN9XSkUgSC7QGpxjwGCkVqJbVddTyA//DPPSyPkR5HH6XGlEaN4TFOo8Ke8lQJBYYGAPFEFd7EJjggAWZBC3mOCv7fPYCqAOmgYFAa9hWCcEYh83xiApyMNKLODwmkWwjBBbpPiL1Q/1QFUtBE/yxoRRdIqoNQgVVMjI5YxbbWg/SpRCrExAbeRLoURnf1RETtKH/kAxKVH6NlmSTAKqn+qhM8BkRYV4JcirM6KQI1UZROyF+w6xakqwNqhXRgSSJOYhvVnxEMIh5mQRkxDRwKjYhSkabSISvqYRE0IkoM0LEaaec1AMMooR3OEKNRUoX2w5cAoXaUUWkEyxzE7KB2whkZB2lsIaJiQxG6quzoyiB64iwk4qR+TyBYYhTl0U4UwLSYp2mYasfSwqeygRbF2ieBGfPMkSkxg+/1wtEyQdE+outxiJYWEzBOyVm2CC6OCNy608pk4xswa5VwZIjQ7YjsbTvJbd0CbuAK7v/gvtY45sI90sMxfiMuGS6QbCM85i0/HFjj8pasvUE9OtdaeJc5Mq5iNC7gTh4cvMnm1sM4BqSokohD6sI6sgEfqi4b9Io89ONF5hJGuohFHmkb/KPaXqrgvuW73KtRRllyRgoZYgpD5GGkJEVLFgpMAJgsJBgxQM2mdMpeFuafiNhY/td/XApLYkKPKUG3pKWLOcarRBSO8eRVsgvwHhUUwNfCzdd90Vew9ByKoCRh0AWtUCUR9CW6Pi8itOViikuVmRTh0qB7fkG4OdvAgE1HoiYNspvRmEFBxFpFbMxjXETDIs/DRMx6tprEqaZ0ahqh6YjRCBtumiaI6lqtHY3/EJmDyUDhFIDNe8lhGpSnPSVpnnWNGipgi3DBEbIFxqRMso3DBc9pFHib1STxP/CnAYvqMHSoXlTChD6ByzCnTJROMxxqGIjC++TNEzCplIpDlY5SFzKN2uHDg1rFPzYBQgQccIRtn/4EjErBG1PFwNkuPzKBoNgX8GzQjHKCj16K6gTs0BJu6Jqg6lVSOLBpCsqNxsHP7QEqIgzMc8yo8lzOqD5qGXce06xpHWRe7gKCStEGIcAxRcjx87ydgTpeHnPHf0yArOiGH6sQIKMULTSB7cmuE0NBRDhETFwgXm4Dsa7BC/bf0bTfc4yNUGkKrV6Qs4ZFTCQsJ2cc0wgr/w8GYEiUBfUdQTc0Tbq2QhSh8m/sq7maK/X1WYz8jgoJxh/nrjKbEb2O4D80LO/mVh4Nw4YYh3Aw8siuQSj+QidtQXywQ2/ipSRZGtdSHoIc7QZ1cluErCmmxCrixm0MyBpUoQtfrMWN808FISUMoRfJxxEShysvxiYmJ0hbiDurxhXJQtNqiG38S4zZMy8fSRfbdE6z0pDqdE/79E8DdVAL9VATdVEb9VEjdVIr9VIzdVM79VNDdVRL9VRTdVVb9VVjdVZr9VZztS350zfck0BFtTVIZIjIRQIgQYbyMkVh1UKdhGYttVTJ9UGPiOUUwqEItUvJRE5Zzj7UlIo9S/+52ImiAG3gSlVFzQ3RDNhCZBSm3Aqi/GSqFIj4BFZgA8RhHsubmfRsKRVTlYECTdWhjRQDaFWpfBRXqfXgHjZcuZtCScYSvLblUAhCXNUXcFXUZgDlfLZaScYEkHaCMdQgDIxClV1hx1ZZedRZrZV0nB0ryLZaeZRxZ6NcM5TQHEqIRQFULXfF4TVDBSkN27VayanDpQRU+U/RBHdq1xZfydVfCZYwODeiqFVg9bRUSYa/lkHloFRmAVXVwdV+S4FPhXd3x/exvI53A4p9Z6NkIVZlvXfTHIrQ2Qte07dOH3YZLAFcpY6EPcy7YBV8q0J354FCEQFl4zVp24uoEMD/AxhjbuuD0FlUNqLWZ62VXeUJV1HOfOO1Tx/2uoF3UVlUbnyUV2HVkAN4VoTUTt01Fdx4SMnYTjFUvgC5sHT1T5eMBo5UlWv57klVBqjYloN5mIv5mLfB5wZJPGZt5EJXuUbEcQ0KwsTj48ofl4XciJi5iOxX35WrmqvSb90jT3xDvyDuZtNJ6C4J5oryjHzk6+oTfRVBgLxD7DyMcGFuozlGLnxkTdsDQj6xzd15q+gSBoqDnT0ABNBF2gDLmdAplfxuo1AQlGkKGbiZfeEYlcUksfiLYvrKIYRkR3oKpAVZ8WElP+CvsyBlKrBKV2pXawzQjz2BPGwQTuP0rneB/6uzi7Mz2VvuVxSFi6ZzZfy+5a6wCvu+eqb4+oFuL0goO/pKgbELGA1OivRa3YCBWEBJ9rLYCsBiShTtV4JJGRVs+33Vb/LwHU/zNCAo2VuamV/W+iGkGV0HycfQsMsUTBVTMKTlMLDZy63li36uhQg2W0diBnvqMBQC8QkrIcYsp3Q9RNZ0jMc/O8JdtDw8h6TLjgKFm9Z4vLXRinvuGew1MYqs/HcO50QocMWL/GEMcQ7fWRjA8Fl0ZjEjzNDgZJA228L82UPwRMf8vJ0hpDdwW9fbEw+n80NUTn6ZQqrHnNXj2se8mxBrD6eRG5Ig8oE690VHaxbTMVV83tpf6f81NEGRGiJm5q4Ixmg88LF97G6Qxqgt//2zh6lKgc9TPMezzBszUMLfZ85vqNQUcEiWpsje5wWa1L3ThQPhj5LoO9+KEwQd8x1AzI0UF2nd3M1MHmrnf4rNUwLucwgeo+slyKA4CITaO6f4PSngCJ72iB2T1L3i5c4aFMOYqtAuyw6rPvvpdauhmHrha+DbMUEDxDJAv34Jer8tv971c3+kbAzbkmrOvd6a7IEy2BP1k4iBXmrzzx6yb/8o2T8QBCQDBONBAAyQhAHACWA6o8rnkzCBBAAFZ0CLkDAyiCjAGzgSCAtvlYpWr9tJpLXppJYBjwa/KsXS4gKIUEig25L/uqNiU7j7g4yUnKR0KkCw7ApAyDgE8JRymghIUMBLKAVAUECiSmpwSghgcEJYcCNIwIx4hCKCgC1TSk06lDBMWlzq3cIkHgD1dTKcrb19chWuA1BQ0IKkGmx7o1Vle4hthoLA/BxVHayUjzUtTvy7zDTb7Ey3QwAmjc6zQ6UkAGBQLw+zMWYOunqii1CThg+01GFVxhABdrE4phsQYV27BLymbROISE+hhlUkmswXYIIqVupSrVpzC0G8eT19VgmgYKY4LaUGeAPqiIiZbt8SJmxVJ8EAqiInOFJwDQ+BQkejRUmQoYE2pkg/QXBicWvKLkLLfrOS4ei3q0e1IpI2/yEDMgANCtzFhoQo3rpZETxwpCXozAZYIyCgGoDnT0lBzU5mOlTTJ6xwpYUdq+ztkwy3GojW46SQggeYIKrGagzCAAZaErolINds46Mig9Im5KivYwBXEaPUM0xBhplOIKD70xXZ4lW0ay5GqADqAqywKH8HH178ePLlzZ9Hn179evaTUreHH1/+fPr17d/Hn1+/nf39/f8HMEABBySwQAMPRDBBBRdksEEHH4QwQgkpS4ABZrCZMEMNN+Sww/UgkOiJeDDzsEQTT0SRQQIYYGCJAgLwDooXYSmAF+gOG8AzVR4YoDUoWERiAe8auEWNBmDhhQGRKgwpRSefhPLEBfMgWGDKKgvI5YkFsDykAFgYgKWmd55g4KAIErDSSrICYK6BQmwh0rDXoqSzTjsPlOAbIe6pYkRNEsgCjV4eUPKWPLuQYE2nRHJiCC9yvDNSSSfVb442MPNzHwIyyrKKPjIgwNIAFF2rizTWoDRVVVdFjyA+RWyHKE48+UoUUhRCxRSc9jHVo44+YTVYYYeVx7JvMMNuMKPMaosqTIx14qnrvjksseF6IzZbbbfltltvvwU3XHHHJbdcc89FN11112W3XXffhTdeeeelt15778U3X3335bdff/8FOGCBBya4YIMPRjhhhRdmuGGHH4Y4YomdCAIAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     CDC. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States. MMWR 2005; 54(RR-02):1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_21_14672=[""].join("\n");
var outline_f14_21_14672=null;
var title_f14_21_14673="Troponin tropomyosin complex";
var content_f14_21_14673=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Troponin-tropomyosin complex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 346px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Interaction of the troponin-tropomyosin complex with the myosin binding site in the actin strands. Top panel: Interaction of the myosin with actin is physically blocked by the presence of the protein tropomyosin, which lies in the groove of the thin filament formed by the two F-actin strands, occupying the myosin binding site. Bottom panel: Calcium (Ca2+) binds to troponin C, leading to a conformational change which moves the tropomyosin molecule and makes the myosin binding site accessible to the myosin head. The other troponins also contribute to this process. Troponin T serves to attach the troponin complex to actin and tropomyosin, and troponin I is an inhibitory protein which inhibits the ATPase of actomyosin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Timothy W Smith, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_21_14673=[""].join("\n");
var outline_f14_21_14673=null;
var title_f14_21_14674="Thyroid goiter";
var content_f14_21_14674=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F71842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F71842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sporadic macrofollicular goiter with normal macrofollicles: Findings on surgical histology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Surgical specimen of a sporadic macrofollicular goiter with normal large thyroid follicules filled with colloid. These follicles are disrupted by needle biopsy so that the colloid will smear across the slide or occassionally aggregate into droplets.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_21_14674=[""].join("\n");
var outline_f14_21_14674=null;
var title_f14_21_14675="Granulomatous periorificial dermatitis";
var content_f14_21_14675=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F50340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F50340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Granulomatous periorificial dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous, small erythematous papules are on the perinasal and perioral skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_21_14675=[""].join("\n");
var outline_f14_21_14675=null;
var title_f14_21_14676="Pincer nails 1";
var content_f14_21_14676=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59295&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59295&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pincer nails deformity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse overcurvature of the nail is seen in pincer nail deformity. The disorder may be hereditary or acquired. In cases of acquired pincer nails, poorly fitting shoes are often responsible. The condition can be painful.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_21_14676=[""].join("\n");
var outline_f14_21_14676=null;
var title_f14_21_14677="Promethazine and phenylephrine: Patient drug information";
var content_f14_21_14677=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Promethazine and phenylephrine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22212?source=see_link\">",
"     see \"Promethazine and phenylephrine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/44/19139?source=see_link\">",
"     see \"Promethazine and phenylephrine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13715219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Promethazine VC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before giving this drug to a child. Check all of your child's drugs, including OTC, with doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700964",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give this drug to a child younger than 2 years of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702804",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to promethazine, phenylephrine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, a fast heartbeat, high blood pressure, or poor blood flow to the legs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have Parkinson's disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most useful if started before contact with the allergen. Take at least 1 to 3 hours before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10998 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-382E3F64B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_21_14677=[""].join("\n");
var outline_f14_21_14677=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13715219\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018070\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018072\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018071\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018076\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018077\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018079\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018074\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018075\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018080\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018081\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22212?source=related_link\">",
"      Promethazine and phenylephrine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/44/19139?source=related_link\">",
"      Promethazine and phenylephrine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_21_14678="Molecular biology and pathogenesis of von Hippel-Lindau disease";
var content_f14_21_14678=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Molecular biology and pathogenesis of von Hippel-Lindau disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/21/14678/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/21/14678/contributors\">",
"     Sharon E Plon, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/21/14678/contributors\">",
"     Eric Jonasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/21/14678/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/21/14678/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/21/14678/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/21/14678/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/21/14678/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/21/14678/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;von Hippel-Lindau (VHL) disease is an inherited, autosomal dominant syndrome manifested by a variety of benign and malignant tumors. VHL is diagnosed in about 1 in 36,000 people [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial manifestations of disease can occur in childhood or adolescence or later (mean age about 26 years). The spectrum of VHL-associated tumors includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemangioblastomas of the central nervous system",
"     </li>",
"     <li>",
"      Retinal angiomas",
"     </li>",
"     <li>",
"      Clear cell renal cell carcinomas (RCCs)",
"     </li>",
"     <li>",
"      Pheochromocytomas",
"     </li>",
"     <li>",
"      Endolymphatic sac tumors of the middle ear",
"     </li>",
"     <li>",
"      Serous cystadenomas and neuroendocrine tumors of the pancreas",
"     </li>",
"     <li>",
"      Papillary cystadenomas of the epididymis and broad ligament",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The molecular biology and pathogenesis of VHL disease, and the relationship of specific gene mutations to the clinical manifestations of the disease are reviewed here. The clinical features, diagnosis, and management of VHL disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MOLECULAR BIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The VHL gene has been mapped to chromosome 3p25 and cloned [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/4\">",
"     4",
"    </a>",
"    ]. Its gene product, pVHL, functions as a tumor suppressor protein [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/5\">",
"     5",
"    </a>",
"    ]. As with mutations in certain other tumor suppressor genes (eg, the RB1 gene), a \"two-hit\" model has been validated for VHL syndrome, in which a germline mutation inactivates one copy of the VHL gene in all cells. For VHL-associated tumors to develop, there must be loss of expression of the second, normal allele, through either somatic mutation or deletion of the second allele, or through hypermethylation of its promoter. In sporadic renal cell cancers, inactivation of VHL through somatic mutation of both alleles is very common.",
"   </p>",
"   <p>",
"    Major advances have been made over the last two decades in understanding the biology that underlies the formation of VHL-associated tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. pVHL targets several proteins for proteasomal degradation, thereby regulating their levels within the cell [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. pVHL forms a stable complex with several other proteins (eg, elongin B, elongin C, and cullin 2). The pVHL component of this complex functions as a receptor for the target molecules. Once bound to the pVHL complex, the target molecules are covalently bound to ubiquitin, facilitating degradation by proteasomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hypoxia-inducible factor-1 and 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoxia-inducible factor-1 alpha and 2 alpha (HIF-1 and HIF2) are two of the major proteins regulated by pVHL. HIF-1a is involved in erythropoiesis, through its ability to induce transcription of mRNA coding for erythropoietin. The role of HIF-1 in erythropoiesis is discussed in detail elsewhere, but will be briefly reviewed here to permit understanding of the events that occur in VHL disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=see_link&amp;anchor=H19#H19\">",
"     \"Regulation of erythropoiesis\", section on 'Hypoxia-inducible factor and the response to hypoxia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transcriptional activation by HIF requires the heterodimerization and nuclear translocation of alpha and beta subunits. The beta subunit is not influenced by the oxygen tension and is not bound by the pVHL protein complex. In contrast, the alpha subunits are sensitive to oxygen levels and are a substrate for the pVHL protein complex. In the presence of normal oxygen tension, HIF-1a and 2a are enzymatically hydroxylated. The hydroxylated HIF- subunits are bound by the VHL protein complex and covalently linked to ubiquitin. Once this occurs, HIFa subunits are rapidly degraded by proteasomes (",
"    <a class=\"graphic graphic_figure graphicRef53801 \" href=\"UTD.htm?3/26/3503\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Under conditions of hypoxia, however, hydroxylation does not occur, and HIFa and HIF2a are not bound to the VHL protein complex and cannot undergo ubiquitination. The levels of HIF1a and HIF2a rise, resulting in increased mRNA transcription of a variety of proteins, thus inducing a physiologic angiogenic response.",
"   </p>",
"   <p>",
"    In patients with VHL disease, loss of the sole functioning VHL allele in somatic tissues causes a situation analogous to hypoxia, despite the presence of normal oxygen tension [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/5,6,9,10\">",
"     5,6,9,10",
"    </a>",
"    ]. Mutations in the VHL gene can result either in pVHL failing to form the necessary protein complex to bind HIF1a and HIF2a or in failure of the binding site on the complex to recognize HIFa proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/8\">",
"     8",
"    </a>",
"    ]. In either case, HIF1a and HIF2a are not linked to ubiquitin and are not degraded in proteasomes. Elevated levels of HIF1a and HIF2a can then induce abnormal production of the same factors that would be produced in conditions of physiologic hypoxia.",
"   </p>",
"   <p>",
"    Contemporary research indicates that HIF1a and HIF2a may possess distinct functional characteristics. Skewing of the ratio of HIF1a and HIF2a towards HIF2a may alter cell signaling, and upregulate Myc activity in cells [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/11\">",
"     11",
"    </a>",
"    ]. The ratio switching is likely due to several factors. Hypoxia activated factor (HAF) was shown to increase HIF2a transactivation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/12\">",
"     12",
"    </a>",
"    ] and HIF1a instability [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/13\">",
"     13",
"    </a>",
"    ], resulting in a more aggressive cellular phenotype. In addition, in RCC tissue, preferential loss of chromosome 14q, the locus for the HIF1a gene, results in decreased levels of HIF1a [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to erythropoietin, other factors known to be regulated through the HIF1a and HIF2a include vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF)-beta and transforming growth factor (TGF)-alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/5,8,9\">",
"     5,8,9",
"    </a>",
"    ]. In addition, pVHL affects several other factors potentially involved in tumorigenesis that are not regulated through the HIF-1alpha system. These targets include matrix metalloproteinases (MMP) such as MMP1, MMP inhibitors, and atypical protein kinase C [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/5,8\">",
"     5,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the mechanism of tumorigenesis remains unproven, the combined effect of various angiogenic factors and other growth factors may be to create an autocrine loop that provides an uncontrolled growth stimulus consistent with the highly vascular CNS tumors found in VHL patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/15\">",
"     15",
"    </a>",
"    ]. Additionally, pVHL regulates several key cellular processes whose disruption may result in a malignant phenotype. These processes include extracellular matrix control, microtubule regulation, cilia centrosome cycle control, and cell cycle control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13348203\">",
"    <span class=\"h2\">",
"     Extracellular matrix control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Presence of functional pVHL was required to maintain proper assembly of an extracellular fibronectin matrix. pVHL binds to and regulates fibronectin in a phosphorylation dependent fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/16\">",
"     16",
"    </a>",
"    ]. Mutations that preserve HIF regulation but are collagen IV binding incompetent, for example the L188V mutation, demonstrate malignant behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13348237\">",
"    <span class=\"h2\">",
"     Microtubule regulation and cilia centrosome control",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary cilium is a nonmotile organelle involved in mechanosensing, cell signaling, and regulation of cellular entry into mitosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/18\">",
"     18",
"    </a>",
"    ]. Loss of ciliary proteins or of signaling via canonical or noncanonical Wnt signaling pathways disrupts regulation of planar cell polarity, and results in cyst formation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/19\">",
"     19",
"    </a>",
"    ]. Coordinate inactivation of pVHL and GSK3B is sufficient to induce loss of primary cilium [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/20\">",
"     20",
"    </a>",
"    ], and in animal models of",
"    <em>",
"     Vhlh",
"    </em>",
"    loss and",
"    <em>",
"     Pten",
"    </em>",
"    loss, increases cyst formation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/21\">",
"     21",
"    </a>",
"    ]. pVHL was found to bind to and stabilize microtubules [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/22\">",
"     22",
"    </a>",
"    ]. The binding of pVHL to mictrotubules is regulated by glycogen synthase 3, which phosphorylates pVHL at serine 68 and requires a priming phosphorylation event on serine 72 by casein kinase 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/23\">",
"     23",
"    </a>",
"    ]. Loss of pVHL or expression of mutated pVHL in cells results in unstable astral microtubules, dysregulation of the spindle assembly checkpoint, and an increase in aneuploidy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13348333\">",
"    <span class=\"h2\">",
"     Cell cycle control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adding back pVHL to the",
"    <em>",
"     VHL",
"    </em>",
"    deficient 786-0 cell line results in acquisition of cell cycle arrest upon serum withdrawal with concomitant upregulation of p27 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/25\">",
"     25",
"    </a>",
"    ]. Nuclear localization and intensity of p27 is inversely associated with tumor grade [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/26\">",
"     26",
"    </a>",
"    ]. pVHL is responsible for Skp2 destabilization, and concomitant upregulation of p27 after DNA damage [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are emerging data that suggest pVHL may also regulate p53. It has been shown that p53 is an important regulator of mitotic checkpoints, and loss of p53 permits aneuploid cells to survive [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/28\">",
"     28",
"    </a>",
"    ]. pVHL has been shown to bind to, stabilize and transactivate p53 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/29\">",
"     29",
"    </a>",
"    ], and this binding may be regulated by phosphorylation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/27,30\">",
"     27,30",
"    </a>",
"    ]. Further work is required to dissect out the significance of these findings and their role in driving tumorigenesis. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13348666\">",
"    <span class=\"h2\">",
"     Animal models of VHL Disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;To date no satisfactory animal models of VHL have been generated. Knockout of the homologous",
"    <em>",
"     Vhlh",
"    </em>",
"    gene in mice does not cause renal cell carcinoma (RCC) formation or hemangioblastomas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/31\">",
"     31",
"    </a>",
"    ]. Attempts to generate murine homologues of human phenotypes have resulted in a replication of Chuvash polycythemia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/32\">",
"     32",
"    </a>",
"    ] but an R167Q homologue did not generate RCC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/33\">",
"     33",
"    </a>",
"    ]. The combination of",
"    <em>",
"     Vhlh",
"    </em>",
"    and",
"    <em>",
"     Pten",
"    </em>",
"    inactivation resulted in accelerated cyst formation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/21\">",
"     21",
"    </a>",
"    ]. Reasons for the failure of",
"    <em>",
"     Vhl",
"    </em>",
"    mutation to generate a phenocopy may be due to species-specificity, or to the lack of hitherto unspecified additional obligate hits that occur in human tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GENE MUTATIONS AND CLINICAL MANIFESTATIONS OF DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific germline mutations or deletions of the",
"    <em>",
"     VHL",
"    </em>",
"    gene can influence the clinical manifestations of VHL disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/5,34\">",
"     5,34",
"    </a>",
"    ]. Deletions in",
"    <em>",
"     VHL",
"    </em>",
"    and nonsense and frameshift mutations appear to be more common in type I disease, while missense mutations may be more common in type II disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\", section on 'Types of VHL disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These relationships can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 138 families with VHL disease, large deletions and mutations in the",
"      <em>",
"       VHL",
"      </em>",
"      gene resulting in a truncated protein were associated with a much lower risk of pheochromocytoma than missense mutations (6 versus 40 percent and 9 versus 59 percent at 30 and 50 years, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/35\">",
"       35",
"      </a>",
"      ]. In particular, missense mutations at codon 167 were associated with a particularly high risk of pheochromocytoma (over 80 percent by age 50). The cumulative probability of RCC and the age-related risk for hemangioblastoma were similar in the two mutation groups. It is important to note that although the risk for pheochromocytomas is diminished with deletions or truncating mutations, the residual risk is high enough to warrant continued screening for pheochromocytomas in this patient population.",
"     </li>",
"     <li>",
"      By contrast, in a report of 274 individuals in 126 unrelated families, gene abnormalities resulting in a truncated protein or large rearrangements led to an increased incidence of RCC compared with missense mutations (81 versus 63 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/36\">",
"       36",
"      </a>",
"      ]. However, missense mutations within two narrow cluster regions of the VHL gene were associated with higher incidence of RCC than missense mutations elsewhere in the",
"      <em>",
"       VHL",
"      </em>",
"      gene.",
"     </li>",
"     <li>",
"      Correlations between the",
"      <em>",
"       VHL",
"      </em>",
"      gene abnormality and the frequency of retinal capillary hemangioblastomas (RCH) have also been observed [",
"      <a class=\"abstract\" href=\"UTD.htm?14/21/14678/abstract/37\">",
"       37",
"      </a>",
"      ]. In a series of 196 patients, RCH were twice as common among patients who had a substitution mutation rather than a gene abnormality resulting in a truncated protein.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      von Hippel-Lindau (VHL) disease is an inherited, autosomal dominant syndrome manifested by a variety of benign and malignant neoplasms, including clear cell renal cell carcinoma, hemangioblastomas, pheochromocytomas, and other rare tumors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link\">",
"       \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The pathogenesis of VHL disease has been linked to mutations in the",
"      <em>",
"       VHL",
"      </em>",
"      gene. The product of the VHL gene is a tumor suppressor protein, which targets several proteins for degradation by the proteasomes, and both copies of the gene are inactivated in tumor tissues. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Molecular biology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The type of mutation in the",
"      <em>",
"       VHL",
"      </em>",
"      gene impacts the disease phenotype. In particular, patients with missense mutations have a significantly greater risk of developing pheochromocytomas compared with patients carrying truncating mutations or deletions.",
"     </li>",
"     <li>",
"      The alpha subunits of hypoxia-inducible factor-1 and 2 (HIF1 and HIF2) are substrates for the product of the VHL gene. In the absence of VHL-induced degradation, HIF1 and HIF2 may contribute to increased levels of erythropoietin, VEGF, and other growth factors, providing a stimulus for tumor growth. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Hypoxia-inducible factor-1 and 2'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Satisfactory animal models for VHL disease have not yet been developed. Efforts are underway to define the necessary molecular steps required to replicate the human VHL disease phenotype in mice. (See",
"      <a class=\"local\" href=\"#H13348666\">",
"       'Animal models of VHL Disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/1\">",
"      Maher ER, Yates JR, Harries R, et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990; 77:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/2\">",
"      Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet 2003; 361:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/3\">",
"      Maher ER, Kaelin WG Jr. von Hippel-Lindau disease. Medicine (Baltimore) 1997; 76:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/4\">",
"      Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/5\">",
"      Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004; 22:4991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/6\">",
"      Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003; 9:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/7\">",
"      Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002; 2:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/8\">",
"      Sufan RI, Jewett MA, Ohh M. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. Am J Physiol Renal Physiol 2004; 287:F1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/9\">",
"      Barry RE, Krek W. The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis. Trends Mol Med 2004; 10:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/10\">",
"      Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. Curr Opin Genet Dev 2001; 11:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/11\">",
"      Gordan JD, Lal P, Dondeti VR, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008; 14:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/12\">",
"      Koh MY, Lemos R Jr, Liu X, Powis G. The hypoxia-associated factor switches cells from HIF-1&alpha;- to HIF-2&alpha;-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. Cancer Res 2011; 71:4015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/13\">",
"      Koh MY, Darnay BG, Powis G. Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation. Mol Cell Biol 2008; 28:7081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/14\">",
"      Monzon FA, Alvarez K, Peterson L, et al. Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis. Mod Pathol 2011; 24:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/15\">",
"      de Paulsen N, Brychzy A, Fournier MC, et al. Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci U S A 2001; 98:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/16\">",
"      Lolkema MP, Gervais ML, Snijckers CM, et al. Tumor suppression by the von Hippel-Lindau protein requires phosphorylation of the acidic domain. J Biol Chem 2005; 280:22205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/17\">",
"      Kurban G, Hudon V, Duplan E, et al. Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. Cancer Res 2006; 66:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/18\">",
"      Pan J, Snell W. The primary cilium: keeper of the key to cell division. Cell 2007; 129:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/19\">",
"      Simons M, Walz G. Polycystic kidney disease: cell division without a c(l)ue? Kidney Int 2006; 70:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/20\">",
"      Thoma CR, Frew IJ, Hoerner CR, et al. pVHL and GSK3beta are components of a primary cilium-maintenance signalling network. Nat Cell Biol 2007; 9:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/21\">",
"      Frew IJ, Thoma CR, Georgiev S, et al. pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J 2008; 27:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/22\">",
"      Hergovich A, Lisztwan J, Barry R, et al. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol 2003; 5:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/23\">",
"      Hergovich A, Lisztwan J, Thoma CR, et al. Priming-dependent phosphorylation and regulation of the tumor suppressor pVHL by glycogen synthase kinase 3. Mol Cell Biol 2006; 26:5784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/24\">",
"      Thoma CR, Toso A, Gutbrodt KL, et al. VHL loss causes spindle misorientation and chromosome instability. Nat Cell Biol 2009; 11:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/25\">",
"      Pause A, Lee S, Lonergan KM, Klausner RD. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci U S A 1998; 95:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/26\">",
"      Kim J, Jonasch E, Alexander A, et al. Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res 2009; 15:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/27\">",
"      Roe JS, Kim HR, Hwang IY, et al. von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage. Oncogene 2011; 30:3127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/28\">",
"      Li M, Fang X, Baker DJ, et al. The ATM-p53 pathway suppresses aneuploidy-induced tumorigenesis. Proc Natl Acad Sci U S A 2010; 107:14188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/29\">",
"      Roe JS, Kim H, Lee SM, et al. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 2006; 22:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/30\">",
"      Lai Y, Song M, Hakala K, et al. Proteomic dissection of the von Hippel-Lindau (VHL) interactome. J Proteome Res 2011; 10:5175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/31\">",
"      Haase VH, Glickman JN, Socolovsky M, Jaenisch R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci U S A 2001; 98:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/32\">",
"      Hickey MM, Lam JC, Bezman NA, et al. von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis. J Clin Invest 2007; 117:3879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/33\">",
"      Lee CM, Hickey MM, Sanford CA, et al. VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo. Oncogene 2009; 28:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/34\">",
"      Couch V, Lindor NM, Karnes PS, Michels VV. von Hippel-Lindau disease. Mayo Clin Proc 2000; 75:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/35\">",
"      Maher ER, Webster AR, Richards FM, et al. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J Med Genet 1996; 33:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/36\">",
"      Gallou C, Chauveau D, Richard S, et al. Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions. Hum Mutat 2004; 24:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14678/abstract/37\">",
"      Dollfus H, Massin P, Taupin P, et al. Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study. Invest Ophthalmol Vis Sci 2002; 43:3067.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5195 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.96.59.103-74FB0B1AEA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_21_14678=[""].join("\n");
var outline_f14_21_14678=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MOLECULAR BIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hypoxia-inducible factor-1 and 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13348203\">",
"      Extracellular matrix control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13348237\">",
"      Microtubule regulation and cilia centrosome control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13348333\">",
"      Cell cycle control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13348666\">",
"      Animal models of VHL Disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GENE MUTATIONS AND CLINICAL MANIFESTATIONS OF DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5195\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5195|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/26/3503\" title=\"figure 1\">",
"      Oxygen sensor model",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=related_link\">",
"      Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=related_link\">",
"      Regulation of erythropoiesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_21_14679="Dactinomycin: Drug information";
var content_f14_21_14679=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dactinomycin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/5/43092?source=see_link\">",
"    see \"Dactinomycin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/61/8150?source=see_link\">",
"    see \"Dactinomycin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F156394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cosmegen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F156395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cosmegen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F156432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antibiotic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F156398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"     <b>",
"      Note: Medication orders for dactinomycin are commonly written in MICROgrams (eg, 150 mcg) although many regimens list the dose in MILLIgrams (eg, mg/kg or mg/m",
"      <sup>",
"       2",
"      </sup>",
"      ).",
"     </b>",
"     The dose intensity per 2-week cycle should not exceed 15 mcg/kg/day for 5 days or 400-600 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days. Some practitioners recommend calculation of the dosage for obese or edematous adult patients on the basis of body surface area in an effort to relate dosage to lean body mass.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Testicular cancer:",
"     </b>",
"     I.V.: 1000 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 (as part of a combination chemotherapy regimen)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Gestational trophoblastic neoplasm:",
"     </b>",
"     I.V.:  12 mcg/kg/day for 5 days (monotherapy)",
"     <b>",
"      or",
"     </b>",
"     500 mcg/dose days 1 and 2 (as part of a combination chemotherapy regimen)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Wilms' tumor, Ewing&rsquo;s sarcoma, rhabdomyosarcoma:",
"     </b>",
"     I.V.: 15 mcg/kg/day for 5 days (in various combination regimens and schedules)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Regional perfusion",
"     </b>",
"     (dosages and techniques may vary by institution; obese patients and patients with prior chemotherapy or radiation therapy may require lower doses): Lower extremity or pelvis: 50 mcg/kg; Upper extremity: 35 mcg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Osteosarcoma (unlabeled use):",
"     </b>",
"     I.V.: 600 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose days 1, 2, and 3 of weeks 15, 31, 34, 39, and 42 (as part of a combination chemotherapy regimen) (Goorin, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Ovarian (germ cell) tumor (unlabeled use):",
"     </b>",
"     I.V.: 500 mcg/day for 5 days every 4 weeks (in combination with vincristine and cyclophosphamide) (Gershenson, 1985)",
"     <b>",
"      or",
"     </b>",
"     300 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 4 weeks (in combination with vincristine and cyclophosphamide) (Slayton, 1985)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F156417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/61/8150?source=see_link\">",
"      see \"Dactinomycin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"     <b>",
"      Note: Medication orders for dactinomycin are commonly written in MICROgrams (eg, 150 mcg) although many regimens list the dose in MILLIgrams (eg, mg/kg or mg/m",
"      <sup>",
"       2",
"      </sup>",
"      ).",
"     </b>",
"     The dose intensity per 2-week cycle should not exceed 15 mcg/kg/day for 5 days or 400-600 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Wilms' tumor, rhabdomyosarcoma, Ewing&rsquo;s sarcoma:",
"     </b>",
"     Children &gt;6 months:  I.V.: 15 mcg/kg/day for 5 days (in various combination regimens and schedules)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Unlabeled dosing:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Rhabdomyosarcoma:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     VAC regimen:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children &lt;1 year: 25 mcg/kg every 3 weeks, weeks 0 to 45 (in combination with vincristine and cyclophosphamide, and mesna); dose omission required following radiation therapy (Raney, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children &ge;1 year: 45 mcg/kg (maximum dose: 2500 mcg) every 3 weeks, weeks 0 to 45 (in combination with vincristine and cyclophosphamide, and mesna); dose omission required following radiation therapy (Raney, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Wilms&rsquo; tumor:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     DD-4A regimen: 45 mcg/kg on day 1 every 6 weeks for 54 weeks (in combination with doxorubicin and vincristine) (Green, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     EE-4A regimen: 45 mcg/kg on day 1 every 3 weeks for 18 weeks (in combination with vincristine) (Green, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     VAD regimen:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children &lt;1 year: 750 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 6 weeks for 1 year (stage III disease) (in combination with vincristine and doxorubicin) (Pritchard, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children &ge;1 year:  1500 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 6 weeks for 1 year (stage III disease) (in combination with vincristine and doxorubicin) (Pritchard, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Osteosarcoma (unlabeled use):",
"     </b>",
"     I.V.: 600 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose days 1, 2, and 3 of weeks 15, 31, 34, 39, and 42 (as part of a combination chemotherapy regimen) (Goorin, 2003)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F156399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Elderly patients are at increased risk of myelosuppression; dosing should begin at the low end of the dosing range.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F156400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer's labeling; however, based on the amount of urinary excretion, dosage adjustments may not be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13865000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     U.S. labeling: No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Mild impairment: No dosage adjustment provided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Moderate-severe impairment: Dose reduction may be considered; 33% to 50% dose reductions for patients with hyperbilirubinemia have been recommended by some clinicians.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Unlabeled dosing: Any transaminase increase: Reduce dose by 50%; may increase by monitoring toxicities (Floyd, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F156372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 0.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cosmegen&reg;: 0.5 mg [contains mannitol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F156356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F156375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Administer by slow I.V. push or infuse over 10-15 minutes. Avoid extravasation.  Do not filter with cellulose ester membrane filters. Do not administer I.M. or SubQ.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F156438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, aztreonam, cefepime, etoposide phosphate, fludarabine, gemcitabine, granisetron, melphalan, ondansetron, sargramostim, teniposide, thiotepa, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Filgrastim.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F156373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma, metastatic testicular tumors (nonseminomatous), gestational trophoblastic neoplasm; regional perfusion (palliative or adjunctive) of locally recurrent or locoregional solid tumors (sarcomas, carcinomas and adenocarcinomas)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F7879832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of ovarian cancer (germ cell or stromal tumors), osteosarcoma, soft tissue sarcoma (other than rhabdomyosarcoma)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F156441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       DACTINomycin may be confused with Dacogen&reg;, DAPTOmycin, DAUNOrubicin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Actinomycin may be confused with achromycin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F156430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, fever, lethargy, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, alopecia (reversible), cheilitis, erythema multiforme, increased pigmentation, sloughing, or erythema of previously irradiated skin; skin eruptions , Stevens-Johnson syndrome, toxic epidermal necrolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Growth retardation, hyperuricemia, hypocalcemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, dysphagia, esophagitis, GI ulceration, mucositis, nausea, pharyngitis, proctitis, stomatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, anemia, aplastic anemia, febrile neutropenia, leukopenia, myelosuppression (onset: 7 days, nadir: 14-21 days, recovery: 21-28 days), neutropenia, pancytopenia, reticulocytopenia, thrombocytopenia, thrombocytopenia (immune mediated)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Ascites, bilirubin increased, hepatic failure, hepatitis, hepatomegaly, hepatopathy thrombocytopenia syndrome, hepatotoxicity, liver function test abnormality, hepatic sinusoidal obstruction syndrome (SOS; veno-occlusive liver disease)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Erythema, edema, epidermolysis, pain, tissue necrosis, and ulceration (following extravasation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Renal function abnormality",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pneumonitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reaction, infection, sepsis (including neutropenic sepsis)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F156378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dactinomycin or any component of the formulation; patients with concurrent or recent chickenpox or herpes zoster",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F156360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: May cause hepatic sinusoidal obstruction syndrome (SOS; formerly called veno-occlusive liver disease [VOD]), increased risk in children &lt;4 years of age; use with caution in hepatobiliary dysfunction. Monitor for signs or symptoms of hepatic SOS,  including bilirubin &gt;1.4 mg/dL, unexplained weight gain, ascites, hepatomegaly, or unexplained right upper quadrant pain (Arndt, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary malignancies: Long-term observation of cancer survivors is recommended due to the increased risk of second primary tumors following treatment with radiation and antineoplastic agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin irritation/extravasation:",
"     <b>",
"      [U.S. Boxed Warning]:  Extremely irritating to tissues; if extravasation occurs during I.V. use, severe damage to soft tissues will occur; has led to contracture of the arms (rare).",
"     </b>",
"     Recommended for I.V. administration only. The manufacturer recommends intermittent ice (15 minutes 4 times/day) for suspected extravasation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Toxic effects: May be delayed in onset (2-4 days following a course of treatment) and may require 1-2 weeks to reach maximum severity. Discontinue treatment with severe myelosuppression, diarrhea, or stomatitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution; may be associated with an increased risk of myelosuppression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Avoid use in infants &lt;6 months of age (toxic effects may occur more frequently). The risk of fatal hepatic SOS is increased in children &lt;4 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Avoid exposure during pregnancy.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Radiation therapy recipients: Potentiates the effects of radiation therapy; use with caution in patients who have received radiation therapy; reduce dosages in patients who are receiving dactinomycin and radiation therapy simultaneously; combination with radiation therapy may result in increased toxicity (eg, GI toxicity, myelosuppression, severe oropharyngeal mucositis). Erythema from prior radiation therapy may be reactivated by dactinomycin. Avoid dactinomycin use within 2 months of radiation treatment for right-sided Wilms' tumor, may increase the risk of hepatotoxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"     <b>",
"      [U.S. Boxed Warning]: Avoid inhalation of vapors or contact with skin, mucous membrane, or eyes; use appropriate precautions for handling and disposal.",
"     </b>",
"     If accidental exposure occurs, immediately irrigate copiously for at least 15 minutes with water, saline, or balanced ophthalmic irrigation solution (eye exposure) and at least 15 minutes with water (skin exposure); prompt ophthalmic or medical consultation is also recommended. Contaminated clothing should be destroyed and shoes thoroughly cleaned prior to reuse.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dosage expression: Dosage is usually expressed in",
"     <b>",
"      MICRO",
"     </b>",
"     grams and should be calculated on the basis of body surface area (BSA) in obese or edematous adult patients (to relate dose to lean body mass).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Regional perfusion therapy: May result in local limb edema, soft tissue damage, and possible venous thrombosis. Dactinomycin leakage into systemic circulation may result in hematologic toxicity, infection, impaired wound healing, and mucositis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines: Avoid administration of live vaccines during dactinomycin treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F156365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F156368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F156380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated teratogenic effects and fetal loss. Women of childbearing potential are advised not to become pregnant. Use only when potential benefit justifies potential risk to the fetus.",
"     <b>",
"      [U.S. Boxed Warning]: Avoid exposure during pregnancy.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F156406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F156381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if dactinomycin is excreted in human breast milk. According to the manufacturer labeling, due to the potential for serious adverse reactions in the nursing infant, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Cosmegen Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (1): $745.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (DACTINomycin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (1): $705.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F156370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count, liver function tests, and renal function tests; monitor for signs/symptoms of hepatic SOS, including unexplained weight gain, ascites, hepatomegaly, or unexplained right upper quadrant pain (Arndt, 2004)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ac-De (MX);",
"     </li>",
"     <li>",
"      Cosmegen (AR, AT, AU, BE, BG, BR, CH, DE, EE, ES, FI, FR, GB, GR, HN, IE, IT, KP, MT, NL, NO, NZ, PH, PK, PT, PY, RU, SE, SK, TR, TW);",
"     </li>",
"     <li>",
"      Cosmegen, Lyovac (GB, HK);",
"     </li>",
"     <li>",
"      Dacmozen (IN);",
"     </li>",
"     <li>",
"      Dactilon (PE);",
"     </li>",
"     <li>",
"      Dactinomicina Ac-De (PE);",
"     </li>",
"     <li>",
"      Trepar (PH);",
"     </li>",
"     <li>",
"      Zenapax (CZ, DK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F156359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to the guanine portion of DNA intercalating between guanine and cytosine base pairs inhibiting DNA and RNA synthesis and protein synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F156377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Children: Extensive extravascular distribution (59-714 L) (Veal, 2005); does not penetrate blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minimal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~36 hours; Children: Range: 14-43 hours (Veal, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: ~30% in urine and feces within 1week",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Arndt C, Hawkins, D, Anderson JR, et al, &ldquo;Age is a Risk Factor for Chemotherapy-Induced Hepatopathy With Vincristine, Dactinomycin and Cyclophosphamide,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(10):1894-901.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/21/14679/abstract-text/15143082/pubmed\" id=\"15143082\" target=\"_blank\">",
"        15143082",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagshawe KD, &ldquo;High-Risk Metastatic Trophoblastic Disease,&rdquo;",
"      <i>",
"       Obstet Gynecol Clin North Am",
"      </i>",
"      , 1988, 15(3):531-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/21/14679/abstract-text/2852333/pubmed\" id=\"2852333\" target=\"_blank\">",
"        2852333",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berkowitz RS and Goldstein DP, &ldquo;Gestational Trophoblastic Disease,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 1995, 76(10 Suppl):2079-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/21/14679/abstract-text/8635004/pubmed\" id=\"8635004\" target=\"_blank\">",
"        8635004",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blatt J, Trigg ME, Pizzo PA, et al, &ldquo;Tolerance to Single-Dose Dactinomycin in Combination Chemotherapy for Solid Tumors,&rdquo;",
"      <i>",
"       Cancer Treat Rep",
"      </i>",
"      , 1981, 65(1-2):145-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carli M, Pastore G, Perilongo G, et al, &ldquo;Tumor Response and Toxicity After Single High-Dose Versus Standard Five-Day Divided Dose Dactinomycin in Childhood Rhabdomyosarcoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1988, 6(4):654-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/21/14679/abstract-text/3357006/pubmed\" id=\"3357006\" target=\"_blank\">",
"        3357006",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Czauderna P, Katski K, Kowalczyk J, et al, \"Venoocclusive Liver Disease (VOD) as a Complication of Wilms' Tumour Management in the Series of Consecutive 206 Patients,\"",
"      <i>",
"       Eur J Pediatr Surg",
"      </i>",
"      , 2000, 10(5):300-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/21/14679/abstract-text/11194540/pubmed\" id=\"11194540\" target=\"_blank\">",
"        11194540",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      D'Antiga L, Baker A, Pritchard J. et al, \"Veno-Occlusive Disease With Multi-Organ Involvement Following Actinomycin-D,\"",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2001, 37(9):1141-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/21/14679/abstract-text/11378345/pubmed\" id=\"11378345\" target=\"_blank\">",
"        11378345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd J, Mirza I, Sachs B, et al, \"Hepatotoxicity of Chemotherapy,\"",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2006, 33(1):50-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/21/14679/abstract-text/16473644/pubmed\" id=\"16473644\" target=\"_blank\">",
"        16473644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gershenson DM, Copeland LJ, Kavanagh JJ, et al, &ldquo;Treatment of Malignant Nondysgerminomatous Germ Cell Tumors of the Ovary With Vincristine, Dactinomycin, and Cyclophosphamide,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 1985, 56(12):2756-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/21/14679/abstract-text/2996746/pubmed\" id=\"2996746\" target=\"_blank\">",
"        2996746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goorin AM, Schwartzentruber DJ, Devidas M, et al, &ldquo;Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(8):1574-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/21/14679/abstract-text/12697883/pubmed\" id=\"12697883\" target=\"_blank\">",
"        12697883",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Green DM, Breslow NE, Beckwith JB, et al, &ldquo;Effect of Duration of Treatment on Treatment Outcome and Cost of Treatment for Wilms' Tumor: A Report From the National Wilms' Tumor Study Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1998, 16(12):3744-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/21/14679/abstract-text/9850017 /pubmed\" id=\"9850017 \" target=\"_blank\">",
"        9850017",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grier HE, Krailo MD, Tarbell NJ, et al, \"Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of Bone,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(8):694-701.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/21/14679/abstract-text/12594313/pubmed\" id=\"12594313\" target=\"_blank\">",
"        12594313",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011, 12(8):806-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/21/14679/abstract-text/21276754/pubmed\" id=\"21276754\" target=\"_blank\">",
"        21276754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pritchard J, Imeson J, Barnes J, et al, &ldquo;Results of the United Kingdom Children's Cancer Study Group First Wilms' Tumor Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1995, 13(1):124-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/21/14679/abstract-text/7799012/pubmed\" id=\"7799012\" target=\"_blank\">",
"        7799012",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raney RB, Walterhouse DO, Meza JL, et al, &ldquo;Results of the Intergroup Rhabdomyosarcoma Study Group D9602 Protocol, Using Vincristine and Dactinomycin With or Without Cyclophosphamide and Radiation Therapy, for Newly Diagnosed Patients With Low-Risk Embryonal Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(10):1312-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/21/14679/abstract-text/21357783/pubmed\" id=\"21357783\" target=\"_blank\">",
"        21357783",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Slayton RE, Park RC, Silverberg SG, et al, &ldquo;Vincristine, Dactinomycin, and Cyclophosphamide in the Treatment of Malignant Germ Cell Tumors of the Ovary. A Gynecologic Oncology Group Study (A Final Report),&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 1985, 56(2):243-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/21/14679/abstract-text/2988740/pubmed\" id=\"2988740\" target=\"_blank\">",
"        2988740",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sulis ML, Bessmertny O, Granowetter L, et al, \"Veno-Occlusive Disease in Pediatric Patients Receiving Actinomycin D and Vincristine Only for the Treatment of Rhabdomyosarcoma,",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 2004, 26(12):843-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Veal GJ, Cole M, Errington J, et al, &ldquo;Pharmacokinetics of Dactinomycin in a Pediatric Patient Population: A United Kingdom Children's Cancer Study Group Study,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2005, 11(16):5893-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/21/14679/abstract-text/16115931/pubmed\" id=\"16115931\" target=\"_blank\">",
"        16115931",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9318 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-0D0D3C1A28-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_21_14679=[""].join("\n");
var outline_f14_21_14679=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708689\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156394\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156395\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156432\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156398\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156417\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156399\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156400\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13865000\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156372\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156356\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156375\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156438\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156373\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7879832\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156441\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156430\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156378\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156360\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299119\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156365\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156368\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156380\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156406\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156381\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323092\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156370\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869371\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156359\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156377\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9318\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9318|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/5/43092?source=related_link\">",
"      Dactinomycin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/61/8150?source=related_link\">",
"      Dactinomycin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_21_14680="Splinter hemorrages 1";
var content_f14_21_14680=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86420%7EDERM%2F85510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86420%7EDERM%2F85510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Splinter hemorrages of the great toe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 428px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Trauma-induced splinter hemorrages are typically located in the distal nail plate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Nail psoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Onycholysis with erythema of the nail bed and splinter hemorrages in a patient with nail psoriasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_21_14680=[""].join("\n");
var outline_f14_21_14680=null;
var title_f14_21_14681="Nervous system Lyme disease";
var content_f14_21_14681=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nervous system Lyme disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/21/14681/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/21/14681/contributors\">",
"     John J Halperin, MD, FAAN, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/21/14681/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/21/14681/contributors\">",
"     Allen C Steere, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/21/14681/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/21/14681/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/21/14681/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/21/14681/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/21/14681/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 10, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H10939433\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lyme disease is a tick-borne illness caused by three pathogenic species of the spirochete Borrelia (B. burgdorferi, B. afzelii and B. garinii). B. burgdorferi is the sole cause of the disease in the United States. All three pathogenic species occur in Europe, and two (B. afzelii and B. garinii) have been identified in Asia. Lyme disease has a broad spectrum of clinical manifestations, and it also varies in severity due, in part, to differences in the infecting species.",
"   </p>",
"   <p>",
"    The neurologic manifestations of Lyme disease will be reviewed here. Other aspects of Lyme disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link\">",
"     \"Clinical manifestations of Lyme disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7225?source=see_link\">",
"     \"Lyme disease: Clinical manifestations in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link\">",
"     \"Diagnosis of Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link\">",
"     \"Treatment of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10939440\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Borrelia burgdorferi, the organism responsible for the multisystem infectious disease known as Lyme disease, appears to preferentially affect several organ systems. Skin, the site of inoculation, is involved in 80 percent or more of infected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/1\">",
"     1",
"    </a>",
"    ]. Joint involvement occurs frequently in patients in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/2\">",
"     2",
"    </a>",
"    ], but less commonly in Europe. The third most common site is the nervous system, which is involved in 10 to 15 percent of infected individuals in both Europe and the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link\">",
"     \"Clinical manifestations of Lyme disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Just as in neurosyphilis, nervous system involvement begins during early disseminated Lyme disease, when spread of the spirochetes can result in meningeal seeding [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/3\">",
"     3",
"    </a>",
"    ]. As in syphilis, untreated Borrelia infection probably subsides in some patients but becomes chronic in others. Also as in syphilis, appropriate antimicrobial treatment results in microbiologic cure in the overwhelming majority of patients, regardless of the duration of the infection.",
"   </p>",
"   <p>",
"    Much of the confusion and controversy surrounding Lyme disease relates to misunderstandings about what does and does not constitute evidence of nervous system infection. Many patients with Lyme disease develop nonspecific symptoms, including headache, fatigue, cognitive slowing, and memory difficulty. However, these symptoms are also common in many other infectious and inflammatory states. Furthermore, at any point in time, indistinguishable cognitive symptoms occur in as many as 2 percent of otherwise healthy people [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/4\">",
"     4",
"    </a>",
"    ], and these symptoms can have a significant impact on the quality of life.",
"   </p>",
"   <p>",
"    Emphasis on these nonspecific symptoms in early studies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/5-7\">",
"     5-7",
"    </a>",
"    ] led some to the erroneous conclusion that such symptoms had a degree of specificity for Lyme disease. This misunderstanding was one of the elements that contributed to misconceptions about which individuals required treatment for Lyme disease, what constituted effective treatment, and how to define cure.",
"   </p>",
"   <p>",
"    An accurate understanding of nervous system Lyme disease is best addressed by considering the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The true scope of nervous system disorders attributable to Lyme disease and the pathophysiologic mechanisms of each",
"     </li>",
"     <li>",
"      Available diagnostic tools",
"     </li>",
"     <li>",
"      Appropriate treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two often repeated assertions are more misleading than helpful &mdash; first, that the diagnosis of Lyme disease is primarily a clinical diagnosis, and second, that Lyme disease can mimic many other diseases. Both are particularly problematic when it comes to nervous system disease, since many clinicians have difficulty differentiating between true nervous system disorders and the effects of extra-neurologic disease on behavior and cognitive function. This difficulty is compounded by phenomenology-based assertions that \"Lyme disease can do anything\" in the nervous system. Such statements represent a failure to recognize the common pathophysiologic threads that unify the disparate clinical phenomena seen in this disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10939447\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphocytic meningitis, cranial neuropathy (particularly facial palsy) and radiculoneuritis (motor or sensory or both) constitute the classic triad of acute, early neurologic Lyme disease. These manifestations may occur alone or in combination, but radiculoneuritis is less common than meningitis or facial palsy.",
"   </p>",
"   <p>",
"    Lyme disease is often described, by analogy to syphilis, as having three stages: early (or acute) localized disease (erythema migrans), early disseminated disease, and late disseminated disease (",
"    <a class=\"graphic graphic_table graphicRef72018 \" href=\"UTD.htm?39/7/40060\">",
"     table 1",
"    </a>",
"    ). Since arbitrary stages convey little information, and since the separation between early and late disease is less clear-cut than in syphilis, we prefer to use descriptive terminology to discuss nervous system Lyme disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations of Lyme disease in adults\", section on 'Clinical stages'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7225?source=see_link\">",
"     \"Lyme disease: Clinical manifestations in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By definition, nervous system involvement only occurs in disseminated Lyme disease. Specific syndromes tend to be divided into those with fairly abrupt onset and dramatic presentations (eg, meningitis, facial nerve palsy, radiculoneuritis, focal encephalitis) and those with more indolent onset and protracted courses (eg, diffuse polyneuropathy). Acute neurologic involvement usually occurs weeks to several months after the tick bite and may be the first manifestation of Lyme disease. It is distinctly unusual for acute facial nerve palsy or meningitis to occur many months or years after the initial infection. In contrast, certain neurologic problems, such as a more indolent, disseminated polyneuropathy, may develop months to a few years after the initial infection.",
"   </p>",
"   <p>",
"    It is unknown whether the time course of these syndromes is related to differences in spirochetal strain, inoculum size, or host response. However, the syndromes associated with abrupt onset typically occur early in infection (within the first few months), whereas those that are more indolent and protracted often present later in the course (eg, many months after initial infection).",
"   </p>",
"   <p>",
"    Consideration of the clinical findings of nervous system Lyme disease is divided into disorders of the peripheral versus central nervous systems. In both, the predominant mechanism appears to be multifocal inflammatory involvement of the affected structure, be it patchy peripheral nerve involvement or, rarely, patchy inflammation of the central nervous system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10939454\">",
"    <span class=\"h2\">",
"     Peripheral nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral nerve disorders can be broadly divided into those due to axon damage, those caused by abnormalities of myelin, and those related to multifocal damage &ndash; the last typically due to a vasculopathic process such as vasculitis or diabetes. Detailed studies in patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/8\">",
"     8",
"    </a>",
"    ] and in experimentally infected rhesus macaque monkeys [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/9\">",
"     9",
"    </a>",
"    ] indicate that peripheral nerve involvement in Lyme disease primarily consists of a multifocal axonal process. Although pathologic studies indicate a role for inflammation, and treatment responsiveness indicates an essential role for active infection, the pathophysiology is not well understood. Spirochetes cannot be demonstrated in peripheral nerve and immunologic cross reactivity theories have not been proven.",
"   </p>",
"   <p>",
"    In early disease, two peripheral nerve manifestations are particularly common (",
"    <a class=\"graphic graphic_table graphicRef77485 \" href=\"UTD.htm?2/58/2987\">",
"     table 2",
"    </a>",
"    ) and form part of the classic triad of meningitis, cranial neuritis, and radiculoneuritis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Both radiculoneuritis and cranial neuropathy often, but not invariably, occur in conjunction with lymphocytic meningitis. In other bacterial meningitides, such cranial nerve and spinal root involvement occurs due to damage as these structures pass through the infected, inflamed subarachnoid space. In contrast, this does",
"    <strong>",
"     not",
"    </strong>",
"    appear to be the mechanism in Lyme disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10939461\">",
"    <span class=\"h3\">",
"     Cranial neuropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cranial neuropathies associated with Lyme disease tend to occur early in infection and are usually abrupt in onset. Virtually any cranial nerve can be involved, but the seventh (facial) is by far the most common, occurring in 8 percent of CDC confirmed cases of Lyme disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/12\">",
"     12",
"    </a>",
"    ]. Most patients have quite elevated concentrations of anti-B. burgdorferi antibody in their peripheral blood, often with a prominent IgM component. Occasionally the cranial neuropathy occurs before the patient has become seropositive; in such patients, a follow-up titer in several weeks is typically diagnostic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link\">",
"     \"Diagnosis of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since facial nerve palsy is uncommon in children, Lyme disease should be strongly considered as the cause of facial nerve palsy affecting a child who has been in an endemic area. In adults in endemic areas, during spring through fall, a significant percentage of facial nerve palsies are attributable to Lyme disease. In one study in an endemic region, one quarter of cases of facial nerve palsy in the summer were likely due to Lyme disease, based upon serologies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/13\">",
"     13",
"    </a>",
"    ]. Involvement can be bilateral, with onset being either simultaneous or in rapid succession. Because bilateral facial nerve palsies are generally uncommon, such cases should bring Lyme disease to mind in patients with potential recent exposure. The differential diagnosis of bilateral facial nerve palsies is limited and includes sarcoidosis, Guillain-Barr&eacute; syndrome, HIV infection and other basilar meningitides.",
"   </p>",
"   <p>",
"    Although facial nerve involvement represents about 80 percent of all Lyme disease-associated cranial neuropathies, other nerves can be affected. Involvement of the nerves innervating the extraocular muscles, the 8th cranial nerve (vestibulocochlear), occasionally the trigeminal, and, infrequently the lower cranial nerves has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/14\">",
"     14",
"    </a>",
"    ]. Papilledema (swelling of the optic nerve head due to transmitted raised intracranial pressure) and papillitis (inflammation of the optic nerve head) have been well described [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Retrospective data suggest that optic neuritis (inflammation of a cranial nerve which is actually part of the central nervous system) occurs rarely, if ever [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10939468\">",
"    <span class=\"h3\">",
"     Radiculoneuritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The other common peripheral nerve manifestation of Lyme disease, and probably the most commonly missed diagnosis, is Lyme radiculoneuritis, which is reported in 3 percent of CDC verified cases of Lyme disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/12\">",
"     12",
"    </a>",
"    ]. This disorder can mimic a mechanical radiculopathy (eg, sciatica) with radicular pain in one or several dermatomes, accompanied by corresponding sensory, motor and reflex changes. In the European literature, involvement is said to parallel the site of the tick bite [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]; this has not been addressed systematically in the United States. Pain is often a prominent element. This disorder should be considered in patients in endemic areas presenting in spring through autumn with severe limb or truncal radicular pain without an apparent mechanical precipitant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30180706\">",
"    <span class=\"h3\">",
"     Bannwarth syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In European neuroborreliosis, the term Garin-Bujadoux-Bannwarth syndrome (or Bannwarth syndrome) has been applied to the constellation of painful radiculoneuritis, often accompanied by meningitis with minimal headache and sometimes with cranial neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Thus, painful radiculoneuritis is usually the hallmark of the syndrome. In the United States, radiculoneuritis is a less prominent part of the picture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10939475\">",
"    <span class=\"h3\">",
"     Other forms of peripheral nerve involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although less common than cranial neuropathy and radiculoneuritis, other forms of peripheral nerve involvement may occur with Lyme disease, and probably represent variants of mononeuropathy multiplex. Early in infection, these include acute disorders such as brachial and lumbosacral plexopathies and mononeuropathies. Later in untreated infection, patients can develop what is referred to as a confluent mononeuropathy multiplex. This type of disorder causes a clinical picture simulating a distal polyneuropathy and appears to reflect involvement of multiple small nerve branches [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/8,21\">",
"     8,21",
"    </a>",
"    ]. Although rare cases of demyelinating neuropathies have been reported in Lyme disease, these are so infrequent as to likely be coincidental [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10939483\">",
"    <span class=\"h2\">",
"     Central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system involvement in Lyme disease can take several forms. The most common is lymphocytic meningitis. Rarely, inflammation of the brain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    spinal cord parenchyma (an encephalomyelitis) can occur. Some children, most of whom had Lyme meningitis, have presented with a picture resembling pseudotumor cerebri.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24976699\">",
"    <span class=\"h3\">",
"     Meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphocytic meningitis, alone or in combination with cranial nerve or spinal nerve root involvement, represents the most common form of central nervous system involvement (",
"    <a class=\"graphic graphic_table graphicRef72123 \" href=\"UTD.htm?3/8/3211\">",
"     table 3",
"    </a>",
"    ). Clinically, the lymphocytic meningitis of Lyme disease is largely indistinguishable from viral meningitis, with headache, fever, other systemic symptoms, photosensitivity, and neck stiffness. Studies in children suggest that it has a slightly more indolent onset than viral meningitis, with a few more days elapsing between the first symptom and clinical presentation. Proposed algorithms to separate Lyme meningitis from viral meningitis rely on this somewhat less abrupt onset coupled with the presence of other findings suggestive of Lyme disease, such as the percentage of mononuclear cells in the cerebrospinal fluid and the presence of cranial neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/24\">",
"     24",
"    </a>",
"    ]. Among Lyme disease cases verified by the CDC, approximately 2 percent have meningitis in isolation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/12\">",
"     12",
"    </a>",
"    ]. Many patients with peripheral or cranial nerve involvement have inflammatory cerebrospinal fluid. Meningeal symptoms in these individuals are highly variable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42451729\">",
"    <span class=\"h3\">",
"     Lyme encephalomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;European patients who have Bannwarth syndrome with radicular symptoms (see",
"    <a class=\"local\" href=\"#H30180706\">",
"     'Bannwarth syndrome'",
"    </a>",
"    above) occasionally have segmental spinal cord involvement at the same level as the affected nerve root [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. This has been emphasized far less in the US literature. There have been rare observations in both the US and Europe of an inflammatory encephalomyelitis associated with Lyme disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Lyme encephalomyelitis represents a true infection of the neuraxis (",
"    <a class=\"graphic graphic_table graphicRef57155 \" href=\"UTD.htm?6/4/6219\">",
"     table 4",
"    </a>",
"    ) that can superficially resemble multiple sclerosis, with inflammatory-appearing parenchymal abnormalities on brain or spinal cord MRI and inflammatory changes in the cerebrospinal fluid, including increased total immunoglobulin synthesis and oligoclonal bands. Years ago this disorder was estimated to occur in one person per million at risk per year. The true incidence is probably even lower now that Lyme disease is better recognized and more likely to be treated early.",
"   </p>",
"   <p>",
"    Lyme encephalomyelitis is highly responsive to appropriate antimicrobial therapy. However, like any process affecting the central nervous system, there may be neurologic impairments caused by injury that occurred prior to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42451858\">",
"    <span class=\"h3\">",
"     Benign intracranial hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pseudotumor cerebri-like picture (benign intracranial hypertension) occurs with increased frequency in children with Lyme disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/16,30,31\">",
"     16,30,31",
"    </a>",
"    ]. Virtually all of the reported cases have had inflammatory cerebrospinal fluid, suggesting that the increased intracranial pressure is a result of meningitis, in contradistinction to the usual picture of pseudotumor in which the cerebrospinal fluid profile is normal. Regardless of the mechanism, the symptoms and potential consequences are identical, including compression of cranial nerves with a particular threat to the optic nerves and vision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10939490\">",
"    <span class=\"h3\">",
"     Encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early studies found that many patients with Lyme disease described fatigue, cognitive slowing, and memory difficulty [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/7\">",
"     7",
"    </a>",
"    ]. However, these symptoms are nonspecific and are frequent concomitants of many inflammatory disorders. They are not, in isolation, diagnostic of either Lyme disease or brain infection. In fact, the term &ldquo;encephalopathy&rdquo; was used to describe this state since this term is most often used to indicate alterations in brain function due to non-neurologic causes. Subsequent work demonstrated that only in rare instances were these symptoms associated with brain infection (ie, a mild encephalitis). In such cases, the diagnosis was readily confirmed by cerebrospinal fluid abnormalities and brain MRI findings [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/5,32-34\">",
"     5,32-34",
"    </a>",
"    ]. In the absence of such objective evidence of brain infection, these symptoms should",
"    <strong>",
"     not",
"    </strong>",
"    be considered evidence of nervous system infection with B. burgdorferi or any other organism.",
"   </p>",
"   <p>",
"    In those instances where nervous system infection can be demonstrated, standard antimicrobial therapy is effective. Multiple studies have shown that prolonged antimicrobial treatment offers such patients no lasting benefit but carries significant risk [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link&amp;anchor=H26#H26\">",
"     \"Treatment of Lyme disease\", section on 'Post-Lyme disease syndrome and chronic Lyme disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10939497\">",
"    <span class=\"h2\">",
"     Post Lyme disease syndrome and chronic Lyme disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A particular challenge has been the sizable population of individuals labeled by some practitioners and patient advocacy groups as having \"chronic Lyme disease\" on the basis of nonspecific symptoms including persistent musculoskeletal pain, cognitive problems, and fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. In a minority of patients, these symptoms have followed microbiologically successful treatment of Lyme disease, a condition termed \"post Lyme disease syndrome\". However, all objective evidence indicates that these individuals, while suffering from debilitating symptoms, do",
"    <strong>",
"     not",
"    </strong>",
"    have chronic infection with B. burgdorferi and that antibiotic treatment is",
"    <strong>",
"     not",
"    </strong>",
"    beneficial. In its typical usage, &ldquo;chronic Lyme disease&rdquo; includes the post-Lyme disease syndrome, as well as illnesses and symptom complexes for which there is no convincing scientific evidence of any relationship to B. burgdorferi infection. Regardless of its etiology, this symptom complex is remarkably common [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/4\">",
"     4",
"    </a>",
"    ], is highly disruptive to day-to-day function, and is poorly understood. These problems are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical manifestations of Lyme disease in adults\", section on 'Post-Lyme disease syndrome and chronic Lyme disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10939504\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of nervous system Lyme disease rests on three elements:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Since the disease is transmitted exclusively by bites of Ixodes ticks, there must be the possibility of exposure",
"     </li>",
"     <li>",
"      The clinical disorder should include objective evidence of nervous system Lyme disease",
"     </li>",
"     <li>",
"      Laboratory testing (positive Lyme serologies with or without positive cerebrospinal fluid [CSF] Lyme antibodies) should support the diagnosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4821958\">",
"    <span class=\"h2\">",
"     Serologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the exception of the first four to six weeks of infection, when the specific immune response may not yet have developed sufficiently to provide a measurable antibody response, serologic testing for antibodies to B. burgdorferi is highly sensitive and specific for the diagnosis of Lyme disease, particularly when using the two-tier approach described below. Apart from those uncommon instances when cranial neuropathies or radiculopathies occur during this very early time window, the diagnosis of nervous system Lyme disease should be made only with extreme caution in patients who are seronegative. Although years ago a few patients were described in whom antibodies were demonstrable in CSF but not blood [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/41\">",
"     41",
"    </a>",
"    ], this is extraordinarily rare with current assays. Thus, aside from the setting when cranial neuropathies or radiculopathies occur in the first six weeks of infection, the absence of detectable antibodies in the serum is strong evidence against the diagnosis.",
"   </p>",
"   <p>",
"    The two-tier strategy, which is recommended by the US Centers for Disease Control and Prevention, uses a sensitive enzyme-linked immunosorbent assay (ELISA) followed by a Western blot. An immunofluorescent assay (IFA) may be substituted for the ELISA. If the ELISA is positive or equivocal, then the same serum sample should be tested by Western blot (IgM and IgG immunoblots if early disease is suspected; IgG Western blot alone if late disease is suspected). If the ELISA is negative, the sample needs no further testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnosis of Lyme disease\", section on 'Indications for serologic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4821965\">",
"    <span class=\"h2\">",
"     CSF analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting with Lyme meningitis, which usually occurs several weeks after erythema migrans, typically have a modest cerebrospinal fluid (CSF) pleocytosis of up to several hundred lymphocytes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    monocytes per mm",
"    <sup>",
"     3",
"    </sup>",
"    ; the median count in acute neuroborreliosis is approximately 160",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. The CSF protein concentration is usually moderately elevated, and is typically no greater than about 200 to 300",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    The CSF glucose concentration is relatively normal.",
"   </p>",
"   <p>",
"    Although headache and neck stiffness are common early symptoms in patients with erythema migrans, particularly with multifocal erythema migrans, a CSF pleocytosis is not necessarily present in these individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4821972\">",
"    <span class=\"h3\">",
"     CSF antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with suspected central nervous system Lyme disease (ie, Lyme meningitis or encephalomyelitis), testing the CSF for intrathecal production of antibodies to B. burgdorferi is useful for establishing the diagnosis. This test is not applicable if involvement is limited to the peripheral nervous system. Even in central nervous system disease, the sensitivity remains unclear. A negative test for Lyme antibodies in the CSF does not exclude central nervous system Lyme disease.",
"   </p>",
"   <p>",
"    As in other infections, in nervous system Lyme disease, specific B cells may migrate to the central nervous system and proliferate locally, resulting in intrathecal production of antibodies to B. burgdorferi. However, even in the absence of nervous system Lyme disease, a substantial proportion of B. burgdorferi-specific antibodies diffuse from the serum to the CSF. Therefore, the presence of B. burgdorferi-specific antibodies in CSF does not itself establish the presence of central nervous system Lyme disease or prove that there is local production of antibodies. Proof requires the simultaneous measurement of B. burgdorferi-specific antibodies in the serum and CSF, adjusting for the total immunoglobulin concentration in each fluid. This can be accomplished by dilution of serum and CSF so that they have the same final concentration of total IgG antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/28\">",
"     28",
"    </a>",
"    ], followed by measurement of B. burgdorferi-specific antibodies in both compartments; a higher level in the CSF compared with the serum suggests local production of specific antibodies in the CSF. Alternatively an antibody capture enzyme immunoassay [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/44\">",
"     44",
"    </a>",
"    ] can be used to obtain these proportions more directly.",
"   </p>",
"   <p>",
"    Although CSF or serum B. burgdorferi antibody concentrations typically decline after treatment, these antibodies may persist for 10 or more years following successful treatment. Thus, determination of active neuroborreliosis requires combining these results with less specific measures of active central nervous system inflammation (ie, a CSF pleocytosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elevated protein).",
"   </p>",
"   <p>",
"    CSF B. burgdorferi antibody measurement is highly specific for nervous system Lyme disease, with cross-reactions occurring primarily in neurosyphilis. However, neurosyphilis usually results in production of reaginic antibodies in the CSF, such as those measured in the venereal disease research laboratory (VDRL) test, and Lyme disease does not. Thus, differentiating between these two spirochetal infections is generally straightforward.",
"   </p>",
"   <p>",
"    Determination of test sensitivity is far more challenging, primarily because the studies that have addressed this issue have used quite different patient populations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. In Europe, where local production of anti-B. burgdorferi antibody was long considered a requirement for diagnosis, sensitivity is reportedly over 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/41,47\">",
"     41,47",
"    </a>",
"    ]. Similarly, in some studies of Lyme meningitis from the United States, sensitivity was approximately 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/28\">",
"     28",
"    </a>",
"    ]. However, in a more heterogeneous population of patients from the US, sensitivity was lower [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/44\">",
"     44",
"    </a>",
"    ]. In a patient with a clinical picture suggesting Lyme disease, a positive study from a reputable laboratory should be viewed as significant evidence in favor of the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/28\">",
"     28",
"    </a>",
"    ]. However, negative CSF studies should not eliminate neurologic Lyme disease from consideration if clinical circumstances support the diagnosis.",
"   </p>",
"   <p>",
"    As in other infections in which there is a prominent antibody response, when nervous system Lyme disease has been present long enough for the B cell response to mature, there are often increases not only in specific anti-B. burgdorferi antibodies but also in nonspecific immunoglobulin concentrations. Measures such as the IgG synthesis rate or IgG index can be elevated, and, particularly in patients in Europe with central nervous system Lyme disease, oligoclonal bands can be seen in the CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/32,48\">",
"     32,48",
"    </a>",
"    ]. The frequency with which these findings are found has varied widely among series. The important point is that oligoclonal bands and increased IgG synthesis occur in infections including central nervous system Lyme disease, and consequently do not help differentiate these disorders from multiple sclerosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35130?source=see_link&amp;anchor=H12#H12\">",
"     \"Diagnosis of multiple sclerosis in adults\", section on 'Oligoclonal bands'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4822015\">",
"    <span class=\"h3\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The polymerase chain reaction (PCR) for B. burgdorferi can be performed on CSF, although it has low sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/49\">",
"     49",
"    </a>",
"    ], probably reflecting the very low number of organisms typically present in spinal fluid. Between this low sensitivity, and a tendency for some laboratories to have difficulty avoiding false positives, the positive and negative predictive values both tend to be low, rendering this test of marginal utility. For that reason, PCR is not recommended for routine testing of CSF in Lyme disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link&amp;anchor=H29#H29\">",
"     \"Diagnosis of Lyme disease\", section on 'Polymerase chain reaction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43076349\">",
"    <span class=\"h3\">",
"     CXCL13",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although elevated concentrations of CXCL13 are not unique to active nervous system Lyme disease, when combined with other diagnostic information, they might serve as a marker of disease activity or response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/50\">",
"     50",
"    </a>",
"    ]. Like patients with neurosyphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/51\">",
"     51",
"    </a>",
"    ], patients with acute untreated nervous system Lyme disease and a CSF pleocytosis have elevated CSF concentrations of the chemokine B lymphocyte chemoattractant, CXCL13 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/52\">",
"     52",
"    </a>",
"    ]. Among 17 such patients, concentrations of CXCL13 were proportionately greater in CSF than in serum and were highly elevated in all CSF samples compared with the CSF of 178 controls without nervous system Lyme disease (mean 15,149",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    versus 247",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/52\">",
"     52",
"    </a>",
"    ]. Five patients who had received at least two weeks of treatment for nervous system Lyme disease did not have substantially elevated CXCL13 concentrations (mean 202",
"    <span class=\"nowrap\">",
"     pg/mL),",
"    </span>",
"    whereas five patients who had been treated for less than two weeks had slightly elevated CXCL13 concentrations (mean 1412",
"    <span class=\"nowrap\">",
"     pg/mL).",
"    </span>",
"    Among the 178 controls, seven had an elevated CXCL13 concentration, five with CNS lymphoma and two with bacterial meningitis. Relapsing-remitting multiple sclerosis has also been reported to cause elevated levels of CXCL13 in the CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations, coupled with polymerase chain reaction-based findings in patients with early nervous system Lyme disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/3\">",
"     3",
"    </a>",
"    ], and the frequent description of increased immunoglobulin production including the presence of oligoclonal bands in CSF of neuroborreliosis patients, suggest the following pathophysiologic sequence. Spirochetes invade the central nervous system very early in infection and elicit a vigorous innate immunity-triggered B cell response, leading to prolonged antibody production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4822126\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since Lyme encephalomyelitis is so rare, MRI of the brain and spine is only rarely abnormal in Lyme disease. When present, encephalomyelitis is evident on MRI as areas of increased signal on T2 and FLAIR sequences [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/54\">",
"     54",
"    </a>",
"    ] When these areas are large and active, positron emission tomography (PET) demonstrates them to be hypermetabolic [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Single photon emission computed tomographic (SPECT) brain scans have been used with increasing frequency. In one study, quantitative SPECT, applied in a highly selected group of patients with well-characterized nervous system Lyme disease, demonstrated patchy brain hypometabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/56\">",
"     56",
"    </a>",
"    ]. However qualitative brain SPECT, the technique used in clinical laboratories, is highly variable even in normal patients, and has no positive or negative predictive value in nervous system Lyme disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H445548\">",
"    <span class=\"h2\">",
"     Electrophysiologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a peripheral neuropathy, electrophysiologic assessment (electromyography and nerve conduction studies) can be helpful. In such patients, these studies typically reveal findings consistent with a patchy axonal polyneuropathy (ie, a mononeuropathy multiplex) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24976859\">",
"    <span class=\"h2\">",
"     Approach to diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of the patient with possible nervous system Lyme disease must be tailored to the specific presentation. In a patient with possible meningitis, cerebrospinal fluid (CSF) examination is mandatory to exclude other, potentially more dangerous pathogens. In these circumstances, CSF studies should include cell count and differential, protein and glucose concentrations, and gram stain and bacterial cultures. CSF and serum should both be studied for anti-B. burgdorferi antibodies and VDRL should be measured. Assessment for oligoclonal bands and IgG synthesis can be informative but is not usually essential. Other potential causes of meningitis should be addressed specifically as appropriate, with testing for herpes simplex virus, West Nile virus, enteroviruses,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other organisms as suggested by individual circumstances. Neuroimaging of the appropriate segment of the neuraxis, preferably by MRI, should precede the lumbar puncture if the patient has clinical evidence of parenchymal brain involvement. Depending on the findings on imaging, additional CSF studies might include oligoclonal bands and IgG synthesis, CSF cytology",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other studies as dictated by the specific circumstances.",
"   </p>",
"   <p>",
"    Whether or not to assess CSF in patients with facial nerve palsy or Garin-Bujadoux-Bannwarth syndrome (see",
"    <a class=\"local\" href=\"#H30180706\">",
"     'Bannwarth syndrome'",
"    </a>",
"    above) is a subject of debate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/57\">",
"     57",
"    </a>",
"    ]. Although European authorities generally favor doing this, multiple European studies have shown that oral antibiotics are as effective as parenteral regimens in Lyme meningitis and in the Garin-Bujadoux-Bannwarth syndrome. In light of this, a reasonable approach would be to perform a lumbar puncture if the diagnosis is unclear, but to simply administer oral antibiotics to patients with recent exposure, a positive serology and an appropriate clinical syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/58\">",
"     58",
"    </a>",
"    ]. In patients with nonfocal cognitive difficulties, memory or psychiatric issues, and nothing to suggest Lyme meningitis or encephalomyelitis, brain imaging and CSF examinations are rarely abnormal. Neuropsychologic testing can help quantitate deficits in such individuals, but generally lacks sufficient specificity to prove that a problem is or is not due to Lyme disease.",
"   </p>",
"   <p>",
"    In patients with peripheral nerve involvement, electrophysiologic assessment (electromyography and nerve conduction studies) can be helpful in assessing both the type and distribution of nerve damage. This may be unnecessary in patients with simple facial nerve palsy, but can be helpful in more complex situations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10939511\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Infectious Diseases Society of America and the American Academy of Neurology published practice guidelines for the treatment of Lyme disease in the United States in 2006 and 2007, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Antibiotic regimens for the treatment of B. burgdorferi infection are summarized in the following table (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"     table 5",
"    </a>",
"    ). The treatment of nervous system Lyme disease in the United States is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of Lyme disease\", section on 'Acute neurologic manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link&amp;anchor=H22#H22\">",
"     \"Treatment of Lyme disease\", section on 'Late neurologic findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lyme meningitis is generally self limited, even without treatment. Although now routinely treated, early studies suggested Bannwarth syndrome (painful radiculoneuritis) can be persistent but generally subsides after weeks or months in the absence of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14681/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/40/30338?source=see_link\">",
"       \"Patient information: Lyme disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/17/32022?source=see_link\">",
"       \"Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/0/27649?source=see_link\">",
"       \"Patient information: Lyme disease prevention (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/41/5778?source=see_link\">",
"       \"Patient information: Lyme disease treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10939518\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nervous system involvement only occurs in disseminated Lyme disease. (See",
"      <a class=\"local\" href=\"#H10939447\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In early Lyme disease, two peripheral nerve manifestations (cranial neuropathy and radiculoneuritis) are particularly common (",
"      <a class=\"graphic graphic_table graphicRef77485 \" href=\"UTD.htm?2/58/2987\">",
"       table 2",
"      </a>",
"      ) and form part of the classic triad of meningitis, cranial neuritis, and radiculoneuritis. (See",
"      <a class=\"local\" href=\"#H10939454\">",
"       'Peripheral nervous system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common form of central nervous system Lyme involvement is lymphocytic meningitis that is often associated with cranial neuropathy or radiculoneuritis (",
"      <a class=\"graphic graphic_table graphicRef72123 \" href=\"UTD.htm?3/8/3211\">",
"       table 3",
"      </a>",
"      ). There have been rare observations of an inflammatory encephalomyelitis associated with Lyme disease. (See",
"      <a class=\"local\" href=\"#H10939483\">",
"       'Central nervous system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fatigue, cognitive slowing and memory difficulty are nonspecific symptoms and are not, in isolation, diagnostic of either Lyme disease or brain infection. (See",
"      <a class=\"local\" href=\"#H10939490\">",
"       'Encephalopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of nervous system Lyme disease rests on three elements (see",
"      <a class=\"local\" href=\"#H10939504\">",
"       'Diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Since the disease is transmitted exclusively by bites of Ixodes ticks, there must be the possibility of exposure",
"     </li>",
"     <li>",
"      The clinical disorder should include features that have been associated with nervous system Lyme disease",
"     </li>",
"     <li>",
"      Laboratory testing (positive Lyme serologies with or without positive Lyme antibodies in the cerebrospinal fluid) should support the diagnosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With the exception of the first four to six weeks of infection, serologic testing is highly sensitive and specific for the diagnosis of Lyme disease, particularly when using the CDC-recommended two-tier approach. Except in those uncommon instances when cranial neuropathies or radiculopathies occur in this very early time window, the diagnosis of nervous system Lyme disease should be made only with extreme caution in patients who are seronegative. The absence of detectable antibodies in the serum is usually strong evidence against the diagnosis. (See",
"      <a class=\"local\" href=\"#H4821958\">",
"       'Serologic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A cerebrospinal fluid (CSF) pleocytosis (typically lymphocytic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      monocytic), a moderately elevated protein concentration, and a relatively normal glucose concentration are often seen in patients presenting with Lyme meningitis several weeks into the infection. (See",
"      <a class=\"local\" href=\"#H4821965\">",
"       'CSF analysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory testing must be tailored to the individual circumstances (see",
"      <a class=\"local\" href=\"#H24976859\">",
"       'Approach to diagnostic testing'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      When considering meningitis, the CSF should be examined, primarily to exclude other diagnoses. CSF and serum assessment for anti-B. burgdorferi antibodies can be informative if an inflammatory CNS process is apparent. PCR for B. burgdorferi is of extremely limited utility and is not recommended for routine testing of CSF in Lyme disease.",
"     </li>",
"     <li>",
"      CSF analysis is of limited utility if disease is limited to the peripheral nervous system.",
"     </li>",
"     <li>",
"      MRI of the neuraxis is helpful when symptoms or clinical findings point to a focal process, primarily to exclude other diagnoses.",
"     </li>",
"     <li>",
"      Electrophysiologic testing (electromyography and nerve conduction studies) can be helpful in addressing the differential diagnosis, particularly if peripheral nerve involvement is disseminated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of nervous system Lyme disease is discussed in detail separately (",
"      <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link&amp;anchor=H14#H14\">",
"       \"Treatment of Lyme disease\", section on 'Acute neurologic manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link&amp;anchor=H22#H22\">",
"       \"Treatment of Lyme disease\", section on 'Late neurologic findings'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/1\">",
"      Gerber MA, Shapiro ED, Burke GS, et al. Lyme disease in children in southeastern Connecticut. Pediatric Lyme Disease Study Group. N Engl J Med 1996; 335:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Lyme disease--United States, 2001-2002. MMWR Morb Mortal Wkly Rep 2004; 53:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/3\">",
"      Luft BJ, Steinman CR, Neimark HC, et al. Invasion of the central nervous system by Borrelia burgdorferi in acute disseminated infection. JAMA 1992; 267:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/4\">",
"      Luo N, Johnson JA, Shaw JW, et al. Self-reported health status of the general adult U.S. population as assessed by the EQ-5D and Health Utilities Index. Med Care 2005; 43:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/5\">",
"      Halperin JJ, Krupp LB, Golightly MG, Volkman DJ. Lyme borreliosis-associated encephalopathy. Neurology 1990; 40:1340.",
"     </a>",
"    </li>",
"    <li>",
"     Halperin, JJ, Heyes, MP, Keller, TL, Whitman, M. Neuroborreliosis - encephalopathy vs encephalitis. Proceedings of the Vth International Conference on Lyme Borreliosis, Arlington, Virginia, May 1992. Abstr. 1. 1992:1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/7\">",
"      Halperin JJ, Pass HL, Anand AK, et al. Nervous system abnormalities in Lyme disease. Ann N Y Acad Sci 1988; 539:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/8\">",
"      Halperin J, Luft BJ, Volkman DJ, Dattwyler RJ. Lyme neuroborreliosis. Peripheral nervous system manifestations. Brain 1990; 113 ( Pt 4):1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/9\">",
"      England JD, Bohm RP Jr, Roberts ED, Philipp MT. Mononeuropathy multiplex in rhesus monkeys with chronic Lyme disease. Ann Neurol 1997; 41:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/10\">",
"      Garin C, Bujadoux A. Paralysis by ticks. 1922. Clin Infect Dis 1993; 16:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/11\">",
"      Reik L, Steere AC, Bartenhagen NH, et al. Neurologic abnormalities of Lyme disease. Medicine (Baltimore) 1979; 58:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/12\">",
"      Centers for Disease Control and Prevention (CDC). Lyme disease--United States, 2003-2005. MMWR Morb Mortal Wkly Rep 2007; 56:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/13\">",
"      Halperin JJ, Golightly M. Lyme borreliosis in Bell's palsy. Long Island Neuroborreliosis Collaborative Study Group. Neurology 1992; 42:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/14\">",
"      Halperin JJ. Lyme disease and the peripheral nervous system. Muscle Nerve 2003; 28:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/15\">",
"      Sibony P, Halperin J, Coyle PK, Patel K. Reactive Lyme serology in optic neuritis. J Neuroophthalmol 2005; 25:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/16\">",
"      Rothermel H, Hedges TR 3rd, Steere AC. Optic neuropathy in children with Lyme disease. Pediatrics 2001; 108:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/17\">",
"      H&ouml;rstrup P, Ackermann R. [Tick born meningopolyneuritis (Garin-Bujadoux, Bannwarth) (author's transl)]. Fortschr Neurol Psychiatr Grenzgeb 1973; 41:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/18\">",
"      Rupprecht TA, Koedel U, Fingerle V, Pfister HW. The pathogenesis of lyme neuroborreliosis: from infection to inflammation. Mol Med 2008; 14:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/19\">",
"      Reimers CD, Neubert U. Garin-Bujadoux-Bannwarth syndrome. Lancet 1990; 336:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/20\">",
"      Stanek G, Strle F. Lyme disease: European perspective. Infect Dis Clin North Am 2008; 22:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/21\">",
"      Logigian EL, Steere AC. Clinical and electrophysiologic findings in chronic neuropathy of Lyme disease. Neurology 1992; 42:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/22\">",
"      Oey PL, Franssen H, Bernsen RA, Wokke JH. Multifocal conduction block in a patient with Borrelia burgdorferi infection. Muscle Nerve 1991; 14:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/23\">",
"      Muley SA, Parry GJ. Antibiotic responsive demyelinating neuropathy related to Lyme disease. Neurology 2009; 72:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/24\">",
"      Garro AC, Rutman M, Simonsen K, et al. Prospective validation of a clinical prediction model for Lyme meningitis in children. Pediatrics 2009; 123:e829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/25\">",
"      Reik L Jr, Burgdorfer W, Donaldson JO. Neurologic abnormalities in Lyme disease without erythema chronicum migrans. Am J Med 1986; 81:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/26\">",
"      Hansen K, Lebech AM. The clinical and epidemiological profile of Lyme neuroborreliosis in Denmark 1985-1990. A prospective study of 187 patients with Borrelia burgdorferi specific intrathecal antibody production. Brain 1992; 115 ( Pt 2):399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/27\">",
"      Ackermann R, Rehse-K&uuml;pper B, Gollmer E, Schmidt R. Chronic neurologic manifestations of erythema migrans borreliosis. Ann N Y Acad Sci 1988; 539:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/28\">",
"      Halperin JJ, Volkman DJ, Wu P. Central nervous system abnormalities in Lyme neuroborreliosis. Neurology 1991; 41:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/29\">",
"      Logigian EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme disease. N Engl J Med 1990; 323:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/30\">",
"      Belman AL, Iyer M, Coyle PK, Dattwyler R. Neurologic manifestations in children with North American Lyme disease. Neurology 1993; 43:2609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/31\">",
"      Zemel L. Lyme disease and pseudotumor. Mayo Clin Proc 2000; 75:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/32\">",
"      Halperin JJ, Luft BJ, Anand AK, et al. Lyme neuroborreliosis: central nervous system manifestations. Neurology 1989; 39:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/33\">",
"      Stoppe G, Wildhagen K, Seidel JW, et al. Positron emission tomography in neuropsychiatric lupus erythematosus. Neurology 1990; 40:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/34\">",
"      Krupp LB, Masur D, Schwartz J, et al. Cognitive functioning in late Lyme borreliosis. Arch Neurol 1991; 48:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/35\">",
"      Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001; 345:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/36\">",
"      Krupp LB, Hyman LG, Grimson R, et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 2003; 60:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/37\">",
"      Fallon BA, Keilp JG, Corbera KM, et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 2008; 70:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/38\">",
"      Halperin JJ. Prolonged Lyme disease treatment: enough is enough. Neurology 2008; 70:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/39\">",
"      Feder HM Jr, Johnson BJ, O'Connell S, et al. A critical appraisal of \"chronic Lyme disease\". N Engl J Med 2007; 357:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/40\">",
"      Marques A. Chronic Lyme disease: a review. Infect Dis Clin North Am 2008; 22:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/41\">",
"      Stiernstedt GT, Granstr&ouml;m M, Hederstedt B, Sk&ouml;ldenberg B. Diagnosis of spirochetal meningitis by enzyme-linked immunosorbent assay and indirect immunofluorescence assay in serum and cerebrospinal fluid. J Clin Microbiol 1985; 21:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/42\">",
"      Lakos A. CSF findings in Lyme meningitis. J Infect 1992; 25:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/43\">",
"      Pachner AR, Steere AC. The triad of neurologic manifestations of Lyme disease: meningitis, cranial neuritis, and radiculoneuritis. Neurology 1985; 35:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/44\">",
"      Steere AC, Berardi VP, Weeks KE, et al. Evaluation of the intrathecal antibody response to Borrelia burgdorferi as a diagnostic test for Lyme neuroborreliosis. J Infect Dis 1990; 161:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/45\">",
"      Blanc F, Jaulhac B, Fleury M, et al. Relevance of the antibody index to diagnose Lyme neuroborreliosis among seropositive patients. Neurology 2007; 69:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/46\">",
"      Lj&oslash;stad U, Skarpaas T, Mygland A. Clinical usefulness of intrathecal antibody testing in acute Lyme neuroborreliosis. Eur J Neurol 2007; 14:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/47\">",
"      Baig S, Olsson T, Hansen K, Link H. Anti-Borrelia burgdorferi antibody response over the course of Lyme neuroborreliosis. Infect Immun 1991; 59:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/48\">",
"      Hansen K, Cruz M, Link H. Oligoclonal Borrelia burgdorferi-specific IgG antibodies in cerebrospinal fluid in Lyme neuroborreliosis. J Infect Dis 1990; 161:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/49\">",
"      Nocton JJ, Bloom BJ, Rutledge BJ, et al. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in cerebrospinal fluid in Lyme neuroborreliosis. J Infect Dis 1996; 174:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/50\">",
"      Tumani H, Cadavid D. Are high CSF levels of CXCL13 helpful for diagnosis of Lyme neuroborreliosis? Neurology 2011; 76:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/51\">",
"      Marra CM, Tantalo LC, Sahi SK, et al. CXCL13 as a cerebrospinal fluid marker for neurosyphilis in HIV-infected patients with syphilis. Sex Transm Dis 2010; 37:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/52\">",
"      Schmidt C, Plate A, Angele B, et al. A prospective study on the role of CXCL13 in Lyme neuroborreliosis. Neurology 2011; 76:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/53\">",
"      Rupprecht TA, Pfister HW, Angele B, et al. The chemokine CXCL13 (BLC): a putative diagnostic marker for neuroborreliosis. Neurology 2005; 65:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/54\">",
"      Halperin JJ. Nervous system Lyme disease. Infect Dis Clin North Am 2008; 22:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/55\">",
"      Kalina P, Decker A, Kornel E, Halperin JJ. Lyme disease of the brainstem. Neuroradiology 2005; 47:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/56\">",
"      Logigian EL, Johnson KA, Kijewski MF, et al. Reversible cerebral hypoperfusion in Lyme encephalopathy. Neurology 1997; 49:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/57\">",
"      Rupprecht TA, Pfister HW. What are the indications for lumbar puncture in patients with Lyme disease? Curr Probl Dermatol 2009; 37:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/58\">",
"      Halperin JJ, Shapiro ED, Logigian E, et al. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2007; 69:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/59\">",
"      Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/60\">",
"      Hansen K. Lyme neuroborreliosis: improvements of the laboratory diagnosis and a survey of epidemiological and clinical features in Denmark 1985-1990. Acta Neurol Scand Suppl 1994; 151:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14681/abstract/61\">",
"      Kristoferitsch W. Neurological manifestations of Lyme borreliosis: clinical definition and differential diagnosis. Scand J Infect Dis Suppl 1991; 77:64.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15247 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-37D25D05A2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_21_14681=[""].join("\n");
var outline_f14_21_14681=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10939518\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10939433\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10939440\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10939447\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10939454\">",
"      Peripheral nervous system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10939461\">",
"      - Cranial neuropathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10939468\">",
"      - Radiculoneuritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30180706\">",
"      - Bannwarth syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10939475\">",
"      - Other forms of peripheral nerve involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10939483\">",
"      Central nervous system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24976699\">",
"      - Meningitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42451729\">",
"      - Lyme encephalomyelitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42451858\">",
"      - Benign intracranial hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10939490\">",
"      - Encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10939497\">",
"      Post Lyme disease syndrome and chronic Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10939504\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4821958\">",
"      Serologic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4821965\">",
"      CSF analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4821972\">",
"      - CSF antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4822015\">",
"      - Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43076349\">",
"      - CXCL13",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4822126\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H445548\">",
"      Electrophysiologic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24976859\">",
"      Approach to diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10939511\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10939518\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/15247\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/15247|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/7/40060\" title=\"table 1\">",
"      Signs of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/58/2987\" title=\"table 2\">",
"      PNS manifestations Lyme",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/8/3211\" title=\"table 3\">",
"      CNS manifestations Lyme",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/4/6219\" title=\"table 4\">",
"      Clin syndrome Lyme",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/35/22078\" title=\"table 5\">",
"      Treatment of Lyme disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=related_link\">",
"      Clinical manifestations of Lyme disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=related_link\">",
"      Diagnosis of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35130?source=related_link\">",
"      Diagnosis of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7225?source=related_link\">",
"      Lyme disease: Clinical manifestations in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/40/30338?source=related_link\">",
"      Patient information: Lyme disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/0/27649?source=related_link\">",
"      Patient information: Lyme disease prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/17/32022?source=related_link\">",
"      Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/41/5778?source=related_link\">",
"      Patient information: Lyme disease treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=related_link\">",
"      Treatment of Lyme disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_21_14682="Cesarean delivery: Technique";
var content_f14_21_14682=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cesarean delivery: Technique",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/21/14682/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/21/14682/contributors\">",
"     Vincenzo Berghella, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/21/14682/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/21/14682/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/21/14682/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/21/14682/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/21/14682/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with most surgical procedures, there is no standard technique for cesarean delivery. The following discussion will review each step in the procedure and provide evidence-based recommendations for surgical technique, when these data are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OPENING THE ABDOMEN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Skin incision",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Transverse or vertical",
"    </span>",
"    &nbsp;&mdash;&nbsp;The advantages and disadvantages of various incisions and the procedure for opening the abdomen from skin to peritoneum are the same as for gynecologic procedures, and are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30265?source=see_link\">",
"     \"Principles of abdominal wall incisions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, a transverse (eg, Pfannenstiel or Joel-Cohen) incision is most commonly used for cesarean delivery since it is associated with less postoperative pain, greater wound strength, and better cosmetic results than the vertical midline incision [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/1\">",
"     1",
"    </a>",
"    ]. However, vertical incisions generally allow faster abdominal entry [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/2\">",
"     2",
"    </a>",
"    ], cause less bleeding and nerve injury, and can be easily extended cephalad if more space is required for access. Randomized trials have not evaluated outcomes related to the choice of skin incision separately from other aspects of cesarean delivery. A prospective cohort study including over 3500 emergency cesarean deliveries confirmed that median incision to delivery intervals were faster for vertical than transverse skin incisions (three versus four minutes for primary cesareans and three and five minutes for repeat cesareans) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/2\">",
"     2",
"    </a>",
"    ]. However, neonatal outcomes were not improved and some maternal and neonatal outcomes were worse in the vertical incision group (eg, need for postpartum maternal transfusion [8.5 versus 5.3 percent], neonatal intubation in the delivery room [17 versus 13 percent]); this was attributed to unidentified confounders.",
"   </p>",
"   <p>",
"    At all stages of the cesarean procedure, we prefer using the scalpel for sharp dissection, rather than an electrocautery device. There are no randomized trials comparing scalpel to electrocautery during cesarean delivery. The bulk of evidence from observational studies shows that neither scalpel nor electrosurgery holds a significant benefit over the other; either approach is acceptable. Of note, it probably isn't necessary to change to a fresh scalpel blade after opening the abdomen [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30265?source=see_link&amp;anchor=H10#H10\">",
"     \"Principles of abdominal wall incisions\", section on 'Skin incision'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Size",
"    </span>",
"    &nbsp;&mdash;&nbsp;The size of the abdominal skin incision needs to be adequate for easy delivery of the fetus. While there are no trials on this technical aspect of cesarean delivery, a 15 cm long incision (the size of a standard Allis clamp) is probably the minimal length that allows atraumatic and expeditious delivery of the term fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Subcutaneous tissue layer",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials comparing techniques for incision and dissection of the subcutaneous tissues at cesarean delivery. We prefer blunt dissection (with fingers) to sharp dissection (with the knife), as blunt dissection has been associated with shorter operative times and less chance of injury to vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Fascial layer",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials comparing different techniques of opening the fascia at cesarean delivery. A small transverse incision is usually made medially with the scalpel, and then extended laterally with scissors. Alternatively, the fascial incision can be extended bluntly by inserting the fingers of each hand under the fascia and then pulling in a cephalad-caudad direction, sometimes referred to as part of the Joel-Cohen or Misgav-Ladach techniques (see",
"    <a class=\"local\" href=\"#H34\">",
"     'Alternative techniques'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/1,4\">",
"     1,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Rectus muscle layer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rectus muscles can be separated bluntly in most cases, avoiding transection of muscles preserves muscle strength [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Dissection of the rectus fascia from the rectus sheath and muscles seems to be unnecessary [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/4,5,9\">",
"     4,5,9",
"    </a>",
"    ], but has not been studied separately in a randomized trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Opening the peritoneum",
"    </span>",
"    &nbsp;&mdash;&nbsp;We, and others [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/4,5,9\">",
"     4,5,9",
"    </a>",
"    ], favor using the fingers to bluntly open the peritoneum to minimize the risk of inadvertent injury to bowel, bladder, or other organs that may be adherent to the underlying surface. Blunt versus sharp entry into the peritoneum has not been compared in a randomized trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20293380\">",
"    <span class=\"h3\">",
"     Dense intraperitoneal adhesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there are dense adhesions between the anterior abdominal wall and the anterior surface of the uterus, we enter the peritoneum bluntly and as close as possible to the upper abdomen to avoid areas of dense scar tissue in the lower abdomen (pelvis). Sharp dissection also may be needed, and should be done cautiously using shallow incisions under direct vision. If pelvic adhesions require extensive dissection with risk of injury to the bowel, urinary tract, or major blood vessels in order to expose the lower uterine segment, and the patient desires tubal ligation, we avoid or minimize adhesiolysis and perform the hysterotomy in the most appropriate accessible location. A case report in which the entire length of the ventral aspect of the uterus and bladder was densely adherent to the rectus sheath described extending the vertical incision above the level of the adhesions and then entering the uterine cavity through an incision across the fundus [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another option is a paravesical or supravesical extraperitoneal approach [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/11\">",
"     11",
"    </a>",
"    ]. Most obstetricians are not familiar with this technique since it was used primarily in the pre-antibiotic era to decrease the risk of intraperitoneal infection. It requires a detailed knowledge of the relationship between the fascial planes and the bladder and lower uterine segment. In experienced hands, it may provide a means of avoiding dense midline adhesions.",
"   </p>",
"   <p>",
"    A surgeon experienced in complex abdominal surgery should be present if meticulous dissection of dense adhesions involving important structures is needed. Insertion of ureteral stents can be useful to facilitate intraoperative identification (and avoidance) of the ureters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Assuring adequate exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The full thickness abdominal incision should be adequate to allow delivery of the fetus. The surgeon and an assistant together can manually stretch apart the opening at the angles of the incisions, but additional sharp dissection may be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Issues in obese women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cesarean delivery of the morbidly obese woman is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44009?source=see_link\">",
"     \"Cesarean delivery of the obese woman\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=see_link\">",
"     \"The impact of obesity on fertility and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INTRAABDOMINAL PROCEDURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Bladder flap",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not routinely create a bladder flap. In two trials that randomly assigned women to undergo or not undergo development of a bladder flap, omitting this procedure reduced the incision-to-delivery interval by an average of one to two minutes and was not associated with an increase in adverse short-term outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. However, the long-term consequences of this intervention have not been evaluated.",
"   </p>",
"   <p>",
"    Some obstetricians choose to selectively perform a bladder flap if a difficult delivery is anticipated, such as when the fetal head is deep in the pelvis or when the bladder is attached well above the lower uterine segment after a previous cesarean delivery. In these cases, creation of the bladder flap may help to keep the bladder dome out of the surgical field if the uterine incision extends.",
"   </p>",
"   <p>",
"    The location of the bladder is best delineated by palpating the catheter, if present. The demarcation between the lower and upper uterine segments is difficult to make clinically, sonographically, or histologically. The location or level of the demarcation also changes based on the clinical situation. In some patients, such as those who are not in labor, it may not be possible to make an incision in the lower uterine segment without first creating a bladder flap.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hysterotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to making a hysterotomy incision, the surgeon should be aware of the general location of the placenta and the fetal lie. Leopold maneuvers or ultrasound can be used to obtain this information, which helps avoid lacerating the placenta and in delivery of the fetus.",
"   </p>",
"   <p>",
"    The uterine incision may be transverse or vertical; no randomized trials have compared the two techniques. The type of incision depends upon several factors, including the position and size of the fetus, location of the placenta, presence of leiomyomas, and development of the lower uterine segment. The principal consideration is that the incision must be large enough to allow atraumatic delivery of the fetus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Transverse incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most cesarean deliveries, we recommend using a transverse incision along the lower uterine segment (ie, Monroe-Kerr or Kerr incision). Compared with vertical incisions, advantages of the transverse incision include less blood loss, less need for bladder dissection, easier reapproximation, and a lower risk of rupture in subsequent pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major disadvantage of the transverse incision is that significant lateral extension is not possible without risking laceration of major blood vessels. A \"J\" or inverted \"T\" extension is often required if a larger incision is needed. This can be problematic because the \"J\" extension goes into the lateral fundus and the angles of the inverted \"T\" incision are poorly vascularized, both of which potentially result in a weaker uterine scar.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Low vertical and classical incisions",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two types of vertical incisions, the low vertical (Kronig, De Lee, or Cornell) and the classical vertical. The low vertical is performed in the lower uterine segment and appears to be as strong as the low transverse incision [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/14\">",
"     14",
"    </a>",
"    ]. The major disadvantage of the low vertical incision is the possibility of extension cephalad into the uterine fundus or caudally into the bladder, cervix, or vagina. It is also difficult to determine that the low vertical incision is truly low, as the separation between lower and upper uterine segments is not easily identifiable clinically.",
"   </p>",
"   <p>",
"    A vertical incision that extends into the upper uterine",
"    <span class=\"nowrap\">",
"     segment/fundus",
"    </span>",
"    is termed a \"classical\" incision. This incision is rarely performed at or near term because in subsequent pregnancies it is associated with a higher frequency of uterine",
"    <span class=\"nowrap\">",
"     dehiscence/rupture",
"    </span>",
"    (4 to 9 percent) compared with low vertical (1 to 7 percent) and low transverse (0.2 to 1.5 percent) incisions; it is also associated with more maternal morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Whether a vertical incision is confined to the lower, noncontractile portion of the myometrium (low vertical) or extends into the upper contractile portion of the myometrium (classical) is a subjective assessment; an objective method for differentiating between the two types of uterine incisions has not been determined. (See",
"    <a class=\"medical medical_review\" href=\"./uterine-rupture-after-previous-cesarean-delivery?source=see_link\">",
"     \"Uterine rupture after previous cesarean delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The generally accepted indications for considering a vertical uterine incision are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poorly developed lower uterine segment in a setting in which more than normal intrauterine manipulation is anticipated (eg, extremely preterm breech presentation, back down transverse lie)",
"     </li>",
"     <li>",
"      Lower uterine segment pathology that precludes a transverse incision (eg, large leiomyoma, anterior placenta previa or accreta)",
"     </li>",
"     <li>",
"      Densely adherent bladder",
"     </li>",
"     <li>",
"      Postmortem delivery",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2329566\">",
"    <span class=\"h4\">",
"     Bandl's ring",
"    </span>",
"    &nbsp;&mdash;&nbsp;A constriction ring of the uterus, called Bandl's ring, is a rare complication of labor. The constriction forms between the upper contractile portion of the uterus and the lower uterine segment, and often leads to cesarean delivery because of dystocia. It may occur between delivery of the first and second twin. At laparotomy, a transverse thickened muscular band can be observed separating the upper and lower segments of the uterus. There is sparse information on the best management of Bandl's ring noted at cesarean delivery. Its presence is not an absolute indication for a vertical uterine incision, as transecting the ring may or may not allow easy delivery of the fetus. Intravascular injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    (50 to 200 mcg) can be administered to relax the uterus if the fetus is difficult to extract [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A scalpel is used to perform the initial part of the hysterotomy. Various techniques are employed to minimize the risk of fetal injury during the myometrial incision. All involve elevating and carefully thinning the inner myometrial and decidual layers to minimize bleeding, maximize exposure, and promote separation of the uterine tissue from the fetal membranes or skin.",
"   </p>",
"   <p>",
"    One technique is to apply Allis clamps to the superior and inferior edges of the myometrial incision and elevate them. Another is to remove the suction tip and directly apply the end of the suction tubing to the center of the myometrial incision to balloon-out and thin-out this layer while providing easily identifiable, relatively blood-free exposure. If possible, membranes are left intact until complete extension of the incision [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/20\">",
"     20",
"    </a>",
"    ]. A third option is to use a surgical device specifically designed to reduce the risk of lacerating the fetus at hysterotomy (eg, C-safe&reg;).",
"   </p>",
"   <p>",
"    When entry into the uterine cavity is achieved, the hysterotomy incision can be extended using bandage scissors or blunt expansion with the surgeon's fingers. In a systematic",
"    <span class=\"nowrap\">",
"     review/meta-analysis",
"    </span>",
"    of four small randomized trials of blunt versus sharp hysterotomy, blunt expansion tended to result in a lower drop in mean postpartum hematocrit and a lower incidence of unintended extension, but the differences were not statistically significant; more and larger trials are needed to determine whether there is a true difference in outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/21\">",
"     21",
"    </a>",
"    ]. We suggest blunt expansion because it is fast and has less risk of inadvertent trauma to the fetus, and it may reduce blood loss and extension of the incision. Extending the uterine incision transversely by pulling vertically (cephalocaudal) with the index fingers reduces the risk of unintended extension and excessive blood loss [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/9,22\">",
"     9,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In four trials, the use of absorbable staples for extension of the hysterotomy and later closure was associated with a slightly longer time to deliver the baby and no benefits in maternal or perinatal outcomes compared with the traditional method [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/23\">",
"     23",
"    </a>",
"    ]. This technique should be reserved for rare indications (eg, ex utero intrapartum treatment [EXIT] procedure).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Fetal extraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies, but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/24,25\">",
"     24,25",
"    </a>",
"    ], have reported a direct association between a prolonged uterine incision-to-delivery time and lower fetal blood gas pH values and Apgar scores, regardless of type of anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/26\">",
"     26",
"    </a>",
"    ]. The mechanism is thought to be hysterotomy induced increased uterine tone, which can interfere with uteroplacental blood flow. Thus, careful attention to the duration of this interval by the surgeon is important, especially in a fetus with a nonreassuring fetal heart rate assessment prior to the onset of surgery.",
"   </p>",
"   <p>",
"    Extraction of the fetus at cesarean is usually uncomplicated, but may be made more difficult by extreme prematurity, a deeply impacted or floating fetal head, or an abnormal lie. Delivery in each of these clinical settings is described separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11414?source=see_link\">",
"       \"Fetal extraction at cesarean delivery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/43/21176?source=see_link\">",
"       \"Delivery of the fetus in breech presentation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22662?source=see_link\">",
"       \"Management of the fetus in transverse lie\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Cord clamping and infant assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed, rather than immediate, cord clamping results in greater neonatal hemoglobin levels and appears to be beneficial for preterm, and some term, infants. The health benefits of delayed cord clamping (eg, slight increase in hemoglobin) of term infants in developed countries may not be as clinically meaningful as in developing countries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33114?source=see_link&amp;anchor=H30#H30\">",
"     \"Management of normal labor and delivery\", section on 'Cord clamping'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33114?source=see_link&amp;anchor=H31#H31\">",
"     \"Management of normal labor and delivery\", section on 'Cord blood'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An appropriately trained clinician should be present to care for the infant [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/27\">",
"     27",
"    </a>",
"    ]. The degree of training depends upon the presence and type of risk factors for neonatal complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36105?source=see_link\">",
"     \"Overview of the routine management of the healthy newborn infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6493856\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic prophylaxis used to be administered after cord clamping to prevent interference with neonatal cultures, but antibiotics are now administered to the mother preoperatively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/5/8282?source=see_link&amp;anchor=H9#H9\">",
"     \"Cesarean delivery: Preoperative issues\", section on 'Antibiotic prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Placental extraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Draining the placenta prior to extraction appears to result in less fetomaternal transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/28\">",
"     28",
"    </a>",
"    ]. Spontaneous extraction (gentle traction on the cord and use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    to enhance uterine contractile expulsive efforts) should be performed, instead of manual extraction, because several randomized trials have shown that manual extraction results in more postoperative endometritis (RR 1.64, 95% CI 1.42-1.90), greater blood loss (weighted mean difference 94 mL, 95% CI 17- 172 mL), more women with blood loss over 1000 mL (RR 1.81, 95% CI 1.11-2.28), and lower postpartum hematocrit [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/29\">",
"     29",
"    </a>",
"    ]. There is no need to change gloves before removal of the placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To ensure that all of the placenta has been removed, the uterus is usually explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus. These manipulations further stimulate uterine contraction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Prevention of hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;As soon as the placenta is delivered, the uterus is massaged to promote contraction, which is the main mechanism for reduction of uterine bleeding.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     Oxytocin",
"    </a>",
"    is administered intravenously to promote uterine contraction and involution [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. The term uterus is very sensitive to oxytocin; most patients at scheduled cesarean delivery will achieve satisfactory contraction of the uterus after an intravenous oxytocin dose no larger than 1 unit over 10 seconds [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41639?source=see_link\">",
"     \"Uterotonic drugs for management of the third stage of labor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is unclear whether the best",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    regimen is a bolus injection, continuous infusion, or a combination of both. The optimum timing, dose, and duration of therapy have not been studied extensively, and may differ depending on whether or not the patient has labored:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If only an",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      infusion is given, the initial infusion should probably be at least 10 units over 30 minutes. In one randomized trial including over 300 laboring women who underwent cesarean delivery, an oxytocin infusion of 80 units in 500 mL Lactated Ringer&rsquo;s over 30 minutes after delivery of the infant was associated with a lower need for another uterotonic agent than a 10 unit dose in 500 mL Lactated Ringer&rsquo;s over 30 minutes, but there were no differences in change in hematocrit [",
"      <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/34\">",
"       34",
"      </a>",
"      ]. Intermediate doses were not evaluated. After the initial dose, all patients also received 20 units of oxytocin in 1 L of Lactated Ringer&rsquo;s solution at a rate of 125",
"      <span class=\"nowrap\">",
"       mL/h",
"      </span>",
"      for eight hours.",
"     </li>",
"     <li>",
"      If only a bolus is given, no more than a 5 units",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      over several minutes is needed to prevent hemorrhage. One trial randomly assigned 40 women undergoing scheduled cesarean delivery to receive oxytocin 5, 10, 15, or 20 units at a rate of 1",
"      <span class=\"nowrap\">",
"       unit/min",
"      </span>",
"      immediately after clamping of the umbilical cord, without routine subsequent infusion [",
"      <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/33\">",
"       33",
"      </a>",
"      ]. Estimated blood loss and postpartum change in hematocrit were similar for all four groups, suggesting there is no benefit to administering more than 5 U of intravenous oxytocin to term parturients undergoing elective cesarean delivery.",
"     </li>",
"     <li>",
"      Combined therapy (bolus and infusion) appears to be unnecessary. A randomized trial found that a bolus injection of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      5 units over 30 seconds before beginning an oxytocin infusion was not more effective than an infusion alone in reducing the subsequent need for uterotonic drugs to prevent or treat postpartum hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For most patients, after cord clamping we administer 20 to 40 units of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    in 1 liter of normal saline over an hour. We give another 1 to 3 liters of the same solution at 125",
"    <span class=\"nowrap\">",
"     mL/hour,",
"    </span>",
"    then discontinue the oxytocin, and also the intravenous fluids if oral hydration has been established.",
"   </p>",
"   <p>",
"    Of note,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/45/33491?source=see_link\">",
"     carbetocin",
"    </a>",
"    has been associated with lower need for additional uterotonics compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    , but this drug is not widely available [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    may be as effective as oxytocin for reducing blood loss, but the available evidence is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PROCEDURES DURING CLOSURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Exteriorizing the uterus",
"    </span>",
"    &nbsp;&mdash;&nbsp;We, and many others, exteriorize the uterus to improve exposure and facilitate closure of the hysterotomy. A meta-analysis of the first six randomized trials (n = 1294 women) on uterine exteriorization found that extra-abdominal closure of the uterine incision was associated with lower febrile morbidity (RR 0.41, 95% CI 0.17-0.97) and longer hospitalization (weighted mean difference 0.24 days, 95% CI 0.08-0.39), but there were no significant differences in other outcomes (eg, blood loss, postoperative change in hematocrit, endometritis, wound complications, analgesia requirements, length of surgery) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/39\">",
"     39",
"    </a>",
"    ]. There was insufficient evidence to conclude that one approach was superior the other, and that more data were needed.",
"   </p>",
"   <p>",
"    Subsequent to this meta-analysis, three additional randomized trials assessing uterine exteriorization versus repair in situ have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Taken together, these nine trials suggest there is no clinically significant difference in outcome between the two techniques, although exteriorization may be associated with shorter operating time [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/42\">",
"     42",
"    </a>",
"    ], more nausea [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/41\">",
"     41",
"    </a>",
"    ], and more pain on the first postoperative day [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/40,42\">",
"     40,42",
"    </a>",
"    ]. Therefore, the surgeon should choose the technique based on individual clinical circumstances and personal preference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Uterine closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine",
"    <span class=\"nowrap\">",
"     manual/instrumental",
"    </span>",
"    cervical dilatation before closing the uterus in an elective cesarean delivery is unnecessary. Controlled studies have reported that this practice does not improve postoperative hemoglobin levels or reduce the incidence of fever or wound infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2329573\">",
"    <span class=\"h3\">",
"     Suture",
"    </span>",
"    &nbsp;&mdash;&nbsp;For closure of the uterine incision, there are no high quality data to guide choice of suture material (eg, chromic catgut versus delayed absorbable synthetic [eg, polyglactin 910, poliglecaprone 25]) or technique (eg, continuous [locked or nonlocked] versus interrupted) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/44\">",
"     44",
"    </a>",
"    ]. A 0- delayed absorbable synthetic monofilament (eg, Monocryl&reg;) or braided (eg, Vicryl&reg;) suture is commonly used in the United States. A new type of suture, barbed suture, has been used successfully for knotless closure of myomectomy incisions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/45,46\">",
"     45,46",
"    </a>",
"    ] and skin closure of the Pfannenstiel incision during cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2329589\">",
"    <span class=\"h3\">",
"     Myometrial closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;When performing uterine closure, we usually perform a two-layer, continuous closure with delayed absorbable synthetic suture incorporating all of the muscle in order to avoid bleeding from the incision edges. We do not use locking sutures unless arterial bleeding is evident.",
"   </p>",
"   <p>",
"    The endometrial layer should probably be included in the full thickness myometrial closure. This opinion is based on a randomized trial that assigned 78 term pregnant patients delivered by cesarean to one layer myometrial closure either including or excluding the endometrial layer [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/48\">",
"     48",
"    </a>",
"    ]. The frequency of a wedge-type healing defect by ultrasound six weeks postpartum was significantly lower in the group treated by full thickness suturing (45 versus 69 percent). Outcomes in subsequent pregnancies were not evaluated, so the clinical significance of this finding is unknown.",
"   </p>",
"   <p>",
"    Use of blunt tip needles during closure is associated with similar maternal outcomes as use of sharp needles, but is safer for the surgeon (glove perforation rate 7.2 versus 17.5 percent with sharp needles [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/49\">",
"     49",
"    </a>",
"    ]) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. However, in some studies physicians were less satisfied with the performance of blunt needles [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h4\">",
"     Single versus double layer closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low transverse uterine incision can be closed in a single layer to decrease operating time [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/44\">",
"     44",
"    </a>",
"    ]; however, there is conflicting evidence regarding the long-term safety of this approach.",
"   </p>",
"   <p>",
"    In the short-term, a large randomized trial (CAESAR) of women undergoing their first cesarean delivery found no difference between those who underwent single versus double layer uterine closure in the rate of infectious morbidity, severity of postpartum pain, or need for blood transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the long-term, however, concerns have been raised that patients who undergo a single layer closure may be at increased risk of uterine rupture during the next pregnancy compared with those who undergo a two-layer closure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. This concern was addressed by a systematic review of studies (6 cohort, 2 case-control, 1 randomized trial; 5810 women) that compared the risk of uterine rupture during a trial of labor (TOL) after single versus double layer closure of a first cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/55\">",
"     55",
"    </a>",
"    ]. Uterine rupture was defined as complete scar separation necessitating an emergency intervention. The risk of uterine rupture during TOL after a single layer closure was not significantly different from that after a double-layer closure (OR 1.71, 95% CI 0.66-4.44). However, the technique used for the single layer closure appeared to be an important factor. A locked single layer closure was associated with a significantly greater risk of rupture than a double layer closure (OR 4.96, 95% CI 2.58-9.52), while an unlocked single layer closure did not increase the risk of rupture (OR 0.49, 95% CI 0.21-1.16).",
"   </p>",
"   <p>",
"    The risk of uterine rupture after single versus double layer uterine closure warrants further study in a well-designed randomized trial, given the limitations of the studies in this meta-analysis. Most of the studies were retrospective, no study directly compared outcomes of locked versus unlocked single layer closure, ascertainment of the technique for single layer closure was based on usual practice at the study site rather than documentation in patient records, and the type of suture material was not considered.",
"   </p>",
"   <p>",
"    We suggest a two-layer uterine closure, even though data supporting this opinion are inconclusive. Given the available data, either a one layer or two layer closure technique is within acceptable standards of medical practice; we suggest an unlocked technique for one layer closure. A double (or even triple) layer closure may be necessary when the myometrium is thick, such as with a classical and some low vertical incisions.",
"   </p>",
"   <p>",
"    Uterine rupture-dehiscence is the major long-term outcome of single versus double layer closure that has been studied. There is a paucity of data on other long-term outcomes. A secondary analysis of data from a prospective study of women undergoing repeat cesarean delivery observed an increased risk of bladder adhesions in women who had undergone single layer closure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/56\">",
"     56",
"    </a>",
"    ]. Further study of possible adverse consequences of single layer closure is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20298701\">",
"    <span class=\"h4\">",
"     Closure of a classical incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no trials comparing techniques for closure of the thick myometrium of the fundus. We use continuous sutures to close the inner myometrial layer; others prefer interrupted sutures, including interrupted vertical figure of eight sutures. It is useful to have an assistant manually reapproximate the incision by pushing the myometrium on each side toward the midline as each suture is placed and tied. This reduces tension on the incision and helps prevent the suture from tearing through the myometrium, especially when closing the first layer. A second layer is used to close the mid-portion of the thick myometrial layer, leaving about 1 cm of outer myometrium still open. We then close the serosa and outer layer using a baseball stitch, which is hemostatic and minimizes exposed raw surfaces, and thus may reduce adhesions. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Abdominal irrigation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraabdominal irrigation after closure of the uterus does not reduce maternal infectious morbidity beyond the reduction achieved with prophylactic intravenous antibiotics alone [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. In one trial, the irrigation increased intraoperative nausea [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Adhesion barriers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formation of adhesions is common after cesarean delivery; rates from 11 to 70 percent have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/59\">",
"     59",
"    </a>",
"    ]. The rate of bowel obstruction after cesarean delivery is much lower, ranging from 0.5 to 9 per 1000 cesarean deliveries, with the highest risk in women who have undergone multiple cesarean deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/59-61\">",
"     59-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no randomized trials evaluating the effectiveness of adhesion barriers in this procedure. One group estimated that women increase their risk of small bowel obstruction by 0.1 percent by undergoing cesarean delivery and that adhesion barriers may mitigate this risk by 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/62\">",
"     62",
"    </a>",
"    ]. Based on these assumptions, 2000 women would need to have an adhesion barrier placed at cesarean delivery to avoid one bowel obstruction and the cost per small bowel obstruction averted would be several hundred thousand dollars. Available evidence does not support the routine use of adhesion barriers in women undergoing cesarean delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Peritoneum",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not close the visceral or parietal peritoneum. There is high quality evidence from randomized trials that peritoneal nonclosure decreases operative time [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/63-66\">",
"     63-66",
"    </a>",
"    ], and has a similar rate of maternal infectious morbidity as closure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of nonclosure on adhesion formation is less clear because of the small number of patients who have undergone follow-up at a second cesarean delivery. Nonclosure might allow the enlarged uterus to adhere to the anterior abdominal wall or impede spontaneous closure of the peritoneum, while closure might cause a foreign body reaction to sutures and tissue damage.",
"   </p>",
"   <p>",
"    Several studies have attempted to evaluate this issue and have reported conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/64,67-74\">",
"     64,67-74",
"    </a>",
"    ]. A systematic review of peritoneal nonclosure and adhesion formation after cesarean delivery found some evidence that nonclosure was associated with greater adhesion formation than closure of the parietal layer or both visceral and parietal layers (OR 2.6, 95% CI 1.48-4.56; three studies, n = 249) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/75\">",
"     75",
"    </a>",
"    ]. The studies were included if the primary objective was to examine adhesion formation in a repeat cesarean delivery, had a clear study design, had an adhesion scoring system, and excluded patients who had adhesions at the primary cesarean or who had interim surgeries after the primary cesarean. Many studies were excluded from this review because of poor methodologic design or clinical heterogeneity. Another systematic review that included many of these studies also found that nonclosure was associated with greater adhesion formation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent to these analyses, a large well-designed trial that randomly assigned 533 women at primary cesarean to peritoneal nonclosure or closure found no significant difference between groups in the proportion of patients with adhesions at any site or time from incision to delivery at repeat cesarean (n = 97 repeat cesareans) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/73\">",
"     73",
"    </a>",
"    ]. Strengths of this trial included that its primary objective was to examine adhesion formation in a repeat cesarean delivery, use of an adhesion scoring system, exclusion of patients who had had prior pelvic or abdominal surgery, use of a standard technique for performing the cesareans, and blinding the surgeon performing the repeat cesarean to patient allocation.",
"   </p>",
"   <p>",
"    At this time, we believe there is good evidence for the benefit of nonclosure (decreased operating time) and inadequate evidence of harm (increased adhesion formation).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Rectus muscles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clinicians believe that the rectus muscles reapproximate naturally and suturing them together may cause unnecessary pain when the woman starts to move after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/1\">",
"     1",
"    </a>",
"    ]. No randomized trial has evaluated rectus muscle closure versus nonclosure. A prospective observational study reported a reduction in dense adhesion formation when the rectus muscles were reapproximated; however, this study did not assess pain or hematoma formation potentially related to this intervention and could not fully adjust for other intraoperative interventions, such as peritoneal closure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Fascia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The method of fascial closure is a critical aspect of incisional closure, as this provides the majority of wound strength during healing. Care should be taken to avoid too much tension when closing the fascia since reapproximation, not strangulation, is the goal. Difficulty with hemostasis is usually not a major issue. Meta-analyses of randomized trials of closure of",
"    <strong>",
"     midline",
"    </strong>",
"    abdominal fascial incisions show that the optimal technique for closure of these incisions is [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Use of a simple running technique",
"     </li>",
"     <li>",
"      Use of #1 or #2 delayed absorbable monofilament suture (eg, polydioxanone [PDS])",
"     </li>",
"     <li>",
"      Use of mass closure to incorporate all layers of the abdominal wall (except skin)",
"     </li>",
"     <li>",
"      Taking wide tissue bites (&ge;1 cm)",
"     </li>",
"     <li>",
"      Use of a short stitch interval (&le;1 cm)",
"     </li>",
"     <li>",
"      Use of a suture length to wound length ratio of 4 to 1",
"     </li>",
"     <li>",
"      Use of non-strangulating tension on the suture",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the majority of fascial closures after cesarean delivery involve a",
"    <strong>",
"     transverse",
"    </strong>",
"    fascial incision and no randomized trials have evaluated the optimum closure technique in this setting. For transverse fascial incisions, a continuous closure with slowly absorbable #1 braided suture is a common approach among general surgeons [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/79\">",
"     79",
"    </a>",
"    ]. Obstetricians also commonly use this technique with #0 or #1 braided suture (eg, polygalactin 910). Polydioxanone has also been used successfully for closure of transverse fascial incisions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/80\">",
"     80",
"    </a>",
"    ]. A randomized trial of closure techniques for repair of transversely incised abdominal fascia in rabbits found that interrupted closure had a greater maximum tensile strength than continuous closure during the first two postoperative weeks, but both repair methods had similar maximum tensile strength at four postoperative weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10633?source=see_link&amp;anchor=H15#H15\">",
"     \"Principles of abdominal wall closure\", section on 'Fascia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=see_link&amp;anchor=H19#H19\">",
"     \"Abdominal surgical incisions: Prevention and treatment of complications\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Subcutaneous tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of irrigation before closure of the subcutaneous tissues has not been studied in a randomized trial, and is probably unnecessary in the setting of routine intravenous antibiotic prophylaxis.",
"   </p>",
"   <p>",
"    We close the subcutaneous adipose layer with interrupted delayed-absorbable sutures if the layer is &ge;2 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. The value of this approach was illustrated in a meta-analysis of randomized trials that showed suture closure of the subcutaneous adipose layer at cesarean delivery decreased the risk of subsequent wound disruption by one-third in women with subcutaneous tissue depth &ge;2 cm, but not in those &lt;2 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/83\">",
"     83",
"    </a>",
"    ]. Closure of the dead space seems to inhibit accumulation of serum and blood, which can lead to a wound seroma and subsequent wound breakdown [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. This occurrence is a major cause of morbidity, can be costly, and lengthens the recovery time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Use of drains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials and meta-analyses have shown that routine use of wound drains is not beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/85,86\">",
"     85,86",
"    </a>",
"    ], even in obese women [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/87\">",
"     87",
"    </a>",
"    ]. Compared to no drain, routine use of drains does not reduce the odds of seroma, hematoma, infection, or wound disruption. Additionally, restricted use of subrectus sheath drains offers no benefit in maternal infectious morbidity compared with liberal use [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/51\">",
"     51",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reapproximation of the skin may be performed with staples or subcuticular suture; available data from randomized trials do not allow a strong recommendation for one method over the other [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/88\">",
"     88",
"    </a>",
"    ]. Meta-analyses have found that staples take less time to place than subcuticular sutures and shorten operating time by about five minutes, but are associated with a doubling of wound complications (infection, separation:13 versus 6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. However, the increased risk of wound separation may have been due to removing staples too early (day 3), rather than an effect of the staples themselves [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/88\">",
"     88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21449?source=see_link&amp;anchor=H2#H2\">",
"     \"Cesarean delivery: Postoperative issues\", section on 'Postoperative care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect on postoperative pain is unclear: one randomized trial reported that the subcuticular closure resulted in less postoperative discomfort six weeks postoperatively than the stapled closure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/91\">",
"     91",
"    </a>",
"    ], while another found that staples resulted in less postoperative discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/92\">",
"     92",
"    </a>",
"    ]. Other randomized trials found that use of staples or subcuticular sutures (absorbable or nonabsorbable monofilament, absorbable multifilament) for skin closure resulted in a similar cosmetic appearance when the scar was assessed six months postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/93\">",
"     93",
"    </a>",
"    ] and similar patient satisfaction in the absence of wound complications [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     ALTERNATIVE TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several techniques to simplify the surgical approach, decrease operating time, and reduce postoperative morbidity have been proposed. The Pelosi [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/9\">",
"     9",
"    </a>",
"    ] and modified",
"    <span class=\"nowrap\">",
"     Joel-Cohen/Misgav-Ladach",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef70112 \" href=\"UTD.htm?9/33/9756\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/4,5\">",
"     4,5",
"    </a>",
"    ] procedures have incorporated many of these modifications.",
"   </p>",
"   <p>",
"    Meta-analyses of randomized trials have found the Joel-Cohen type incision has significant advantages compared to the Pfannenstiel incision, including lower rates of fever, pain, and use of analgesia; less blood loss; and shorter operating time (overall and incision-to-delivery) and hospital stay [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. For example, compared to the Pfannenstiel incision, the modified",
"    <span class=\"nowrap\">",
"     Joel-Cohen/Misgav-Ladach",
"    </span>",
"    decreased incision to delivery time by 2 to 6 minutes, blood loss by 37 to 92 mL, and total operating time by 12 to 25 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/96\">",
"     96",
"    </a>",
"    ]. In addition, a randomized trial observed that the Joel-Cohen technique was associated with fewer patients with intraperitoneal adhesions at repeat cesarean delivery (11 percent versus 36 percent after standard Pfannenstiel-Kerr approach) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Pelosi technique is illustrated in the following pictures (",
"    <a class=\"graphic graphic_picture graphicRef82474 graphicRef68054 graphicRef59263 graphicRef59263 graphicRef66859 \" href=\"UTD.htm?0/7/118\">",
"     picture 1A-C, 1C-D",
"    </a>",
"    ). There are no randomized trials comparing the Pelosi to other techniques.",
"   </p>",
"   <p>",
"    However, it is impossible to assess which technical aspects of a particular method of cesarean delivery are advantageous when several aspects are studied at the same time [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/98\">",
"     98",
"    </a>",
"    ]. Long-term outcomes also have not been adequately evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     INCIDENTAL PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common incidental procedure at cesarean delivery is tubal sterilization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15018?source=see_link\">",
"     \"Surgical sterilization of women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Major uterine surgery should be avoided due to the potential for severe blood loss. Myomectomy is generally contraindicated for this reason, although a few small case series have described successful excision in selected women [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. Pedunculated myomas can usually be removed safely and without excessive blood loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15065?source=see_link\">",
"     \"Pregnancy in women with uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The adnexae are examined for solid and cystic masses. An ovarian cyst or mass identified incidentally at the time of cesarean delivery should be removed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/101\">",
"     101",
"    </a>",
"    ]. Complete surgical removal is preferred over aspiration and cytologic evaluation of cystic fluid since malignancy could be missed with the latter. In most cases, the patient will not have an appropriate incision for surgical staging. Therefore, gynecologic oncologists suggest a frozen section of the resected neoplasm. If it is malignant, oophorectomy can be performed and, postpartum, the patient is referred to a gynecologic oncologist for counseling, staging, and possible hysterectomy within the next one to two weeks.",
"   </p>",
"   <p>",
"    A randomized trial found that elective appendectomy at the time of cesarean delivery did not increase inpatient morbidity, and increased operative time by about nine minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/21/14682/abstract/102\">",
"     102",
"    </a>",
"    ]. The authors suggested consideration of elective appendectomy at the time of cesarean delivery in women at increased risk of having subsequent surgery to rule out appendicitis (eg, women with a palpable fecalith, abnormal appearing appendix, or history of pelvic pain or endometriosis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/21/16723?source=see_link\">",
"       \"Patient information: C-section (cesarean delivery) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=see_link\">",
"       \"Patient information: C-section (cesarean delivery) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For opening the abdomen, we suggest a transverse (eg, Pfannenstiel or Joel-Cohen) rather than a vertical skin incision (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A transverse incision is associated with less postoperative pain, greater wound strength, and better cosmetic results than the vertical midline incision. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Transverse or vertical'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not routinely create a bladder flap. This saves time and reduces blood loss. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Bladder flap'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the hysterotomy, we suggest a transverse rather than a vertical incision for most women (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The transverse incision is associated with less blood loss, less need for bladder dissection, is easier to reapproximate, and has a lower risk of rupture in subsequent pregnancies. However, a vertical hysterotomy is indicated in some settings (eg, poorly developed lower uterine segment, lower uterine segment pathology). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Hysterotomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest blunt rather than sharp expansion of the hysterotomy incision (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Blunt expansion is quick and has less risk of inadvertent trauma to the fetus, and may reduce blood loss and extension of the incision. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Hysterotomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend spontaneous, rather than manual, extraction of the placenta (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Spontaneous extraction is associated with lower rates of endometritis and bleeding. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Placental extraction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exteriorization or nonexteriorization of the uterus and one layer or two layer closure of the hysterotomy are all acceptable options. The choice depends on personal preference and the specific clinical setting. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Exteriorizing the uterus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who would consider a trial of labor after a previous cesarean delivery, we suggest a two-layer uterine closure (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Single versus double layer closure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not closing the visceral or parietal peritoneum (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Peritoneal closure prolongs operative time, but may decrease adhesion formation. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Peritoneum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with subcutaneous tissue depth &ge;2 cm, we recommend closure of the subcutaneous tissue layer with sutures (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Closure decreases the risk of subsequent wound disruption. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Subcutaneous tissue'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/1\">",
"      Berghella V, Baxter JK, Chauhan SP. Evidence-based surgery for cesarean delivery. Am J Obstet Gynecol 2005; 193:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/2\">",
"      Wylie BJ, Gilbert S, Landon MB, et al. Comparison of transverse and vertical skin incision for emergency cesarean delivery. Obstet Gynecol 2010; 115:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/3\">",
"      Hasselgren PO, Hagberg E, Malmer H, et al. One instead of two knives for surgical incision. Does it increase the risk of postoperative wound infection? Arch Surg 1984; 119:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/4\">",
"      Holmgren G, Sj&ouml;holm L, Stark M. The Misgav Ladach method for cesarean section: method description. Acta Obstet Gynecol Scand 1999; 78:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/5\">",
"      Wallin G, Fall O. Modified Joel-Cohen technique for caesarean delivery. Br J Obstet Gynaecol 1999; 106:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/6\">",
"      Berthet J, Peresse JF, Rosier P, Racinet C. [Comparative study of Pfannenstiel's incision and transverse abdominal incision in gynecologic and obstetric surgery]. Presse Med 1989; 18:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/7\">",
"      Giacalone PL, Daures JP, Vignal J, et al. Pfannenstiel versus Maylard incision for cesarean delivery: A randomized controlled trial. Obstet Gynecol 2002; 99:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/8\">",
"      Ayers JW, Morley GW. Surgical incision for cesarean section. Obstet Gynecol 1987; 70:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/9\">",
"      Wood RM, Simon H, Oz AU. Pelosi-type vs. traditional cesarean delivery. A prospective comparison. J Reprod Med 1999; 44:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/10\">",
"      Kroon N, Reginald PW. Parietal peritoneal closure at caesarean section revisited. J Obstet Gynaecol 2007; 27:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/11\">",
"      Hibbard LT. Extraperitoneal cesarean section. Clin Obstet Gynecol 1985; 28:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/12\">",
"      Hohlagschwandtner M, Ruecklinger E, Husslein P, Joura EA. Is the formation of a bladder flap at cesarean necessary? A randomized trial. Obstet Gynecol 2001; 98:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/13\">",
"      Tuuli MG, Odibo AO, Fogertey P, et al. Utility of the bladder flap at cesarean delivery: a randomized controlled trial. Obstet Gynecol 2012; 119:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/14\">",
"      Shipp TD, Zelop CM, Repke JT, et al. Intrapartum uterine rupture and dehiscence in patients with prior lower uterine segment vertical and transverse incisions. Obstet Gynecol 1999; 94:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/15\">",
"      Patterson LS, O'Connell CM, Baskett TF. Maternal and perinatal morbidity associated with classic and inverted T cesarean incisions. Obstet Gynecol 2002; 100:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/16\">",
"      Magann EF, Chauhan SP, Bufkin L, et al. Intra-operative haemorrhage by blunt versus sharp expansion of the uterine incision at caesarean delivery: a randomised clinical trial. BJOG 2002; 109:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/17\">",
"      Chedraui PA, Insuasti DF. Intravenous nitroglycerin in the management of retained placenta. Gynecol Obstet Invest 2003; 56:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/18\">",
"      Jha S, Chiu JW, Yeo IS. Intravenous nitro-glycerine versus general anaesthesia for placental extraction--a sequential comparison. Med Sci Monit 2003; 9:CS63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/19\">",
"      Lowenwirt IP, Zauk RM, Handwerker SM. Safety of intravenous glyceryl trinitrate in management of retained placenta. Aust N Z J Obstet Gynaecol 1997; 37:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/20\">",
"      Morrison JJ, Rennie JM, Milton PJ. Neonatal respiratory morbidity and mode of delivery at term: influence of timing of elective caesarean section. Br J Obstet Gynaecol 1995; 102:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/21\">",
"      Xu LL, Chau AM, Zuschmann A. Blunt vs. sharp uterine expansion at lower segment cesarean section delivery: a systematic review with metaanalysis. Am J Obstet Gynecol 2013; 208:62.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/22\">",
"      Cromi A, Ghezzi F, Di Naro E, et al. Blunt expansion of the low transverse uterine incision at cesarean delivery: a randomized comparison of 2 techniques. Am J Obstet Gynecol 2008; 199:292.e1.",
"     </a>",
"    </li>",
"    <li>",
"     Wilkinson, C, Enkin, MW. Absorbable staples for uterine incision at caesarean section. The Cochrane database of systematic reviews. 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/24\">",
"      Andersen HF, Auster GH, Marx GF, Merkatz IR. Neonatal status in relation to incision intervals, obstetric factors, and anesthesia at cesarean delivery. Am J Perinatol 1987; 4:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/25\">",
"      Fontanarosa M, Fontanarosa N. Incision-to-delivery interval and neonatal wellbeing during cesarean section. Minerva Ginecol 2008; 60:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/26\">",
"      Bader AM, Datta S, Arthur GR, et al. Maternal and fetal catecholamines and uterine incision-to-delivery interval during elective cesarean. Obstet Gynecol 1990; 75:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/27\">",
"      Gordon A, McKechnie EJ, Jeffery H. Pediatric presence at cesarean section: justified or not? Am J Obstet Gynecol 2005; 193:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/28\">",
"      Leavitt BG, Huff DL, Bell LA, Thurnau GR. Placental drainage of fetal blood at cesarean delivery and feto maternal transfusion: a randomized controlled trial. Obstet Gynecol 2007; 110:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/29\">",
"      Anorlu RI, Maholwana B, Hofmeyr GJ. Methods of delivering the placenta at caesarean section. Cochrane Database Syst Rev 2008; :CD004737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/30\">",
"      Atkinson MW, Owen J, Wren A, Hauth JC. The effect of manual removal of the placenta on post-cesarean endometritis. Obstet Gynecol 1996; 87:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/31\">",
"      Balki M, Ronayne M, Davies S, et al. Minimum oxytocin dose requirement after cesarean delivery for labor arrest. Obstet Gynecol 2006; 107:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/32\">",
"      Carvalho JC, Balki M, Kingdom J, Windrim R. Oxytocin requirements at elective cesarean delivery: a dose-finding study. Obstet Gynecol 2004; 104:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/33\">",
"      Sarna MC, Soni AK, Gomez M, Oriol NE. Intravenous oxytocin in patients undergoing elective cesarean section. Anesth Analg 1997; 84:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/34\">",
"      Munn MB, Owen J, Vincent R, et al. Comparison of two oxytocin regimens to prevent uterine atony at cesarean delivery: a randomized controlled trial. Obstet Gynecol 2001; 98:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/35\">",
"      King KJ, Douglas MJ, Unger W, et al. Five unit bolus oxytocin at cesarean delivery in women at risk of atony: a randomized, double-blind, controlled trial. Anesth Analg 2010; 111:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/36\">",
"      Boucher M, Horbay GL, Griffin P, et al. Double-blind, randomized comparison of the effect of carbetocin and oxytocin on intraoperative blood loss and uterine tone of patients undergoing cesarean section. J Perinatol 1998; 18:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/37\">",
"      Dansereau J, Joshi AK, Helewa ME, et al. Double-blind comparison of carbetocin versus oxytocin in prevention of uterine atony after cesarean section. Am J Obstet Gynecol 1999; 180:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/38\">",
"      Hua J, Chen G, Xing F, et al. Effect of misoprostol versus oxytocin during caesarean section: a systematic review and meta-analysis. BJOG 2013; 120:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/39\">",
"      Jacobs-Jokhan D, Hofmeyr G. Extra-abdominal versus intra-abdominal repair of the uterine incision at caesarean section. Cochrane Database Syst Rev 2004; :CD000085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/40\">",
"      Nafisi S. Influence of uterine exteriorization versus in situ repair on post-Cesarean maternal pain: a randomized trial. Int J Obstet Anesth 2007; 16:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/41\">",
"      Siddiqui M, Goldszmidt E, Fallah S, et al. Complications of exteriorized compared with in situ uterine repair at cesarean delivery under spinal anesthesia: a randomized controlled trial. Obstet Gynecol 2007; 110:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/42\">",
"      Coutinho IC, Ramos de Amorim MM, Katz L, Bandeira de Ferraz AA. Uterine exteriorization compared with in situ repair at cesarean delivery: a randomized controlled trial. Obstet Gynecol 2008; 111:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/43\">",
"      Liabsuetrakul t, Peeyananjarassri K. Mechanical dilatation of the cervix at non-labour caesarean section for reducing postoperative morbidity. Cochrane Database Syst Rev 2011; :CD008019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/44\">",
"      Dodd JM, Anderson ER, Gates S. Surgical techniques for uterine incision and uterine closure at the time of caesarean section. Cochrane Database Syst Rev 2008; :CD004732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/45\">",
"      Alessandri F, Remorgida V, Venturini PL, Ferrero S. Unidirectional barbed suture versus continuous suture with intracorporeal knots in laparoscopic myomectomy: a randomized study. J Minim Invasive Gynecol 2010; 17:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/46\">",
"      Greenberg JA, Einarsson JI. The use of bidirectional barbed suture in laparoscopic myomectomy and total laparoscopic hysterectomy. J Minim Invasive Gynecol 2008; 15:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/47\">",
"      Murtha AP, Kaplan AL, Paglia MJ, et al. Evaluation of a novel technique for wound closure using a barbed suture. Plast Reconstr Surg 2006; 117:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/48\">",
"      Yazicioglu F, G&ouml;kdogan A, Kelekci S, et al. Incomplete healing of the uterine incision after caesarean section: Is it preventable? Eur J Obstet Gynecol Reprod Biol 2006; 124:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/49\">",
"      Sullivan S, Williamson B, Wilson LK, et al. Blunt needles for the reduction of needlestick injuries during cesarean delivery: a randomized controlled trial. Obstet Gynecol 2009; 114:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/50\">",
"      Stafford MK, Pitman MC, Nanthakumaran N, Smith JR. Blunt-tipped versus sharp-tipped needles: wound morbidity. J Obstet Gynaecol 1998; 18:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/51\">",
"      CAESAR study collaborative group. Caesarean section surgical techniques: a randomised factorial trial (CAESAR). BJOG 2010; 117:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/52\">",
"      Bujold E, Bujold C, Hamilton EF, et al. The impact of a single-layer or double-layer closure on uterine rupture. Am J Obstet Gynecol 2002; 186:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/53\">",
"      Durnwald C, Mercer B. Uterine rupture, perioperative and perinatal morbidity after single-layer and double-layer closure at cesarean delivery. Am J Obstet Gynecol 2003; 189:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/54\">",
"      Bujold E, Goyet M, Marcoux S, et al. The role of uterine closure in the risk of uterine rupture. Obstet Gynecol 2010; 116:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/55\">",
"      Roberge S, Chaillet N, Boutin A, et al. Single- versus double-layer closure of the hysterotomy incision during cesarean delivery and risk of uterine rupture. Int J Gynaecol Obstet 2011; 115:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/56\">",
"      Blumenfeld YJ, Caughey AB, El-Sayed YY, et al. Single- versus double-layer hysterotomy closure at primary caesarean delivery and bladder adhesions. BJOG 2010; 117:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/57\">",
"      Harrigill KM, Miller HS, Haynes DE. The effect of intraabdominal irrigation at cesarean delivery on maternal morbidity: a randomized trial. Obstet Gynecol 2003; 101:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/58\">",
"      Viney R, Isaacs C, Chelmow D. Intra-abdominal irrigation at cesarean delivery: a randomized controlled trial. Obstet Gynecol 2012; 119:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/59\">",
"      Andolf E, Thorsell M, K&auml;ll&eacute;n K. Cesarean delivery and risk for postoperative adhesions and intestinal obstruction: a nested case-control study of the Swedish Medical Birth Registry. Am J Obstet Gynecol 2010; 203:406.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/60\">",
"      Silver RM, Landon MB, Rouse DJ, et al. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet Gynecol 2006; 107:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/61\">",
"      Al-Sunaidi M, Tulandi T. Adhesion-related bowel obstruction after hysterectomy for benign conditions. Obstet Gynecol 2006; 108:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/62\">",
"      Albright CM, Rouse DJ. Adhesion barriers at cesarean delivery: advertising compared with the evidence. Obstet Gynecol 2011; 118:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/63\">",
"      Bamigboye AA, Hofmeyr GJ. Closure versus non-closure of the peritoneum at caesarean section. Cochrane Database Syst Rev 2003; :CD000163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/64\">",
"      Komoto Y, Shimoya K, Shimizu T, et al. Prospective study of non-closure or closure of the peritoneum at cesarean delivery in 124 women: Impact of prior peritoneal closure at primary cesarean on the interval time between first cesarean section and the next pregnancy and significant adhesion at second cesarean. J Obstet Gynaecol Res 2006; 32:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/65\">",
"      Malomo OO, Kuti O, Orji EO, et al. A randomised controlled study of non-closure of peritoneum at caesarean section in a Nigerian population. J Obstet Gynaecol 2006; 26:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/66\">",
"      Huchon C, Raiffort C, Chis C, et al. [Caesarean section: closure or non-closure of peritoneum? A randomized trial of postoperative morbidity]. Gynecol Obstet Fertil 2005; 33:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/67\">",
"      Tulandi T, Al-Jaroudi D. Nonclosure of peritoneum: a reappraisal. Am J Obstet Gynecol 2003; 189:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/68\">",
"      Woyto J, Florjaski J, Zimmer M. [Nonclosure of the visceral peritoneum during Cesarean sections]. Ginekol Pol 2000; 71:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/69\">",
"      Weerawetwat W, Buranawanich S, Kanawong M. Closure vs non-closure of the visceral and parietal peritoneum at cesarean delivery: 16 year study. J Med Assoc Thai 2004; 87:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/70\">",
"      Mocanau C, Anton E, Chiril R. [Peritoneal suture vs. non-suture at caesarean section]. Rev Med Chir Soc Med Nat Iasi 2005; 109:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/71\">",
"      Lyell DJ, Caughey AB, Hu E, Daniels K. Peritoneal closure at primary cesarean delivery and adhesions. Obstet Gynecol 2005; 106:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/72\">",
"      Zareian Z, Zareian P. Non-closure versus closure of peritoneum during cesarean section: a randomized study. Eur J Obstet Gynecol Reprod Biol 2006; 128:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/73\">",
"      Kapustian V, Anteby EY, Gdalevich M, et al. Effect of closure versus nonclosure of peritoneum at cesarean section on adhesions: a prospective randomized study. Am J Obstet Gynecol 2012; 206:56.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/74\">",
"      Lyell DJ, Caughey AB, Hu E, et al. Rectus muscle and visceral peritoneum closure at cesarean delivery and intraabdominal adhesions. Am J Obstet Gynecol 2012; 206:515.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/75\">",
"      Cheong YC, Premkumar G, Metwally M, et al. To close or not to close? A systematic review and a meta-analysis of peritoneal non-closure and adhesion formation after caesarean section. Eur J Obstet Gynecol Reprod Biol 2009; 147:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/76\">",
"      Shi Z, Ma L, Yang Y, et al. Adhesion formation after previous caesarean section-a meta-analysis and systematic review. BJOG 2011; 118:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/77\">",
"      Diener MK, Voss S, Jensen K, et al. Elective midline laparotomy closure: the INLINE systematic review and meta-analysis. Ann Surg 2010; 251:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/78\">",
"      Ceydeli A, Rucinski J, Wise L. Finding the best abdominal closure: an evidence-based review of the literature. Curr Surg 2005; 62:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/79\">",
"      Rahbari NN, Knebel P, Diener MK, et al. Current practice of abdominal wall closure in elective surgery - Is there any consensus? BMC Surg 2009; 9:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/80\">",
"      Seiler CM, Deckert A, Diener MK, et al. Midline versus transverse incision in major abdominal surgery: a randomized, double-blind equivalence trial (POVATI: ISRCTN60734227). Ann Surg 2009; 249:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/81\">",
"      Maxwell GL, Soisson AP, Brittain PC, et al. Repair of transversely incised abdominal wall fascia in a rabbit model. Obstet Gynecol 1996; 87:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/82\">",
"      Anderson ER, Gates S. Techniques and materials for closure of the abdominal wall in caesarean section. Cochrane Database Syst Rev 2004; :CD004663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/83\">",
"      Chelmow D, Rodriguez EJ, Sabatini MM. Suture closure of subcutaneous fat and wound disruption after cesarean delivery: a meta-analysis. Obstet Gynecol 2004; 103:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/84\">",
"      Naumann RW, Hauth JC, Owen J, et al. Subcutaneous tissue approximation in relation to wound disruption after cesarean delivery in obese women. Obstet Gynecol 1995; 85:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/85\">",
"      Gates S, Anderson ER. Wound drainage for caesarean section. Cochrane Database Syst Rev 2005; :CD004549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/86\">",
"      Hellums EK, Lin MG, Ramsey PS. Prophylactic subcutaneous drainage for prevention of wound complications after cesarean delivery--a metaanalysis. Am J Obstet Gynecol 2007; 197:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/87\">",
"      Ramsey PS, White AM, Guinn DA, et al. Subcutaneous tissue reapproximation, alone or in combination with drain, in obese women undergoing cesarean delivery. Obstet Gynecol 2005; 105:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/88\">",
"      Mackeen AD, Berghella V, Larsen ML. Techniques and materials for skin closure in caesarean section. Cochrane Database Syst Rev 2012; 9:CD003577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/89\">",
"      Tuuli MG, Rampersad RM, Carbone JF, et al. Staples compared with subcuticular suture for skin closure after cesarean delivery: a systematic review and meta-analysis. Obstet Gynecol 2011; 117:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/90\">",
"      Clay FS, Walsh CA, Walsh SR. Staples vs subcuticular sutures for skin closure at cesarean delivery: a metaanalysis of randomized controlled trials. Am J Obstet Gynecol 2011; 204:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/91\">",
"      Frishman GN, Schwartz T, Hogan JW. Closure of Pfannenstiel skin incisions. Staples vs. subcuticular suture. J Reprod Med 1997; 42:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/92\">",
"      Rousseau JA, Girard K, Turcot-Lemay L, Thomas N. A randomized study comparing skin closure in cesarean sections: staples vs subcuticular sutures. Am J Obstet Gynecol 2009; 200:265.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/93\">",
"      Cromi A, Ghezzi F, Gottardi A, et al. Cosmetic outcomes of various skin closure methods following cesarean delivery: a randomized trial. Am J Obstet Gynecol 2010; 203:36.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/94\">",
"      Basha SL, Rochon ML, Qui&ntilde;ones JN, et al. Randomized controlled trial of wound complication rates of subcuticular suture vs staples for skin closure at cesarean delivery. Am J Obstet Gynecol 2010; 203:285.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/95\">",
"      Mathai M, Hofmeyr GJ. Abdominal surgical incisions for caesarean section. Cochrane Database Syst Rev 2007; :CD004453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/96\">",
"      Hofmeyr JG, Novikova N, Mathai M, Shah A. Techniques for cesarean section. Am J Obstet Gynecol 2009; 201:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/97\">",
"      Nabhan AF. Long-term outcomes of two different surgical techniques for cesarean. Int J Gynaecol Obstet 2008; 100:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/98\">",
"      Hofmeyr GJ, Mathai M, Shah A, Novikova N. Techniques for caesarean section. Cochrane Database Syst Rev 2008; :CD004662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/99\">",
"      Burton CA, Grimes DA, March CM. Surgical management of leiomyomata during pregnancy. Obstet Gynecol 1989; 74:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/100\">",
"      Febo G, Tessarolo M, Leo L, et al. Surgical management of leiomyomata in pregnancy. Clin Exp Obstet Gynecol 1997; 24:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/101\">",
"      Dede M, Yenen MC, Yilmaz A, et al. Treatment of incidental adnexal masses at cesarean section: a retrospective study. Int J Gynecol Cancer 2007; 17:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/21/14682/abstract/102\">",
"      Pearce C, Torres C, Stallings S, et al. Elective appendectomy at the time of cesarean delivery: a randomized controlled trial. Am J Obstet Gynecol 2008; 199:491.e1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5405 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-BD9846CABD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_21_14682=[""].join("\n");
var outline_f14_21_14682=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OPENING THE ABDOMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Skin incision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Transverse or vertical",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Subcutaneous tissue layer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Fascial layer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Rectus muscle layer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Opening the peritoneum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20293380\">",
"      - Dense intraperitoneal adhesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Assuring adequate exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Issues in obese women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INTRAABDOMINAL PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Bladder flap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hysterotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Transverse incision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Low vertical and classical incisions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2329566\">",
"      Bandl's ring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Fetal extraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Cord clamping and infant assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6493856\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Placental extraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Prevention of hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PROCEDURES DURING CLOSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Exteriorizing the uterus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Uterine closure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2329573\">",
"      - Suture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2329589\">",
"      - Myometrial closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Single versus double layer closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20298701\">",
"      Closure of a classical incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Abdominal irrigation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Adhesion barriers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Peritoneum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Rectus muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Fascia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Subcutaneous tissue",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Use of drains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      ALTERNATIVE TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      INCIDENTAL PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5405\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5405|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/54/33641\" title=\"picture 1A\">",
"      Pelosi cesarean technique 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/21/19801\" title=\"picture 1B\">",
"      Pelosi cesarean technique 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/9/12441\" title=\"picture 1C\">",
"      Pelosi technique 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/27/27065\" title=\"picture 1D\">",
"      Pelosi technique 4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5405|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/33/9756\" title=\"table 1\">",
"      Misgav-Ladach Joel Cohen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=related_link\">",
"      Abdominal surgical incisions: Prevention and treatment of complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44009?source=related_link\">",
"      Cesarean delivery of the obese woman",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21449?source=related_link\">",
"      Cesarean delivery: Postoperative issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/5/8282?source=related_link\">",
"      Cesarean delivery: Preoperative issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/43/21176?source=related_link\">",
"      Delivery of the fetus in breech presentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11414?source=related_link\">",
"      Fetal extraction at cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33114?source=related_link\">",
"      Management of normal labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22662?source=related_link\">",
"      Management of the fetus in transverse lie",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36105?source=related_link\">",
"      Overview of the routine management of the healthy newborn infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/21/16723?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15065?source=related_link\">",
"      Pregnancy in women with uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10633?source=related_link\">",
"      Principles of abdominal wall closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30265?source=related_link\">",
"      Principles of abdominal wall incisions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15018?source=related_link\">",
"      Surgical sterilization of women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=related_link\">",
"      The impact of obesity on fertility and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./uterine-rupture-after-previous-cesarean-delivery?source=related_link\">",
"      Uterine rupture after previous cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41639?source=related_link\">",
"      Uterotonic drugs for management of the third stage of labor",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_21_14683="Characteristics of NOS isoforms";
var content_f14_21_14683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of the three nitric oxide synthase (NOS) isoforms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Enzyme designation",
"      </td>",
"      <td class=\"subtitle1\">",
"       Gene designation",
"      </td>",
"      <td class=\"subtitle1\">",
"       Chromosomal location and gene size (kbp)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Cell type where first identified",
"      </td>",
"      <td class=\"subtitle1\">",
"       Regulated by Ca++ flux",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Type I, (nNOS)",
"      </td>",
"      <td>",
"       nos1",
"      </td>",
"      <td>",
"       12q; &gt;100",
"      </td>",
"      <td>",
"       Nerve",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Type II, (iNOS)",
"      </td>",
"      <td>",
"       nos2",
"      </td>",
"      <td>",
"       17cen-q; 37",
"      </td>",
"      <td>",
"       Macrophage",
"      </td>",
"      <td>",
"       No",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Type III, (eNOS)",
"      </td>",
"      <td>",
"       nos3",
"      </td>",
"      <td>",
"       7q; 21",
"      </td>",
"      <td>",
"       Vascular endothelium",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NOS: nitric oxide synthetase; eNOS: endothelial cell NOS; iNOS: inducible NOS; nNOS: neuronal cell NOS.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_21_14683=[""].join("\n");
var outline_f14_21_14683=null;
var title_f14_21_14684="Activities with dental risk";
var content_f14_21_14684=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recreational activities and sports associated with risk of oral injury",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td>",
"          Acrobatics",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Baseball",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Basketball",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Bicycling",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Boxing",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Equestrian events",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Field hockey",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Football",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Gymnastics",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Handball",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ice hockey",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Inline skating",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Lacrosse",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Martial arts",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td>",
"          Racquetball",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Rugby",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Shotputting",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Skateboarding",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Skiing",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Skydiving",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Soccer",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Softball",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Squash",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Surfing",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Volleyball",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Water polo",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Weightlifting",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Wrestling",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Ranalli, DN. Prevention of sports-related traumatic dental injuries. Dent Clin North Am 2000; 44:35.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_21_14684=[""].join("\n");
var outline_f14_21_14684=null;
var title_f14_21_14685="Impact of age on adverse cerebral outcomes after CABG";
var content_f14_21_14685=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Impact of age on adverse cerebral outcomes after coronary bypass surgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 281px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The incidence of adverse cerebral events after coronary artery bypass surgery is 6.1 percent, of which half are type I (focal injury, coma, or stupor at discharge) and half are type II (deterioration in intellectual function, memory defect, or seizures). The incidence of both type I and II events increase with age.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Roach GW, Kanchuger M, Mangano M, et al, and the Ischemia Research and Education Foundation Investigators. N Engl J Med 1996; 335:1857.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_21_14685=[""].join("\n");
var outline_f14_21_14685=null;
var title_f14_21_14686="Diary record of PEFR";
var content_f14_21_14686=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peak flow rate diary in asthma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 280px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diary record of peak expiratory flow rate (PEFR) from an asthmatic patient over a one week period. The patient recorded PEF three times a day at waking (AM), noon (N) and upon retiring (PM). The red zone is set at 50 percent of the personal best, whereas the yellow is from 50 to 80 percent and the green zone is &gt;80 percent. Notice the reproducible morning (AM) falls in PEFR characteristic of the patient with nocturnal asthma. Also note the improvement in PEFR as inhaled corticosteroids are added to the treatment regime.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_21_14686=[""].join("\n");
var outline_f14_21_14686=null;
var title_f14_21_14687="No heparin regimen in HD";
var content_f14_21_14687=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F56596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F56596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schematic diagram showing no heparin regimen in hemodialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 229px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of no heparin regimen for anticoagulation during hemodialysis. Boluses of isotonic saline are given every 15 minutes to minimize the degree of hemoconcentration and to flush fibrin strands from the dialyzer into the bubble trap.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_21_14687=[""].join("\n");
var outline_f14_21_14687=null;
